

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

STANDARDISED Diagnostic Assessment for children and young people with emotional difficulties (STADIA): protocol for a multi-centre randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053043
Article Type:	Protocol
Date Submitted by the Author:	26-Aug-2021
Complete List of Authors:	Day, Florence; University of Nottingham, Bhardwaj, Anupam; Cambridgeshire and Peterborough NHS Foundation Trust Dubicka, Bernadka; The University of Manchester; Pennine Care NHS Foundation Trust Ewart, Colleen Gledhill, Julia; Central and North West London NHS Foundation Trust James, Marilyn; University of Nottingham, School of Medicine Lang, Alexandra; University of Nottingham Marshall, Tamsin; Berkshire Healthcare NHS Foundation Trust Montgomery, Alan; University of Nottingham Reynolds, Shirley; University of Reading Sprange, Kirsty; University of Nottingham, Nottingham Clinical Trials Research Unit Thomson, Louise; University of Nottingham, Psychiatry Bradley, Ellen; University of Nottingham Lathe, James; University of Nottingham Newman, Kristina; Nottinghamshire Healthcare NHS Foundation Trust Partlett, Chris; University of Nottingham, Starr, Kath; University of Nottingham Sayal, Kapil; University of Nottingham
Keywords:	Child & adolescent psychiatry < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY, HEALTH ECONOMICS

SCHOLARONE™
Manuscripts

1
2
3 **STANDARDISED Diagnostic Assessment for children and young people with emotional difficulties**
4 **(STADIA): protocol for a multi-centre randomised controlled trial**
5

6 **Authors:**

7 Florence Day¹, Anupam Bhardwaj², Bernadka Dubicka³, Colleen Ewart⁴, Julia Gledhill⁵, Marilyn
8 James¹, Alexandra Lang⁶, Tamsin Marshall⁷, Alan Montgomery¹, Shirley Reynolds⁸, Kirsty Sprange¹,
9 Louise Thomson⁹, Ellen Bradley⁹, James Lathe¹, Kristina Newman⁹, Chris Partlett¹, Kath Starr¹ & Kapil
10 Sayal⁹
11
12

13 **Corresponding author:**

14 Professor Kapil Sayal
15 Institute of Mental Health
16 University of Nottingham
17 Nottingham, NG8 1BB
18

19
20 Email: kapil.sayal@nottingham.ac.uk
21
22

23 Word count, excluding title page, abstract, references, figures and tables: 3918
24

- 25
26 1 Nottingham Clinical Trials Unit, University of Nottingham, Nottingham NG7 2RD
27 2 Cambridge and Peterborough Foundation Trust, Brookside CAMHS, Cambridge CB2 8AH
28 3 Pennine Care NHS Foundation Trust, Ashton-under-Lyne OL6 7SR
29 4 STADIA Patient and Public Involvement co-lead, Institute of Mental Health, University of
30 Nottingham, Nottingham NG8 1BB
31 5 Central and North West London NHS Foundation Trust, Harrow CAMHS, Ash Tree Clinic, South
32 Harrow HA2 8EQ
33 6 Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD
34 7 Berkshire Healthcare NHS Foundation Trust, Fitzwilliam House, Bracknell RG12 1BQ
35 8 School of Psychology and Clinical Language Sciences, University of Reading, Reading RG6 6DZ
36 9 Institute of Mental Health, University of Nottingham, Nottingham NG8 1BB
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Introduction

Emotional disorders (such as anxiety and depression) are associated with considerable distress and impairment in day-to-day function for affected children and young people and for their families. Effective evidence-based interventions are available but require appropriate identification of difficulties to enable timely access to services. Standardised Diagnostic Assessment (SDA) tools may aid in the detection of emotional disorders, but there is limited evidence on the utility of SDA tools in routine care and equipoise amongst professionals about their clinical value.

Methods and analysis

A multi-centre, two-arm, parallel group RCT, with embedded qualitative and health economic components. Participants will be randomised in a 1:1 ratio to either the Development and Wellbeing Assessment (DAWBA) SDA tool as an adjunct to usual clinical care, or usual care only.

A total of 1,210 participants (Children and Young People referred to outpatient, specialist Child and Adolescent Mental Health Services (CAMHS) with emotional difficulties and their parent/carers) will be recruited from at least 6 sites in England.

The primary outcome is diagnosis of an emotional disorder within 12-months post-randomisation. Secondary outcomes include referral acceptance, diagnosis and treatment of emotional disorders, symptoms of emotional difficulties and comorbid disorders and associated functional impairment.

Ethics and dissemination

The study received favourable opinion from the South Birmingham Research Ethics Committee (Ref. 19/WM/0133). Results of this trial will be reported to the funder and published in full in the HTA Journal series and also submitted for publication in a peer reviewed journal.

Registration details

The STADIA trial was prospectively registered as ISRCTN15748675 on 29 May 2019.

Keywords

RCT; CAMHS; standardised diagnostic assessment; DAWBA; emotional disorders; diagnosis; outcomes; health economics; cost effectiveness; cost utility.

ARTICLE SUMMARY

Strengths and limitations of this study

- Large real-world multicentre randomised controlled trial of the DAWBA SDA tool as an adjunct to usual care versus usual care only.
- Trial procedures are carried out remotely with all data collection and the DAWBA completed online or via telephone, facilitating post-trial implementation into future service delivery models and routine clinical care.
- The embedded health economic component permits evaluation of both clinical and cost effectiveness.
- Embedded qualitative work will support optimal delivery and implementation to enhance acceptability, effectiveness and long-term uptake.
- Participants, researchers and clinicians cannot be blinded to treatment allocation.

INTRODUCTION

Emotional disorders cause considerable distress for affected children and young people (CYP) and their families, with adverse effects on family and peer relationships, quality of life, social involvement and activities, academic attainment and occupational opportunities, ultimately affecting life chances.[1-4] Emotional disorders are frequently comorbid with other disorders [2, 5], and are associated with self-harm and completed suicide. Effective evidence-based interventions are available but require appropriate identification of presenting difficulties to enable timely access to services and earlier recovery.[3]

The prevalence of emotional disorders has increased considerably over the past two decades.[1] In the UK, CYP with clinically significant emotional difficulties may be referred to outpatient specialist Child and Adolescent Mental Health Services (CAMHS). However, insufficient information is a common reason for referrals being declined.[6] There is limited evidence to inform optimal approaches to determine which referrals should be accepted, contributing to a large variation in acceptance rates.[6] Likewise there is a lack of evidence on how best to conduct assessments for suspected emotional difficulties to optimise outcomes. Acceptance criteria and assessment procedures differ across services and there is no single standardised approach.

The multi-disciplinary nature of CAMHS means CYP are assessed by practitioners from different professional backgrounds, with variations in training, ethos and conceptualisations of presenting difficulties. The type and scope of assessments offered vary. Assessments are often conducted by practitioners without formal diagnostic training.[7] The validity and value of mental health diagnoses have been questioned, reflecting concerns around stigma or labelling.[7-9] This can mean that in routine practice, assessments are often undertaken without the aim of making or recording a diagnosis.

However, NICE guidelines for management and treatment are usually based on diagnostic classification of disorders, so the ability to offer evidence-based interventions requires that the CYP's difficulties are appropriately identified. Although NICE Quality Standards[10] state that CYP with suspected depression should have the diagnosis confirmed and recorded, this is highly variable in practice.[7, 11] The use of diagnostic assessments has been recommended so that important problems are detected and appropriate interventions are offered.[3, 9] The NICE guidelines for depression have recommended the use of standardised diagnostic assessment (SDA) tools as potential adjuncts in the detection of depression within CAMHS.[12] It has further been recommended that SDA tools should be used as an adjunct to clinical assessments, potentially at the point of referral receipt, to enable the allocation of cases to the most appropriate professional.[8, 13, 14]

One such SDA tool is the Development and Well-Being Assessment (DAWBA), a structured package of questionnaires and interviews which can be completed online or by telephone and yields algorithm-based diagnostic information.[15] The DAWBA has established reliability and validity [15] and has been widely used for screening, diagnosis and outcome measurement in research in both clinical and community settings [16, 17], including trials of SDAs [18, 19] and large scale epidemiological research.[1, 20, 21] A previous randomised controlled trial (RCT) using the DAWBA highlighted that, for emotional disorders, disclosing DAWBA diagnosis information to clinicians can improve the level of agreement between the DAWBA and clinical diagnoses, suggesting that the DAWBA can aid clinical detection of emotional disorders.[19] It also improved detection of comorbid disorders. A UK trial found higher levels of agreement between DAWBA and clinical diagnoses, following disclosure of DAWBA information, in relation to anxiety disorders.[18] Practitioners

1
2
3 acknowledged that the additional information could supplement the assessment and aid detection
4 of difficulties.[8]
5

6 Hence, it might be expected that the introduction of an SDA tool following CAMHS referral receipt
7 could enable resources to be better targeted and a timely conclusion to assessments with a
8 diagnostic decision, increase the likelihood that an appropriate evidence-based treatment is offered,
9 and lead to improved outcomes and better experience of care for CYP and their families. However,
10 there is limited evidence on the utility of SDA tools for informing optimal approaches to assessment
11 within routine clinical practice.
12
13

14 **Aims and Objectives**

15 The aim is to evaluate the clinical and cost effectiveness of the DAWBA SDA tool, as an adjunct to
16 usual clinical care for CYP presenting with emotional difficulties referred to CAMHS.
17

18 Specific objectives are to:
19

- 20 1. Conduct an RCT to determine the effectiveness of the DAWBA as an adjunct to usual clinical care
21 on diagnosis and treatment of emotional disorders, symptoms of emotional difficulties and
22 comorbid disorders and associated functional impairment.
23
- 24 2. Undertake an internal pilot to assess recruitment and acceptability.
25
- 26 3. Include a qualitative component within the pilot phase to address:
27 a) The feasibility of recruitment.
28 b) The acceptability and usability of the interventions and procedure.
29 c) How the intervention is used and could be refined for the main trial.
30
- 31 4. Conduct a process evaluation alongside the main trial which will:
32 a) Optimise the design and delivery of the DAWBA to enhance acceptability, effectiveness and
33 long-term uptake.
34 b) Identify the barriers and facilitators to implementation of the DAWBA from the perspectives
35 of CYP, parents, and CAMHS practitioners, managers and commissioners.
36
- 37 5. Estimate cost effectiveness of the use of the DAWBA versus usual care.
38
- 39 6. Make evidence-based recommendations for assessment procedures within CAMHS and produce
40 practice guidelines for clinical decision-making around the referral acceptance and assessment
41 processes.
42
43
44
45
46

47 **METHODS AND ANALYSIS**

48 **Design**

49 A multi-centre, two-arm, parallel group RCT, with embedded qualitative and health economic
50 components.
51

52 An internal pilot period, completed in the first 9 months of recruitment, will determine feasibility of
53 recruitment and follow-up, assessed by the independent Trial Steering Committee against pre-
54 defined stop/go criteria.
55
56

57 **Setting**

Recruitment will take place in at least six NHS Trusts in England, providing outpatient multidisciplinary specialist CAMHS. Sites are geographically dispersed covering urban and rural areas, thus are likely to be socio-demographically representative of CAMHS referrals in England, enabling nationally generalisable findings.

Recruitment and eligibility

Participant identification

The population is CYP presenting with emotional difficulties referred to CAMHS. Participants are identified through the usual referral pathways for the participating sites, which includes NHS and local authority managed Single/Central Point of Access referral points as well as referrals directly received and processed by CAMHS teams.

The STADIA researchers (NHS personnel, based within the CAMHS SPA/triage team to carry out research activities on behalf of the team and authorised to access referral information) at each site review the referrals received by CAMHS to identify CYP presenting with emotional difficulties, according to a standard proforma (Appendix 1. Screening form). Potentially eligible participants are invited to consider taking part in the trial and provided with written information. The initial invitation follows standardised wording to ensure clarity and consistency of approach.

Identification of participants takes place after referral receipt, but prior to referral acceptance (Figure 1).

Consent

Prior to consent, eligibility will be confirmed (**Error! Reference source not found.**) during telephone contact with the local STADIA researcher, who will also provide written and verbal information about the trial, answer questions and support the electronic consent/assent process. Participants who are eligible and provide verbal consent to participation during the call will be provided with a personal link to the online electronic Informed Consent/Assent Form (Table 2), enabling them to provide written informed consent/assent.

Table 1. Eligibility criteria

<p><i>Inclusion criteria for the CYP</i></p> <ul style="list-style-type: none"> • Aged 5 to 17 years. • Referred to outpatient multidisciplinary specialist CAMHS. • Presenting with emotional difficulties. • If aged <16, has an eligible individual with parental responsibility (see parent/carer eligibility criteria below) willing and able to participate in the trial. • If aged 16-17, has capacity to provide valid written informed consent. • If aged 16-17 and participating without a parent/carer, able to complete the assessment tool in English. • If aged 16-17 and participating without a parent/carer, access to internet and email or telephone.
<p><i>Exclusion criteria for the CYP</i></p> <ul style="list-style-type: none"> • Emergency or urgent referral to outpatient multidisciplinary specialist CAMHS (i.e. requires an expedited assessment) according to local risk assessment procedures. • Severe learning disability. • Previously randomised in the STADIA trial.
<p><i>Inclusion criteria for the parent/carer</i></p>

<ul style="list-style-type: none"> • Individual with parental responsibility for the CYP referred to CAMHS; this will be the CYP's mother or father, legally appointed guardian or a person with a residence order concerning the CYP. • Adequate knowledge of the CYP to be able to complete the assessment tool (i.e., known for at least 6 months). • Has capacity to provide valid written informed consent. • Access to internet and email or telephone. • Able to complete the assessment tool in English.
<p><i>Exclusion criteria for the parent/carer</i></p> <ul style="list-style-type: none"> • Local authority representatives designated to care for the CYP.

The participation and consent/assent requirements for the trial are shown in Table 2.

Table 2: Consent & Participation

WHO WAS REFERRED TO CAMHS?	CYP aged <11	CYP aged 11-15			CYP aged 16-17
WHO IS INITIALLY CONTACTED?		Parent/carer			Depends on contact details provided with the CAMHS referral*
WHO CONSENTS?	Parent/carer	Parent/carer	Parent/carer	CYP AND parent/carer (optional)	CYP
WHO ASSENTS?	None	CYP (optional)	None	None	None
WHO ARE THE PARTICIPANTS?	Parent/carer only	CYP and parent/carer dyad	Parent/carer only	CYP and parent/carer dyad	CYP only
WHO IS THE PRIMARY PARTICIPANT?***	Parent/carer	Parent/carer	Parent/carer	CYP	CYP
WHO IS THE SECONDARY PARTICIPANT?	None	CYP	Non	Parent/carer	None
WHO IS INVITED TO COMPLETE THE DAWBA?	Parent/carer	Parent/carer AND CYP	Parent/carer	CYP AND parent/carer	CYP
WHO IS INVITED TO COMPLETE RESEARCH QUESTIONNAIRES?	Parent/carer report on CYP Parent/carer self-report	Parent/carer report on CYP Parent/carer self-report CYP self-report	Parent/carer report on CYP Parent/carer self-report	CYP self-report Parent/carer report on CYP Parent/carer self-report	CYP self-report
<p>For all CYP aged <16 the initial contact about the study will be with the parent/carer. The involvement of CYP aged 11-15 will be at the discretion of the parent/carer.</p> <p>* For CYP aged 16-17 if the CYP's contact details are provided on the CAMHS referral the first contact about the study will be with the CYP who can choose to nominate a parent/carer to participate in the trial alongside them or participate alone. If the parent/carer's contact details only are available the first contact will be with the parent/carer and the parent/carer will be asked</p>					

whether the CYP can also be contacted but may choose to refuse this. The parent/carer will not be able to participate in the STADIA trial without the involvement or consent of the CYP.

** The primary participant is the person who must provide consent as a minimum requirement in order for randomisation to take place. Assent (of CYP aged 11-15) and parental consent (for CYP aged 16 and 17) may also be sought but is not mandatory and therefore will not be required prior to randomisation.

Participants are free to withdraw at any time and for any reason. Participants may withdraw from the intervention, follow-up questionnaires and/or data collection from records in any combination (e.g., participants who do not complete the intervention will continue to be followed-up, participants withdrawing from follow-up questionnaire completion may continue to consent for data collection from records). Withdrawn participants will not be replaced. Data collected prior to withdrawal will be retained and used in the analysis.

Where CYP aged 16 or 17 have consented for their own involvement they can continue to participate in the trial in the event of their parent/carer's withdrawal, however, the parent/carer involvement would not continue should the CYP withdraw consent.

Randomisation and concealment

Participants will be randomised in a 1:1 ratio to either intervention or control. Allocation will be assigned using a minimisation algorithm balancing on recruiting site, CYP age (5-10, 11-15, 16-17 years) and sex, incorporating a probabilistic element to allocation. The allocation algorithm was created by Nottingham Clinical Trials Unit (NCTU) in accordance with their Standard Operating Procedures (SOPs). Allocation is concealed using an automated web system operated by NCTU.

Randomisation is automatically generated within the online system following submission, and automated verification, of baseline data by the primary participant. Participants are presented with their allocation and further instructions on-screen with email confirmation. Instructions for DAWBA completion are included for those in the intervention arm. Email confirmation is sent to the coordinating centre and site research team.

It will not be possible to blind participants, clinicians and some trial staff to treatment allocation, but treatment allocation data will be restricted to those trial staff who require access to facilitate trial conduct.

The risk of contamination between arms is considered low. Access to the DAWBA, and provision of the DAWBA report, is only provided to participants in the intervention arm. SDA tools are not current practice in standard care and it is unlikely that control participants will be asked to complete these at the point of referral receipt. DAWBA completion occurring outside the trial for control arm participants will be collected during follow-up.

Interventions

Development and wellbeing assessment (DAWBA)

The trial intervention is the DAWBA. [22] The DAWBA has a modular structure, with only those modules relevant to emotional and comorbid disorders included (Table 3). No freetext responses are collected.

Table 3: DAWBA modules

DAWBA Module	Included in STADIA-specific DAWBA report?
--------------	-------------------------------------------

Strengths and Difficulties Questionnaire	Does not generate diagnostic predictions so not included in the DAWBA report
Separation Anxiety	Yes
Specific Phobia	Yes
Social Phobia	Yes
Panic and Agoraphobia	Yes
Generalised Anxiety	Yes
Post-traumatic stress disorder (PTSD)	Yes
Obsessive compulsive disorder (OCD)	Yes
Depression	Yes
Bipolar disorder	Does not generate diagnostic predictions so not included in the DAWBA report
Body dysmorphic disorder (BDD)	Does not generate diagnostic predictions so is not included in the DAWBA report
Oppositional defiant disorder (ODD)	Yes
Conduct Disorder	Yes

The DAWBA will be self-reported by participants via the secure, standalone online platform created and maintained by the DAWBA developer.[22] Access is by a unique ID number and password, assigned at the point of randomisation via a stock control system integrated into the randomisation system, ensuring accountability of DAWBA slot allocation.

The DAWBA may be completed by the parent/carer and/or CYP aged 11+, depending on the consent and participation arrangements (Table 2). DAWBA completion will be monitored and the STADIA researcher will support and encourage completion. Participants will be able to complete the DAWBA in a telephone call with the STADIA researcher if required. Participants are asked to complete all modules of the DAWBA presented to them. Should the DAWBA be only partially completed by respondents the report will be based only on fully answered modules with missing responses identified as such.

A trial-specific DAWBA report will be prepared for each participant, based on a standard, study-specific template (*Error! Reference source not found.*). The algorithm-derived diagnostic predictions will be used to highlight the likelihood of a CYP meeting ICD-10 criteria for the disorders assessed; the report is based entirely on the algorithm-derived predictions and is not clinically rated. The report will be sent to participants (via post or email) and CAMHS clinicians (via upload to the clinical record), as an adjunct to usual clinical practice.

Control

CYP randomised to the control arm will receive usual care (i.e., referral review as usual). Based on standard information provided with the referral a clinical decision is made about whether the referral is accepted and, if so, a clinician conducts the initial CAMHS assessment as per usual practice in the service.

Sample size

A target sample size of 1210 participants will be recruited and randomised, with equal allocation to intervention or control.

Assuming 45% of control participants have a confirmed diagnosis within 12 months (based on unpublished data obtained from the trial sites), detection of an absolute increase of 10% with 90% power and 5% two-sided alpha, requires 544 participants per arm for analysis. Allowing for up to 10% non-collection of the primary outcome, we will randomise 1210 participants.

Measures and outcomes

Primary outcome

The primary outcome is a clinician-made diagnosis decision about the presence of an emotional disorder within 12 months of randomisation. Diagnosis of an emotional disorder will be coded as 'yes'; absence or uncertainty (for example, reflecting ongoing assessment or investigation) will be coded as 'no'. Eligible diagnoses are those that reflect 'emotional' or 'internalizing' disorders in ICD/DSM (Appendix 3. Eligible emotional disorder diagnoses). The diagnosis must be documented in the clinical record within 12 months of randomisation by a mental health services clinician in an NHS-delivered or NHS-commissioned service.

Diagnoses will be collected from clinical records using a standard proforma. Alternative possible diagnoses identified from the clinical notes will be recorded verbatim on the data capture form and will be subject to adjudication by members of the Trial Management Group (**Error! Reference source not found.**).

Secondary outcomes

Secondary outcomes are listed in and further detailed in **Error! Reference source not found.**

Table 4. Secondary outcomes

Outcome	Measurement
Acceptance of index referral	Collected from records
Acceptance of any referral within 12 months of randomisation	Collected from records
Discharge from CAMHS within 12 months	Collected from records
Re-referral to CAMHS within 12 months	Collected from records
Confirmed diagnosis decision	Collected from records
Time from randomisation to diagnosis of emotional disorder	Collected from records
Diagnoses made over the 12 month period from randomisation	Collected from records
Treatment offered for diagnosed emotional disorder	Collected from records
Any treatment / interventions given	Collected from records
Time from randomisation to the decision to offer treatment for a diagnosed emotional disorder	Collected from records
Time from randomisation to start of first treatment for a diagnosed emotional disorder	Collected from records
Time from randomisation to the decision to offer any treatment	Collected from records
Time from randomisation to start of any treatment	Collected from records
Participant-reported diagnoses received from CAMHS in the 12 months post-randomisation	Participant self-report
Depression symptoms (CYP)	Mood and Feelings Questionnaire (MFQ)[23]
Anxiety symptoms (CYP)	Revised Child's Anxiety Depression Scale (RCADS)[24]
Oppositional defiant / conduct disorder symptoms (CYP)	Strengths and Difficulties Questionnaire (SDQ)[25]

Functional Impairment (CYP)	Strengths and Difficulties Questionnaire (SDQ)[25]
Self-harm thoughts (CYP)	CYP self-report self-harm measure
Self-harm behaviour (CYP)	CYP self-report self-harm measure
Depression symptoms (parent/carer)	Patient Health Questionnaire (PHQ-9)[26]
Anxiety symptoms (parent/carer)	Generalised Anxiety Disorder Assessment (GAD-7)[27]
Time off education, employment or training because of emotional difficulties for the CYP	Resource use questionnaire

Health economic measures

Outcomes

Health related quality of life (HRQoL) of the CYP assessed using the Child Health Utility 9D (CHU9D)[28] and EuroQol-5D youth (EQ-5D-Y).[29] These measures will be self-reported by CYP aged 11 and over, with proxy versions also completed by the parent/carer for CYP <16.

HRQoL for the parent/carer assessed using the EuroQol-5D five level version (EQ-5D-5L).[30]

Resource Use

Data will be collected on health care, education, and social care resource use for both the CYP and parents/carers, using a purposely designed resource use collection tool. The questionnaire was developed by health economists, in tandem with feedback from PPI representatives, addressing primary, secondary, and social care costs, alongside the broader patient-borne costs. These data will be attributable to the emotional difficulties of the young person and be self-reported by the parent/carer with supplementary information obtained from CYP aged 16 and 17. Administrative records of treatments/interventions offered by CAMHS during the trial period may be considered as a supplementary source of data.

Data collection

Data will be collected through participant reported questionnaires (parent/carer and CYP self-report aged 11+) and from clinical records. Participant reported outcomes will be collected at baseline and 6- and 12-months post-randomisation (**Error! Reference source not found.**). Questionnaires are intended to be completed online by participants in the first instance - to maximise rates of completion and retention there will be an option for telephone completion, should participants have difficulty accessing or completing the questionnaires online.

Outcomes collected from records will be reported for the 12-month period following randomisation.

Data management and analysis

Data management

Arrangements for data handling are specified in the Data Management Plan (DMP). Central and on-site monitoring will be carried out as required following a risk assessment and as documented in the monitoring plan. Monitoring activities will be carried out by the coordinating centre on behalf of the trial sponsor.

Data will be held on servers located within The University of Nottingham data centres. Security is both physical (secure limited access) and electronic (behind firewalls, access via user accounts). Personal data recorded on all documents will be regarded as strictly confidential and handled and stored in accordance with the Data Protection Act 2018.

Statistical analysis

The primary approach to between-group comparative analyses will be by modified intention-to-treat (i.e. including all participants who have been randomised and without imputation of missing outcome data).

The primary comparative analysis will employ a generalised linear mixed model to compare the proportions in each group with a clinician-made diagnosis decision within 12 months of randomisation, adjusted for minimisation variables. The comparison will be presented as both an absolute (risk difference) and relative (risk ratio) effect, along with 95% confidence intervals.

Secondary outcomes will be analysed using appropriate mixed effect regression models dependent on data type and will adjust for factors used in the minimisation and baseline value of the outcome where measured. For outcomes measured at multiple time points, these will be analysed using a mixed model with a treatment by time interaction to obtain estimates of treatment effect at each follow-up time.

Appropriate interaction terms will be included in the primary regression analyses in order to conduct subgroup analyses according to sex and age of the CYP.

Health economic analysis

In accordance with NICE guidance, primary analysis will take an NHS and personal social services perspective. Unit costs will be attached to participant reports of health care resource use or recorded treatments/interventions offered by CAMHS. The cost of the DAWBA itself will be distributed at the participant-level across the intervention arm of the trial. Sensitivity analyses will take a wider perspective to capture the broader societal costs inclusive of out-of-pocket expenses and productivity losses. Indices of HRQoL for the EQ-5D, EQ-5D-Y, and CHU9D will be derived using relevant population tariffs, and quality adjusted life years estimated using area under the curve (AUC).

The economic evaluation will take an incremental approach between the two groups using an intention-to-treat (ITT) population (irrespective of treatment received) and a 12-month time horizon. The outcome for the primary cost utility analysis will be the joint young person and parent/carer QALYs. The outcome for the secondary cost effectiveness analysis will be confirmed diagnosis decisions. Outcomes will be paired with their respective direct-to-NHS costs, bootstrapped, and scattered on the cost effectiveness plane to characterise the uncertainty in incremental estimates. Using the net monetary benefit framework,^[31] Cost Effectiveness Acceptability Curves (CEACs) will be constructed to show the non-parametric probability the intervention is a cost effective option, compared to usual care, across a range of willingness to pay thresholds per QALY, and within the secondary analysis per confirmed diagnosis decision. While the receipt of any diagnosis of emotional difficulties in young people would likely lead to large divergences in lifecourse outcomes, the heterogeneity of conditions considered for diagnosis (**Error! Reference source not found.**) renders CUA modelling across the lifecourse infeasible. Secondary analysis is expected to be fully captured within the 12-month time horizon.

A full statistical analysis plan (SAP) and health economics analysis plan (HEAP) will be developed and agreed prior to database lock and un-blinding of the analysing statistician and health economist.

Embedded qualitative study

During the internal pilot, semi-structured interviews are undertaken with a sample of participants who consented to be invited to participate in qualitative interviews. Researchers, clinicians, service

1
2
3 managers and commissioners are identified by site leads. The proposed sample size is 25
4 participants (parent/carer and CYP aged 16-17), 25 staff and 15 service managers and
5 commissioners. Interviews address: a) the feasibility of recruitment; b) the acceptability and usability
6 of the interventions and procedure; c) how the intervention is used and how this deployment could
7 be refined for the main trial. Interviews are conducted by the qualitative researcher (KN) in person,
8 or by phone or video call based on participant preferences and pandemic restrictions.
9

10
11 A process evaluation, conducted during the main trial phase, will aim to identify the barriers and
12 facilitators to implementation of the intervention. Semi-structured interviews will be conducted with
13 a further sample of participants and clinicians to explore the perceived functioning of the
14 intervention, the organisation of the service and reflective experiences on outcomes.
15

16
17 Qualitative interview data will be recorded and encrypted on a password protected Dictaphone and
18 transferred securely to medical transcription company Dict8 for transcription. Transcriptions will be
19 anonymised. Audio files will be destroyed after transcripts have been checked. Anonymised
20 transcriptions will be analysed and stored on password protected computers and the secure
21 University of Nottingham server.
22

23 Qualitative analysis

24 All qualitative interview data will be initially analysed by the qualitative researcher (KN) using
25 interpretative thematic approaches to coding, and adopt the framework method,[32] with input
26 from the qualitative lead (LT), Chief Investigator (KSa) and PPI leads (CE & AL). NVIVO 12 will be used
27 to manage the qualitative data.
28

29 Patient and public involvement

30
31 Prior to submission, the proposal was informed by consultations with a person with lived
32 parent/carer experience of CAMHS, including contribution to and review of the proposal,
33 recruitment strategy, participant trial experience and consideration of burden of the intervention,
34 and establishing a PPI workstream.
35

36
37 Following award, the PPI Co-I team recruited two representatives naïve of the study design to
38 provide independent review of the trial via their membership of the Trial Steering Committee (TSC).
39 Both TSC members are persons with lived parent/carer experience of CAMHS.
40

41
42 During study set up, PPI Co-I expertise was utilised to support researcher recruitment via the design
43 and deployment of role plays within interviews.[33] This was to gain insight into candidates'
44 capabilities when dealing with sensitive and challenging participant scenarios. Additionally, they
45 contributed to design of researcher training materials, to support standardised approaches across
46 trial sites. Iterative and creative design PPI activities were integral in the development of the STADIA
47 trial logo and branding to ensure accessibility and acceptability to CYP and parents.
48

49
50 Since study commencement participatory design approaches have seen PPI co-design of the
51 resource use questionnaire, qualitative interviews and the protocol for a Study Within A Trial (SWAT)
52 to support participant engagement with follow-up. Additionally, collaborative working between the
53 PPI and Qualitative workstreams has enabled examination of the qualitative themes using principles
54 of the Framework Method[32] for independent verification of those themes.
55

56
57 Two PPI advisory panels have been established, meeting on average every 3 months since month 9
58 of the study. "STADIA PPI Panel" has 8 adult members, with lived parent/carer experience of
59 CAMHS. "STADIA Labs" has 6 CYP members, aged 15 to 19 at inception, with lived experience of
60 CAMHS. These groups have been involved in many traditional activities such as review of PIS and

1
2
3 consent forms, consultation on language and content for participant reminder text messages. PPI co-
4 production activities are also seeing the development of age appropriate study newsletters and the
5 design of STADIA information videos including decision making about video concept, audience,
6 message, aesthetic and content. PPI group members are provided with supplementary training
7 about PPI practices and involvement opportunities. Due to the Covid-19 pandemic, PPI meetings
8 have had to move online and so the PPI team are investing in knowledge transfer and upskilling PPI
9 representatives in different ways of working and collaborating online.
10
11

12 There are a range of planned flexible opportunities for participating in project feedback and
13 dissemination activities including co-facilitating and presenting at the interactive dissemination
14 workshop / consensus meeting, publication authorship as peer researcher and presenting at
15 conferences to showcase the project findings.
16
17

18 **ETHICS AND DISSEMINATION**

19 **Ethics**

20 The study was reviewed and received favourable opinion from the South Birmingham Research
21 Ethics Committee (Ref. 19/WM/0133) on 12 June 2019; subsequent amendments have been
22 approved. The current, approved protocol is version 3.0 dated 13 August 2020.
23
24

25 **Safety**

26 The trial intervention is conceptually similar to usual clinical practice (i.e., CYP referred to CAMHS
27 may be sent questionnaires about their difficulties), therefore the risks of the trial are considered
28 comparable. The DAWBA is widely used in research for data collection therefore, although utilised as
29 an intervention in the STADIA trial, the risks may be regarded as similar to those of an
30 observational/questionnaire study. Data to inform safety oversight will therefore be collected during
31 routine follow-up, from existing outcome measures. There is no separate adverse event or serious
32 adverse event reporting.
33
34

35 The number of participants meeting pre-defined safety outcomes will be reported on an ongoing
36 basis to the Trial Management Group (TMG) and TSC. Data will be presented by arms to the Data
37 Monitoring Committee (DMC).
38
39

40 **Trial oversight**

41 Nottinghamshire Healthcare NHS Foundation Trust will undertake role of Sponsor as defined by the
42 UK Policy Framework for Health and Social Care Research.[34] Delegated responsibilities will be
43 assigned to the Chief Investigator, participating NHS Trusts and the trial coordinating centre,
44 Nottingham Clinical Trials Unit (NCTU).
45
46

47 The full co-applicant team and NCTU staff responsible for the day-to-day management of the trial
48 will form the TMG, responsible for monitoring recruitment and retention rates and implementing
49 strategies to ensure targets are met. Independent Trial Steering and Data Monitoring Committees
50 will operate in accordance with trial-specific Charters.
51
52

53 **Dissemination**

54 Results of this trial will be reported to the funder and published in full in the HTA Journal series and
55 also submitted for publication in a peer reviewed journal.
56
57

58 **Data Sharing**

1
2
3 Anonymised trial data may be shared with researchers external to the trial research team in
4 accordance with the NCTU's data sharing procedure.
5

6 **Figures**

7 Figure 1: Participant flow
8
9

10 **Authors' contributions**

11 All authors made substantial contributions to conception and design, acquisition of data, or analysis
12 and interpretation of data; took part in drafting the article or revising it critically for important
13 intellectual content; agreed to submit to the current journal; gave final approval of the version to be
14 published; and agree to be accountable for all aspects of the work.
15

16 **Funding statement**

17 This study was funded as a result of a commissioned call by the National Institute for Health
18 Research (NIHR) Health Technology Assessment programme (Grant Reference Number 16/96/09).
19 The views expressed are those of the authors and not necessarily those of the NIHR or the
20 Department of Health and Social Care.
21

22
23 The funder will have no role in the collection, management, analysis, and interpretation of data;
24 writing of the report; and the decision to submit the report for publication.
25

26 **Competing interests**

27 The authors declare no competing interests.
28
29

30 **Acknowledgements**

31 We would like to acknowledge and thank all the parent/carers and young people participating in the
32 trial and the research sites involved in recruiting participants and data collection. The authors would
33 also like to thank the wider STADIA team for their input, including the PPI Advisory Panels, members
34 of the independent Trial Steering and Data Monitoring Committees, and the Nottingham Clinical
35 Trials Unit, who are the trial coordinating centre.
36

37
38 Finally, thanks to the trial sponsor, Nottinghamshire Healthcare NHS Foundation Trust
39 (research@nottshc.nhs.uk).
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


REFERENCES

1. Sadler, K., et al. *Mental Health of Children and Young People in England, 2017*. 2018 06 February 2019]; Available from: <https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-of-children-and-young-people-in-england/2017/2017>.
2. Goodyer IM, R.S., Barrett B, Byford S, Dubicka B, Hill J, Holland F, Kelvin R, Midgley N, Roberts C, Senior R, Target M, Widmer B, Wilkinson P, Fonagy P, *Cognitive behavioural therapy and short-term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised controlled trial*. Health Technology Assessment, 2017. **21**(12).
3. Simmons, M., P. Wilkinson, and B. Dubicka, *Measurement Issues: Depression measures in children and adolescents*. Child and Adolescent Mental Health, 2015. **20**(4): p. 230-241.
4. Colman, I.W., MEJ. Croudace, TJ. Jones, PB., *Forty-Year Psychiatric Outcomes Following Assessment for Internalizing Disorder in Adolescence*. American Journal of Psychiatry, 2007. **164**(1): p. 126-133.
5. Orchard, F., et al., *Clinical characteristics of adolescents referred for treatment of depressive disorders*. Child and Adolescent Mental Health, 2017. **22**(2): p. 61-68.
6. Frith, E. *Access and waiting times in children and young people's mental health services*. 2017 08 January 2019]; Available from: https://epi.org.uk/wp-content/uploads/2018/01/EPI_Access-and-waiting-times.pdf.
7. Michelson, D., et al., *Improving psychiatric diagnosis in multidisciplinary child and adolescent mental health services*. The Psychiatrist, 2011. **35**: p. 454-459.
8. Martin, A.-M., et al., *Practitioners' attitudes towards the use of standardized diagnostic assessment in routine practice: A qualitative study in two Child and Adolescent Mental Health Services*. Clinical Child Psychology and Psychiatry, 2011. **16**(3): p. 407-420.
9. Craddock, N., et al., *Wake-up call for British psychiatry*. British Journal of Psychiatry, 2008. **193**(1): p. 6-9.
10. National Institute for Health and Clinical Excellence. *Depression in Children and Young People: Quality Standard*. 2013 08 January 2019]; Available from: <https://www.nice.org.uk/guidance/cg28>.
11. Fitzpatrick C, A.N.-N., Kehoe A, Devlin N, Glackin S, Power L, et al, *Do we miss depressive disorders and suicidal behaviours in clinical practice*. Clinical Child Psychology and Psychiatry, 2012. **17**: p. 449-458.
12. National Institute for Health and Clinical Excellence. *Depression in Children and Young People: Identification and Management in Primary, Community and Secondary Care – Update*. 2015 08 January 2019]; Available from: <https://www.nice.org.uk/guidance/cg28>.
13. Last, A., Henley, W., Norman, S., Goodman, R., Ford, T., *Innovations in Practice: Feasibility of the development and well-being assessment as an adjunct to clinical assessment in child and adolescent mental health services*. Child and Adolescent Mental Health, 2014. **19**: p. 142-146.
14. Reeves, K., E. Charter, and T. Ford, *Measurement Issues: Is standardised diagnostic assessment feasible as an adjunct to clinical practice? A systematic review*. Child and Adolescent Mental Health, 2016. **21**(1): p. 51-63.
15. Goodman, R., et al., *The Development and Well-Being Assessment: Description and Initial Validation of an Integrated Assessment of Child and Adolescent Psychopathology*. Journal of Child Psychology and Psychiatry, 2000. **41**(5): p. 645-655.
16. Hall, C.L., et al., *Investigating a therapist-guided, parent-assisted remote digital behavioural intervention for tics in children and adolescents—'Online Remote Behavioural Intervention for Tics' (ORBIT) trial: protocol of an internal pilot study and single-blind randomised controlled trial*. BMJ Open, 2019. **9**(1): p. e027583.

17. Pickles, A., et al., *Parent-mediated social communication therapy for young children with autism (PACT): long-term follow-up of a randomised controlled trial*. *The Lancet*, 2016. **388**(10059): p. 2501-2509.
18. Ford, T., et al., *Can standardized diagnostic assessment be a useful adjunct to clinical assessment in child mental health services? A randomized controlled trial of disclosure of the Development and Well-Being Assessment to practitioners*. *Social Psychiatry and Psychiatric Epidemiology*, 2013. **48**(4): p. 583-593.
19. Aebi, M., et al., *The use of the development and well-being assessment (DAWBA) in clinical practice: a randomized trial*. *European child & adolescent psychiatry*, 2012. **21**(10): p. 559-567.
20. Meltzer, H., et al. *The mental health of children and adolescents in Great Britain*. 2000 07 February 2019]; Available from: <http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/r/el/psychiatric-morbidity/the-mental-health-of-children-and-adolescents-in-great-britain/1999-survey/mental-health-of-children-and-adolescents-in-great-britain.pdf>.
21. Green, H., et al. *Mental health of children and young people in Great Britain, 2004*. 2005 07 February 2019]; Available from: <https://webarchive.nationalarchives.gov.uk/20180307185414/http://digital.nhs.uk/catalogue/PUB06116>.
22. Youth in Mind. *Information for researchers and clinicians about the Development and Well-Being Assessment*. 2012 08 January 2019]; Available from: <http://www.dawba.info/>.
23. Angold, A., et al., *Development of a short questionnaire for use in epidemiological studies of depression in children and adolescents*. *International Journal of Methods in Psychiatric Research*, 1995. **5**(4): p. 237-249.
24. Chorpita, B.F., et al., *Assessment of symptoms of DSM-IV anxiety and depression in children: a revised child anxiety and depression scale*. *Behaviour Research and Therapy*, 2000. **38**(8): p. 835-855.
25. Goodman, R., *The Extended Version of the Strengths and Difficulties Questionnaire as a Guide to Child Psychiatric Caseness and Consequent Burden*. *Journal of Child Psychology and Psychiatry*, 1999. **40**(5): p. 791-799.
26. Kroenke, K., R.L. Spitzer, and J.B. Williams, *The PHQ-9: validity of a brief depression severity measure*. *Journal of general internal medicine*, 2001. **16**(9): p. 606-613.
27. Spitzer, R.L., et al., *A brief measure for assessing generalized anxiety disorder: The gad-7*. *Archives of Internal Medicine*, 2006. **166**(10): p. 1092-1097.
28. Stevens, K., *Developing a descriptive system for a new preference-based measure of health-related quality of life for children*. *Quality of Life Research*, 2009. **18**(8): p. 1105-1113.
29. Wille, N., et al., *Development of the EQ-5D-Y: a child-friendly version of the EQ-5D*. *Qual Life Res*, 2010. **19**(6): p. 875-86.
30. Herdman, M., et al., *Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)*. *Quality of Life Research*, 2011. **20**(10): p. 1727-1736.
31. Hoch, J.S., A.H. Briggs, and A.R. Willan, *Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis*. *Health Economics*, 2002. **11**(5): p. 415-430.
32. Gale, N.K., et al., *Using the framework method for the analysis of qualitative data in multi-disciplinary health research*. *BMC Medical Research Methodology*, 2013. **13**(1): p. 117.
33. Furniss, D., A.R. Lang, and C. Ewart, *Enhancing Patient Ergonomics with Patient and Public Involvement in Research Projects*. , in *The Patient Factor: A Handbook on Patient Ergonomics*, R.J. Holden and R.S. Valdez, Editors. 2001, CRC Press.
34. Health Research Authority. *UK Policy Framework for Health and Social Care Research*. 2017 18 December 2018]; Available from: <https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/>

- 1
2
3 35. Wood, A., et al., *Properties of the mood and feelings questionnaire in adolescent psychiatric*
4 *outpatients: a research note.* 1995. **36**: p. 327-334.
5
6 36. Daviss, W.B., et al., *Criterion validity of the Mood and Feelings Questionnaire for depressive*
7 *episodes in clinic and non-clinic subjects.* 2006. **47**: p. 927-934.
8
9 37. Chorpita, B.F., C.E. Moffitt, and J. Gray, *Psychometric properties of the Revised Child Anxiety*
10 *and Depression Scale in a clinical sample.* Behaviour Research and Therapy, 2005. **43**(3): p.
11 309-322.
12
13 38. Yao, S., et al., *Measuring Adolescent Psychopathology: Psychometric Properties of the Self-*
14 *Report Strengths and Difficulties Questionnaire in a Sample of Chinese Adolescents.* Journal
15 of Adolescent Health, 2009. **45**(1): p. 55-62.
16
17 39. Goodman, R., *Psychometric Properties of the Strengths and Difficulties Questionnaire.*
18 Journal of the American Academy of Child & Adolescent Psychiatry, 2001. **40**(11): p. 1337-
19 1345.
20
21 40. Muris, P., C. Meesters, and F. van den Berg, *The Strengths and Difficulties Questionnaire*
22 *(SDQ).* European child & adolescent psychiatry, 2003. **12**(1): p. 1-8.
23
24 41. Lundh, L.G., Wangby-Lundh, M., & Bjarehed, J. , *Self reported emotional and behavioral*
25 *problems in Swedish 14 to 15-year-old adolescents: A study with the self-report version of the*
26 *Strengths and Difficulties Questionnaire.* Scandinavian Journal of Psychology, 2008. **49**: p.
27 523-532.
28
29 42. Perrin, S., R. Meiser-Stedman, and P. Smith, *The children's revised impact of event scale*
30 *(CRIES): Validity as a screening instrument for PTSD.* Behavioural and Cognitive
31 Psychotherapy, 2005. **33**(4): p. 487-498.
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Participant flow



* For sites where the waiting time for the CAMHS acceptance decision usually exceeds 10 working days from referral receipt, recruitment activities may start and/or continue beyond 10 working days from referral receipt, providing the intervention period can be completed prior to the CAMHS referral decision.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STANDARDISED Diagnostic Assessment for children and adolescents with emotional difficulties (STADIA): a multi-centre randomised controlled trial

SCREENING

Site Number:	<input type="text"/>
Screening Number:	<input type="text"/>
Sponsor:	Nottinghamshire Healthcare NHS Foundation Trust
CRF Version:	Final v1.1 – 30 April 2019

Site Number:

--	--	--

Screening Number:

--	--	--	--



REFERRAL SCREENING

Complete for all referrals screened for eligibility:

NHS Number

Local use only

--	--	--	--	--

Trust Number

Local use only

--	--	--	--	--

Date of referral receipt
(dd-mmm-yyyy)

		-										
--	--	---	--	--	--	--	--	--	--	--	--	--

Date of screening
(dd-mmm-yyyy)

		-										
--	--	---	--	--	--	--	--	--	--	--	--	--

Young person's sex

Male Female

Young person's age

If <5 or >17 do not proceed

--	--	--

Has the young person been previously enrolled and randomised in the STADIA trial?

Yes No *If yes, do not proceed*

Does the referral mention any of the following Covid-19 related words/phrases?

*Tick all that apply.*Covid-19 / Covid Coronavirus Lockdown School closure / exams cancelled

Does the referral mention emotional difficulties*?

Yes No *If no, do not proceed*

Is this an emergency or urgent referral (according to local CAMHS triage / SPA team risk assessment)?

Yes No *If yes, do not proceed*

Does the young person have severe learning disability (e.g., the referral mentions this or that they attend a special school for children with severe learning difficulties)?

Yes No Not known *If 'yes' do not proceed**If not known, confirm during telephone eligibility check at enrolment*

1 **Site Number:**

2

3 **Screening Number:**

4



5

6

7 **REFERRAL SCREENING**

8

9 If the young person is <16:	Yes	<input type="checkbox"/>
10 Does the referral information include contact details for a named parent/carer?	No	<input type="checkbox"/>
11 <i>If 'no' await parent/carer contact details before proceeding</i>	N/A	<input type="checkbox"/>
12		
13 If the young person is <16:	Yes	<input type="checkbox"/>
14 Is the named parent/carer a local authority representative designated to care	No	<input type="checkbox"/>
15 for the child/young person?	Not known	<input type="checkbox"/>
16 <i>If 'yes' do not proceed</i>	N/A	<input type="checkbox"/>
17 <i>If not known, confirm during telephone eligibility check at enrolment</i>		
18		
19 If the young person is aged 16 or 17:	Young person	<input type="checkbox"/>
20 Whose contact details are given on the referral form?	Parent/carer	<input type="checkbox"/>
21 <i>If young person contact details are provided, they should be contacted in</i>	Both	<input type="checkbox"/>
22 <i>the first instance</i>	N/A	<input type="checkbox"/>
23		
24		
25		
26		

27

28

29 **EMOTIONAL DIFFICULTIES**

30

31 **Emotional difficulties may be indicated by the use of any of the following key words or phrases.*

32 *Tick all that apply. If 'other' record details and seek advice from the PI or NCTU before proceeding.*

33

34 None	<input type="checkbox"/>
35 Agitated / agitation	<input type="checkbox"/>
36 Anger	<input type="checkbox"/>
37 Anxiety / anxious / generalised anxiety	<input type="checkbox"/>
38 Avoids things/people/places	<input type="checkbox"/>
39 Can't leave the house	<input type="checkbox"/>
40 Completing rituals / asking parents to carry out rituals	<input type="checkbox"/>
41 Compulsions	<input type="checkbox"/>
42 Depressed / depression / low / low mood / sad	<input type="checkbox"/>
43 Difficulties sleeping	<input type="checkbox"/>
44 Distress	<input type="checkbox"/>
45 Fears and worries / fears relating to safety (germs, fire)	<input type="checkbox"/>
46 Feeling low	<input type="checkbox"/>
47 Feels flat / empty / blank	<input type="checkbox"/>
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1 **Site Number:**

--	--	--

2
3
4 **Screening Number:**

--	--	--	--



EMOTIONAL DIFFICULTIES

**Emotional difficulties may be indicated by the use of any of the following key words or phrases.*

Tick all that apply. If 'other' record details and seek advice from the PI or NCTU before proceeding.

13 Feels hopeless	<input type="checkbox"/>
14 Feels worthless / stupid	<input type="checkbox"/>
16 Flashbacks	<input type="checkbox"/>
19 Hypervigilance	<input type="checkbox"/>
21 Irritable	<input type="checkbox"/>
23 Low motivation	<input type="checkbox"/>
25 Low self-esteem / Hates self	<input type="checkbox"/>
27 Mood swings / moody	<input type="checkbox"/>
29 Negative thoughts	<input type="checkbox"/>
31 Nightmares (if trauma also present)	<input type="checkbox"/>
33 No (or loss of) energy	<input type="checkbox"/>
35 No (or loss of) interest in things / gave up... / lack of wanting to do things	<input type="checkbox"/>
37 Not going to school / unable to go to school	<input type="checkbox"/>
39 Not sleeping / poor sleep	<input type="checkbox"/>
41 Obsessions	<input type="checkbox"/>
43 OCD	<input type="checkbox"/>
45 Phobia	<input type="checkbox"/>
47 Panic / panic attacks	<input type="checkbox"/>
49 PTSD	<input type="checkbox"/>
51 Self-harm / DSH / Cutting	<input type="checkbox"/>
53 Suicidal	<input type="checkbox"/>
55 Suicidal thoughts / thoughts of ending life / thinks about killing self	<input type="checkbox"/>
57 Tearful	<input type="checkbox"/>
59 Thoughts of death	<input type="checkbox"/>

1 **Site Number:**

2 | | |

3 **Screening Number:**

4 | | | |



7 **EMOTIONAL DIFFICULTIES**

8 **Emotional difficulties may be indicated by the use of any of the following key words or phrases.*

9 *Tick all that apply. If 'other' record details and seek advice from the PI or NCTU before proceeding.*

10 Tiredness / fatigue	<input type="checkbox"/>
11 Touching objects	<input type="checkbox"/>
12 Trauma	<input type="checkbox"/>
13 Weepy	<input type="checkbox"/>
14 Withdrawal / withdrawn	<input type="checkbox"/>
15 Worried / worrying (incl. worries/concerns about their appearance)	<input type="checkbox"/>
16 Other (please specify)	<input type="checkbox"/>

20 **FOR ALL REFERRALS SCREENED, ENTER SUMMARY DATA ON THE SCREENING & ENROLMENT LOG.**

21 **IF THE YOUNG PERSON APPEARS TO BE ELIGIBLE PROCEED TO THE INVITATION TELEPHONE CALL (CALL 1)**

22 **AND ENTER DETAILS ON THE TRIAL DATABASE.**

30 **SIGN-OFF STATEMENT**

31 *Completed by the researcher conducting the referral screening.*

32 To the best of my knowledge, I confirm that I have made every reasonable effort to ensure that ALL of

33 the data in this Case Record Form is a true, accurate and complete report.

34 Print Name

35 Signature

36 Date

37 | | | - | | | | | - | | | | |

DAWBA Report

The DAWBA collects information about a range of common emotional and behavioural difficulties, and uses this information to produce a report to highlight the level of difficulties.

How to understand the ratings

These ratings compare your responses with the responses from large numbers of other parents and young people across the UK. Many parents and young people find this sort of comparison helpful, but it is just a guide and not the same as a face-to-face assessment with a specialist.

To make it easier to read, we have grouped the ratings into four categories. Each category is different. This shows how your [child's] (*delete as appropriate*) difficulties compare with other children / young people:



Close to average

In the general population most children/ young people (roughly 80 out of 100) are in the "close to average" category.



Slightly raised

If the ratings are in the "slightly raised" category this means the difficulties are slightly higher than average. Roughly 10 out of 100 children / young people are in this category.



High

Around 5 in 100 children / young people score in the "high" category. This means that the difficulties are more severe than average.



Very high

Around 5 in 100 children score in the "very high" category. This means that the difficulties appear to be more severe than we find in 95 out of every 100 children / young people.



The rating is only a rough guide. As high ratings can be a "false alarm", please use your own judgement. Not all difficulties need treating. Some difficulties get better by themselves, particularly if they are mild or if they have only been there for a short time.

Most strengths and difficulties lie on a scale. There will be children / young people at each end of the scale but most children / young people will fall somewhere in between.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Your [child's] (*delete as appropriate*) ratings:

- **Close to average / Slightly raised / High / Very high** for worrying a lot about different things (general fears and worries)
- **Close to average / Slightly raised / High / Very high** for worries about separation from key "attachment figures" such as parents (separation anxiety)
- **Close to average / Slightly raised / High / Very high** for specific fears (specific phobia)
- **Close to average / Slightly raised / High / Very high** for social fears (social anxiety)
- **Close to average / Slightly raised / High / Very high** for panic attacks
- **Close to average / Slightly raised / High / Very high** for fears of crowds, public places, open spaces etc (agoraphobia)
- **Close to average / Slightly raised / High / Very high** for stress linked to particularly frightening events (post-traumatic stress)
- **Close to average / Slightly raised / High / Very high** for obsessions or compulsions
- **Close to average / Slightly raised / High / Very high** for depression or loss of interest
- **Close to average / Slightly raised / High / Very high** for disruptive and uncooperative behaviours (troublesome behaviour)
- **Close to average / Slightly raised / High / Very high** for antisocial or aggressive behaviours that can get people into serious trouble (troublesome behaviour)

1
2
3 **APPENDICES**
4

5 *Appendix 1. Screening form*
6
7

8
9 *Appendix 2. Template DAWBA report*
10

11
12 *Appendix 3. Eligible emotional disorder diagnoses*
13

Anxiety disorder
Separation anxiety disorder
Specific phobia (any)
Social phobia or Social anxiety disorder
Agoraphobia
Panic disorder (DSM5 additionally has Panic Attack with a specifier)
Phobic anxiety disorder (unspecified)
Selective mutism
Generalized anxiety disorder
Obsessive-compulsive and related disorders
Body dysmorphic disorder
Acute stress reaction
Post-traumatic stress disorder
Adjustment Disorder
Other anxiety disorder
Mixed anxiety and depressive disorder
Depression
Depressive episode (any / mild / moderate / severe)
Depressive disorder
Recurrent depressive disorder (any / mild / moderate / severe)
Major Depressive disorder
Persistent Depressive disorder
Other depressive episode
Persistent mood (affective) disorder (including cyclothymic disorder / dysthymic disorder)
Other / Unspecified mood (affective) disorder
Bipolar disorder
Bipolar affective disorder
Manic episode
Childhood emotional disorder unspecified (F93.9)

14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51 *Appendix 4. Outcome Definition and Adjudication Plan*
52
53
54
55
56
57
58
59
60

Appendix 5. Secondary outcome definitions

Outcome	Measurement	Definition
Acceptance of index referral	Collected from records	Whether the index referral (i.e., the referral made to CAMHS at the point of recruitment to the STADIA trial) was accepted or declined. Acceptance is defined as being offered an appointment within CAMHS, whether or not the initial appointment was attended or subsequent appointments were offered/attended.
Acceptance of any referral within 12 months of randomisation	Collected from records	Whether the index referral or any subsequent referral to CAMHS (if made) was accepted or not. Acceptance as defined above for index referral.
Discharge from CAMHS within 12 months	Collected from records	Whether the CYP was discharged from CAMHS (following acceptance of the index referral) during the 12-months post-randomisation.
Re-referral to CAMHS within 12 months	Collected from records	Whether the CYP was re-referred to CAMHS (for those whose index referral was turned down by CAMHS or those whose index referral was accepted but were subsequently discharged) during the 12-months post-randomisation.
Confirmed diagnosis decision	Collected from records	Diagnosis of an emotional disorder or confirmed absence of an emotional disorder coded as 'yes' vs. uncertainty about the presence of an emotional disorder coded as 'no'. Diagnosis as defined for primary outcome.
Time from randomisation to diagnosis of emotional disorder	Collected from records	Date of diagnosis will be the first documented eligible diagnosis. Diagnosis as defined for primary outcome.
Diagnoses made over the 12 month period from randomisation	Collected from records	The diagnosis must be documented in the clinical record within 12 months of randomisation by a mental health services clinician in an NHS-delivered or NHS-commissioned service. All diagnoses made within 12 months will be included.
Treatment offered for diagnosed emotional disorder	Collected from records	Whether treatment was offered for a diagnosed emotional disorder, as defined for primary outcome.
Any treatment / interventions given	Collected from records	All treatments/interventions offered by CAMHS for any reason within 12 months of randomisation, whether or not there is a documented diagnosis will be included.
Time from randomisation to the decision to offer treatment for a diagnosed emotional disorder	Collected from records	Date of decision will be the first date that the decision to offer treatment for a diagnosed emotional disorder is documented in the clinical notes.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Outcome	Measurement	Definition
Time from randomisation to start of first treatment for a diagnosed emotional disorder	Collected from records	Date of treatment will be the first date that any treatment offered for a diagnosed emotional disorder is started. Treatment and diagnosed emotional disorder as defined.
Time from randomisation to the decision to offer any treatment	Collected from records	Date of decision will be the first date that the decision to offer any treatment is documented in the clinical notes.
Time from randomisation to start of any treatment	Collected from records	Date of treatment will be the first date that any treatment offered is started. Treatment as defined.
Participant-reported diagnoses received in the 12 months post-randomisation	Participant self-report	Participants will be asked to report whether or not they received a diagnosis of the CYP's difficulties from CAMHS in the 12 months post-randomisation and if so, what diagnosis was given and by whom.
Depression symptoms in the CYP	Mood and Feelings Questionnaire (MFQ)	Mood and Feelings Questionnaire (MFQ) [23] MFQ is a valid and reliable measure of depression in CYP.[35, 36] 33-items are answered on a 3-point scale ("not true" = 0, "somewhat true" = 1 point, "true" = 2 points). Scores range from 0 to 66 with higher scores indicating more severe depressive symptoms. A score of 27 or higher may be indicative of depression.

Outcome	Measurement	Definition
Anxiety symptoms in the CYP	Revised CYP's Anxiety Depression Scale (RCADS)	<p>Revised CYP's Anxiety and Depression Scale (RCADS)[24]</p> <p>RCADS is a 47-item questionnaire that measures the reported frequency of various symptoms of anxiety and low mood. Each item is rated on a 4-point scale (never = 0, sometimes = 1, often = 2, always = 3).</p> <p>An overall anxiety and low mood score is generated, with separate sub-scale scores for separation anxiety, social phobia, generalised anxiety, panic, obsessive compulsive disorder and major depression.</p> <p>RCADS demonstrates good psychometric properties.[37]</p> <p>Total anxiety and depression scores range from 0 to 141.</p> <p>We will record scores for each of the 6 sub-scales. For analysis metric, we will use the total anxiety score.</p>
Comorbid oppositional defiant / conduct disorder symptoms in the CYP	Strengths and Difficulties Questionnaire (SDQ)	<p>Strengths & Difficulties Questionnaire (SDQ):[25] A 25-item emotional and behavioural screening questionnaire for CYP.</p> <p>Each item is rated on a 3-point scale (not true, somewhat true, certainly true). Values of 0, 1 or 2 are assigned to each response.</p> <p>SDQ comprises 5 sub-scales and an impact supplement. The impact supplement asks effect of difficulties on homelife, friendships, education and leisure activities.</p> <p>SDQ has demonstrated reasonable psychometric properties.[38-41]</p> <p>Scores on the 'conduct problems' subscale will be used in the analysis of this outcome.</p> <p>Sub-scale scores range from 0 to 10.</p>
Functional Impairment in the CYP	Strengths and Difficulties Questionnaire (SDQ)	Impact supplement scores will be used to determine functional impairment. Impact scores range from 0 to 10.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Outcome	Measurement	Definition
Self-harm thoughts in the CYP	CYP self-report self-harm measure	CYP will be asked to report the frequency of thoughts of self-harm. Frequency of thoughts of self-harm are rated over the last 6 months in the following categories and scored accordingly: Not at all (0) Once or twice (1) Three or more times (2)
Self-harm behaviour in the CYP	CYP self-report self-harm measure	CYP will be asked to report frequency of instances of self-harm behaviour. Frequency of self-harm behaviour are rated over the last 6 months in the following categories and scored accordingly: Not at all (0) Once (1) Two or more times (2)
Depression symptoms in the parent/carer	Patient Health Questionnaire (PHQ-9)	PHQ-9:[26] PHQ-9 is frequently used as a screening tool for depression in general populations. Each of the nine DSM-IV depression criteria are scored as "0" (not at all) to "3" (nearly every day) depending on the frequency with which they were experienced over the last 2 weeks. Total scores range from 0 to 27 with higher scores indicating increased severity of depression.
Anxiety symptoms in the parent/carer	Generalised Anxiety Disorder Assessment (GAD-7)	GAD-7:[27] GAD-7 is a measure of the severity of anxiety in general populations. 7 items are rated according to the frequency with which they have been experienced over the past 2 weeks (0 = 'not at all', 1 = 'several days', 2 = 'more than half the days', and 3 = 'nearly every day'). Total scores range from 0 to 21 with higher scores indicating more severe anxiety.
Time off education, employment or training because of emotional difficulties for the CYP	Resource use questionnaire	Days missed from education, employment or training (as applicable) for the CYP due to emotional difficulties.

Appendix 6. Summary of assessments

Time-point	Maximum 10 working days from referral receipt ¹			6 months post-randomisation	12 months post-randomisation	
Activity	Screening and invitation	Eligibility and enrolment	Consent and baseline	Intervention	Follow-Up	
Initial eligibility screen of referral information	X					Randomisation DAWBA in addition to usual practice Or Usual practice only
Telephone invitation to participate	X					
Verbal agreement to participate		X				
Confirm eligibility		X				
Obtain enrolment data		X				
Participant enrolment		X				
Written informed consent/assent (online)			X			
Baseline demographics (parent/carer and CYP aged 16 & 17)			X			
Mood and Feelings Questionnaire (MFQ)			X	X	X	
Revised Child's Anxiety Depression Scale (RCADS)			X	X	X	
Strengths and Difficulties Questionnaire (SDQ) ²			X	X	X	
Child Revised Impact of Events Scale (CRIES-8)[42] ³			X	X	X	
CYP self-report self-harm measure			X	X	X	
Patient Health Questionnaire (PHQ-9) - parent/carer only			X	X	X	
Generalised Anxiety Disorder Assessment (GAD-7) - parent/carer only			X	X	X	
Child Health Utility 9D (CHU9D)			X	X	X	
EuroQol-5D youth (EQ-5D-Y)			X	X	X	
EuroQol-5D five level (EQ-5D-5L)			X	X	X	
Resource Use Questionnaire - parent/carer and CYP aged 16 & 17			X	X	X	
Data collection from records ⁴			X	X	X	

¹ For sites where the waiting time for the CAMHS acceptance decision usually exceeds 10 working days from referral receipt, recruitment activities may start and/or continue beyond 10 working days from referral receipt, providing the intervention period can be completed prior to the CAMHS referral decision.
² For participants in the intervention arm, the baseline SDQ will be collected as part of the DAWBA, completed post-randomisation.
³ Additional data collection undertaken to explore post-traumatic stress disorder symptoms in CYP during the Covid-19 pandemic
⁴ Data collection from records will be completed periodically throughout the 12 month follow-up period.



STANDARDISED Diagnostic Assessment for children and adolescents with emotional difficulties (STADIA):
A multi-centre randomised controlled trial

OUTCOME DEFINITION & ADJUDICATION PLAN

Final 1.0 – 25 February 2020

EMOTIONAL DISORDER DIAGNOSES RECORDED IN THE 12 MONTHS POST-RANDOMISATION

CONSTITUTES A CLINICAL DIAGNOSIS	REFER FOR ADJUDICATION	DOES NOT CONSTITUTE A CLINICAL DIAGNOSIS
<ul style="list-style-type: none"> - The presence of an <u>eligible diagnosis</u> within the diagnosis tab of the clinical record. - The presence of an <u>eligible diagnosis</u> in the clinical record preceded by the heading 'diagnosis'. - The presence of an <u>eligible diagnosis</u> in the clinical record preceded by a heading such as 'current difficulties' or 'presenting problems', except where this has been documented in the write up of the first appointment or in reference to the information received at referral (as this may simply reflect a pre-existing or referrer-made diagnosis). - A clear confirmatory statement including use of an <u>eligible diagnosis</u>, for example: <i>Meets the diagnostic criteria for...</i> <i>Presentation is explained by a diagnosis of...</i> 	<ul style="list-style-type: none"> - The presence of <u>similar diagnostic terms</u> within the diagnosis tab of the clinical record. - The presence of an <u>eligible diagnosis</u> preceded by a heading such as 'current difficulties' or 'presenting problems', documented in the write up of the first appointment or in reference to the information received at referral. - The presence of <u>similar diagnostic terms</u> preceded by a heading such as 'diagnosis', 'current difficulties' or 'presenting problems'. - Reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>, but where the context does not provide a clear confirmatory statement, for example: <i>?...</i> <i>Possible...</i> <i>Assessed for...</i> <i>...-type symptoms / behaviour</i> <i>...-like symptoms / behaviour</i> <i>Symptoms of...</i> <i>History of...</i> 	<ul style="list-style-type: none"> - No reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>. - A clear statement about the absence of an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>, for example: <i>No evidence of...</i> <i>...not meeting criteria for disorder</i>
<i>Data collection and entry: instructions for researchers</i>		
<i>Use the checklist of eligible emotional disorder diagnoses.</i>	<i>Document these as other emotional disorders.</i>	<i>Check 'none of the above' in the checklist of emotional disorder diagnoses and answer 'no' to 'other emotional disorder diagnoses'.</i>

Note: For definition of underlined terms see the Glossary below.

NO EMOTIONAL DISORDER

If there are no emotional disorder diagnoses documented in the CAMHS notes in 12 months post-randomisation, researchers will select one of the following options:

1. A clinician has documented the absence of emotional disorder.
2. Uncertainty about the presence of an emotional disorder is documented in the notes (for example, reflecting ongoing assessment / investigation).
3. There is no diagnostic information relating to emotional disorders documented in the CAMHS record.

A clinician has documented the <u>absence</u> of emotional disorder.	Uncertainty about the presence of an emotional disorder is documented in the notes (for example, reflecting ongoing assessment / investigation).	There is <u>no diagnostic information</u> relating to emotional disorders documented in the CAMHS record.
<ul style="list-style-type: none"> - Nothing in the clinical record is assessed to constitute a documented clinical diagnosis, AND - There is a clear statement about the absence of one or more of the <u>eligible diagnoses</u> or <u>similar diagnostic terms</u>, for example: <div style="text-align: center;"><i>No evidence of...</i> <i>...not meeting criteria for disorder</i></div> 	<ul style="list-style-type: none"> - Nothing in the clinical record is assessed to constitute a documented clinical diagnosis, AND - Reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>, but where the context does not provide a clear confirmatory statement, for example: <div style="text-align: center;">?... <i>Possible...</i> <i>Assessed for...</i> <i>...-type symptoms / behaviour</i> <i>...-like symptoms / behaviour</i> <i>Symptoms of...</i> <i>History of...</i></div> 	<ul style="list-style-type: none"> - Nothing in the clinical record is assessed to constitute a documented clinical diagnosis, AND - There is no reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>.* - If emotional difficulties are identified they are described only by reference to the presenting symptoms with no attempt made to link these to an eligible diagnosis, for example: <div style="text-align: center;"><i>Presenting issue - Mood swings</i> <i>Describing examples of ruminating thoughts.</i></div> <p>* Note that this includes children/young people who have <u>not been seen by CAMHS</u> in the 12-months post-randomisation.</p>
<i>Document these as absence of emotional disorder.</i>	REFER FOR ADJUDICATION	MAY REQUIRE ADJUDICATION

EMOTIONAL DISORDER DIAGNOSIS ADJUDICATION OUTCOME

<p>The Adjudication Committee will first consider whether the record:</p> <ol style="list-style-type: none"> 1) Constitutes a clinical diagnosis 2) Does not constitute a clinical diagnosis 	<p>If (1) then the Adjudication Committee will determine which of the eligible emotional disorder diagnoses apply.</p> <p>If (2) then the Adjudication Committee will determine whether the record constitutes:</p> <ol style="list-style-type: none"> a) Absence of emotional disorder b) Uncertainty about the presence of emotional disorder c) No diagnostic information
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

TREATMENTS / INTERVENTIONS GIVEN

CONSTITUTES A TREATMENT / INTERVENTION	REFER FOR ADJUDICATION
- The presence of an <u>eligible treatment / intervention</u> documented within the clinical record.	- Documented intervention by CAMHS where the description does not include an <u>eligible treatment / intervention</u> .
<i>Data collection and entry: instructions for researchers</i>	
<i>Use the checklist of eligible treatments / interventions.</i>	<i>Document these as other treatments / interventions.</i>

TREATMENTS / INTERVENTIONS ADJUDICATION OUTCOME

The Adjudication Committee will first consider whether the record: 1) Constitutes a treatment / intervention 2) Does not constitute a treatment / intervention	If (1) then the Adjudication Committee will determine whether the record should be categorised: a) As an existing treatment / intervention b) As an 'other' treatment / intervention
----------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GLOSSARY

Eligible diagnosis	One of the pre-specified diagnoses listed on the data collection form. These should be considered present only when the <u>exact phrase</u> and/or corresponding ICD/DSM code is documented.
Similar diagnostic terms	Words or phrases which are similar to the eligible diagnoses, but without use of the exact wording or corresponding ICD/DSM code (e.g., separation anxiety WITHOUT use of the term disorder) or where the exact words are used alongside additional phrases (e.g., OCD-type behaviour or OCD-like symptoms).
Eligible treatment / intervention	One of the pre-specified treatments / interventions listed on the data collection form.
Adjudication Committee	The Adjudication Committee will comprise the clinician members of the Trial Management Group. A minimum of two clinicians will review terms referred for adjudication, with a third consulted if a consensus is not reached. The Adjudication Committee will be blinded to treatment allocation for the purposes of adjudication.

BMJ Open

STANDARDISED Diagnostic Assessment for children and young people with emotional difficulties (STADIA): protocol for a multi-centre randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053043.R1
Article Type:	Protocol
Date Submitted by the Author:	25-Feb-2022
Complete List of Authors:	<p>Day, Florence; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Wyatt, Laura; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Bhardwaj, Anupam; Cambridgeshire and Peterborough NHS Foundation Trust</p> <p>Dubicka, Bernadka; The University of Manchester; Pennine Care NHS Foundation Trust</p> <p>Ewart, Colleen; University of Nottingham, STADIA Patient and Public Involvement co-lead, Institute of Mental Health</p> <p>Gledhill, Julia; Central and North West London NHS Foundation Trust</p> <p>James, Marilyn; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Lang, Alexandra; University of Nottingham, Faculty of Engineering</p> <p>Marshall, Tamsin; Berkshire Healthcare NHS Foundation Trust</p> <p>Montgomery, Alan; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Reynolds, Shirley; University of Reading, School of Psychology and Clinical Language Sciences</p> <p>Sprange, Kirsty; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Thomson, Louise; University of Nottingham, Institute of Mental Health, School of Medicine</p> <p>Bradley, Ellen; University of Nottingham, Institute of Mental Health, School of Medicine</p> <p>Lathe, James; University of Nottingham, Nottingham Clinical Trials Unit, University of Nottingham</p> <p>Newman, Kristina; Nottinghamshire Healthcare NHS Foundation Trust, Institute of Mental Health</p> <p>Partlett, Chris; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Starr, Kath; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Sayal, Kapil; University of Nottingham, Institute of Mental Health, School of Medicine; Nottinghamshire Healthcare NHS Foundation Trust, Institute of Mental Health</p>
Primary Subject Heading:	Mental health

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Mental health
Keywords:	Child & adolescent psychiatry < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY, HEALTH ECONOMICS



1
2
3 **1 STandardised Diagnostic Assessment for children and young people with emotional difficulties**
4 **(STADIA): protocol for a multi-centre randomised controlled trial**
5
6

7 **4 Authors:**

8 Florence Day^{1*}, Laura Wyatt^{1*}, Anupam Bhardwaj², Bernadka Dubicka³, Colleen Ewart⁴, Julia Gledhill⁵,
9 Marilyn James¹, Alexandra Lang⁶, Tamsin Marshall⁷, Alan Montgomery¹, Shirley Reynolds⁸, Kirsty
10 Sprange¹, Louise Thomson⁹, Ellen Bradley⁹, James Lathe¹, Kristina Newman¹⁰, Chris Partlett¹, Kath
11 Starr¹ & Kapil Sayal^{9,10}

12 *joint first authors
13

14 **11 Corresponding author:**

15 Professor Kapil Sayal
16 Institute of Mental Health
17 School of Medicine
18 University of Nottingham
19 Nottingham, NG8 1BB
20

21 Email: kapil.sayal@nottingham.ac.uk
22
23
24
25

26 Word count, excluding title page, abstract, references, figures and tables: 4339
27

28 1 Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham NG7
29 2RD

30 2 Cambridge and Peterborough Foundation Trust, Brookside CAMHS, Cambridge CB2 8AH

31 3 Pennine Care NHS Foundation Trust, Ashton-under-Lyne OL6 7SR

32 4 STADIA Patient and Public Involvement co-lead, Institute of Mental Health, University of
33 Nottingham, Nottingham NG8 1BB

34 5 Central and North West London NHS Foundation Trust, Harrow CAMHS, Ash Tree Clinic, South
35 Harrow HA2 8EQ

36 6 Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD

37 7 Berkshire Healthcare NHS Foundation Trust, Fitzwilliam House, Bracknell RG12 1BQ

38 8 School of Psychology and Clinical Language Sciences, University of Reading, Reading RG6 6DZ

39 9 Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham NG8 1BB

40 10 Nottinghamshire Healthcare NHS Foundation Trust, Institute of Mental Health, Nottingham NG8
41 1BB
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 38 **ABSTRACT**
4
5 39

6 40 **Introduction**

7 41 Emotional disorders (such as anxiety and depression) are associated with considerable distress and
8 42 impairment in day-to-day function for affected children and young people and for their families.
9 43 Effective evidence-based interventions are available but require appropriate identification of
10 44 difficulties to enable timely access to services. Standardised Diagnostic Assessment (SDA) tools may
11 45 aid in the detection of emotional disorders, but there is limited evidence on the utility of SDA tools
12 46 in routine care and equipoise amongst professionals about their clinical value.
13 47

14 48 **Methods and analysis**

15 49 A multi-centre, two-arm, parallel group RCT, with embedded qualitative and health economic
16 50 components. Participants will be randomised in a 1:1 ratio to either the Development and Wellbeing
17 51 Assessment (DAWBA) SDA tool as an adjunct to usual clinical care, or usual care only.
18 52

19 53 A total of 1,210 participants (Children and Young People referred to outpatient, specialist Child and
20 54 Adolescent Mental Health Services (CAMHS) with emotional difficulties and their parent/carers) will
21 55 be recruited from at least 6 sites in England.
22 56

23 57 The primary outcome is a clinician-made diagnosis about the presence of an emotional disorder
24 58 within 12-months of randomisation. Secondary outcomes include referral acceptance, diagnosis and
25 59 treatment of emotional disorders, symptoms of emotional difficulties and comorbid disorders and
26 60 associated functional impairment.
27 61

28 62 **Ethics and dissemination**

29 63 The study received favourable opinion from the South Birmingham Research Ethics Committee (Ref.
30 64 19/WM/0133). Results of this trial will be reported to the funder and published in full in the HTA
31 65 Journal series and also submitted for publication in a peer reviewed journal.
32 66

33 67 **Registration details**

34 68 The STADIA trial was prospectively registered as ISRCTN15748675 on 29 May 2019.
35 69

36 70 **Keywords**

37 71 RCT; CAMHS; standardised diagnostic assessment; DAWBA; emotional disorders; diagnosis;
38 72 outcomes; health economics; cost effectiveness; cost utility.
39 73
40 74

41 75 **ARTICLE SUMMARY**
42 76

43 77 **Strengths and limitations of this study**

- 44 78
- 45 79 • Large real-world multicentre randomised controlled trial of the DAWBA SDA tool as an adjunct
46 80 to usual care versus usual care only.
 - 47 81 • Trial procedures are carried out remotely with all data collection and the DAWBA completed
48 82 online or via telephone, facilitating post-trial implementation into future service delivery models
49 83 and routine clinical care.
 - 50 84 • The embedded health economic component permits evaluation of both clinical and cost
51 85 effectiveness.
 - 52 86 • Embedded qualitative work will support optimal delivery and implementation to enhance
53 87 acceptability, effectiveness and long-term uptake.
 - 54 88 • Participants, researchers and clinicians cannot be blinded to treatment allocation.
- 55 89
56 90

89 INTRODUCTION

90
91 Emotional disorders cause considerable distress for affected Children and Young People (CYP) and
92 their families, with adverse effects on family and peer relationships, quality of life, social
93 involvement and activities, academic attainment and occupational opportunities, ultimately
94 affecting life chances.(1-4) Emotional disorders are frequently comorbid with other disorders (2, 5),
95 and are associated with self-harm and completed suicide. Effective evidence-based interventions are
96 available but require appropriate identification of presenting difficulties to enable timely access to
97 services and earlier recovery.(3)

98
99 The prevalence of emotional disorders has increased considerably over the past two decades.(1) In
100 the UK, CYP with clinically significant emotional difficulties may be referred to outpatient specialist
101 Child and Adolescent Mental Health Services (CAMHS). However, insufficient information is a
102 common reason for referrals being declined.(6) There is limited evidence to inform optimal
103 approaches to determine which referrals should be accepted, contributing to a large variation in
104 acceptance rates.(6) Likewise there is a lack of evidence on how best to conduct assessments for
105 suspected emotional difficulties to optimise outcomes. Acceptance criteria and assessment
106 procedures differ across services and there is no single standardised approach.

107
108 The multi-disciplinary nature of CAMHS means CYP are assessed by practitioners from different
109 professional backgrounds, with variations in training, ethos and conceptualisations of presenting
110 difficulties. The type and scope of assessments offered vary. Assessments are often conducted by
111 practitioners without formal diagnostic training(7) and recording of potential diagnostic information
112 can be influenced by patient, clinician and service related contextual considerations(8). The validity
113 and value of mental health diagnoses have been questioned, reflecting concerns around restricting
114 service access (9), stigma or labelling.(7, 10, 11) This can mean that in routine practice, assessments
115 are often undertaken without the aim of making or recording a diagnosis.

116
117 However, NICE guidelines for management and treatment are usually based on diagnostic
118 classification of disorders, so the ability to offer evidence-based interventions requires that the CYP's
119 difficulties are appropriately identified. Although NICE Quality Standards(12) state that CYP with
120 suspected depression should have the diagnosis confirmed and recorded, this is highly variable in
121 practice.(7, 13) The use of diagnostic assessments has been recommended so that important
122 problems are detected and appropriate interventions are offered.(3, 11) The NICE guidelines for
123 depression have recommended the use of standardised diagnostic assessment (SDA) tools as
124 potential adjuncts in the detection of depression within CAMHS.(14) It has further been
125 recommended that SDA tools should be used as an adjunct to clinical assessments, potentially at the
126 point of referral receipt, to enable the allocation of cases to the most appropriate professional.(10,
127 15, 16)

128
129 One such SDA tool is the Development and Well-Being Assessment (DAWBA), a structured package
130 of questionnaires and interviews which can be completed online or by telephone and yields
131 algorithm-based diagnostic information.(17) The DAWBA has established reliability and validity (17)
132 and has been widely used for screening, diagnosis and outcome measurement in research in both
133 clinical and community settings (18, 19), including trials of SDAs (20, 21) and large scale
134 epidemiological research.(1, 22, 23) A previous randomised controlled trial (RCT) using the DAWBA
135 highlighted that, for emotional disorders, disclosing DAWBA diagnosis information to clinicians can
136 improve the level of agreement between the DAWBA and clinical diagnoses, suggesting that the
137 DAWBA can aid clinical detection of emotional disorders.(21) It also improved detection of comorbid
138 disorders. A UK trial found higher levels of agreement between DAWBA and clinical diagnoses,
139 following disclosure of DAWBA information, in relation to anxiety disorders.(20) Practitioners

1
2
3 140 acknowledged that the additional information could supplement the assessment and aid detection
4 141 of difficulties.(10)

5 142
6 143 Hence, it might be expected that the introduction of an SDA tool following CAMHS referral receipt
7 144 could enable resources to be better targeted and a timely conclusion to assessments with a
8 145 diagnostic decision, increase the likelihood that an appropriate evidence-based treatment is offered,
9 146 and lead to improved outcomes and better experience of care for CYP and their families. However,
10 147 there is limited evidence on the utility of SDA tools for informing optimal approaches to assessment
11 148 within routine clinical practice.

12 149

13 150 **Aims and Objectives**

14 151 The aim is to evaluate the clinical and cost effectiveness of the DAWBA SDA tool, as an adjunct to
15 152 usual clinical care for CYP presenting with emotional difficulties referred to CAMHS.

16 153

17 154 Specific objectives are to:

- 18 155
19 156
20 157
21 158
22 159
23 160
24 161
25 162
26 163
27 164
28 165
29 166
30 167
31 168
32 169
33 170
34 171
35 172
36 173
37 174
38 175
39 176
40 177
41 178
42 179
43 180
44 181
45 182
46 183
47 184
48 185
49 186
50 187
51 188
52 189
53 190
54 191
55 192
56 193
57 194
58 195
59 196
60 197
1. Conduct an RCT to determine the effectiveness of the DAWBA as an adjunct to usual clinical care on diagnosis and treatment of emotional disorders, symptoms of emotional difficulties and comorbid disorders and associated functional impairment.
 2. Undertake an internal pilot to assess recruitment and acceptability.
 3. Include a qualitative component within the pilot phase to address:
 - a) The feasibility of recruitment.
 - b) The acceptability and usability of the interventions and procedure.
 - c) How the intervention is used and could be refined for the main trial.
 4. Conduct a process evaluation alongside the main trial which will:
 - a) Optimise the design and delivery of the DAWBA to enhance acceptability, effectiveness and long-term uptake.
 - b) Identify the barriers and facilitators to implementation of the DAWBA from the perspectives of CYP, parents, and CAMHS practitioners, managers and commissioners.
 5. Estimate cost effectiveness of the use of the DAWBA versus usual care.
 6. Make evidence-based recommendations for assessment procedures within CAMHS and produce practice guidelines for clinical decision-making around the referral acceptance and assessment processes.

177

178

179 **METHODS AND ANALYSIS**

180

181 **Design**

182 A multi-centre, two-arm, parallel group RCT, with embedded qualitative and health economic
183 components.

184

185 An internal pilot period, completed in the first 9 months of recruitment, will determine feasibility of
186 recruitment and follow-up, assessed by the independent Trial Steering Committee against pre-
187 defined stop/go criteria. The study start date is 01-Nov-2018 and end date is 31-Oct-2022.

188

189 **Setting**

190

191

192

190 Recruitment will take place in at least six NHS Trusts in England, providing outpatient
 191 multidisciplinary specialist CAMHS. Sites are geographically dispersed covering urban and rural
 192 areas, thus are likely to be socio-demographically representative of CAMHS referrals in England,
 193 enabling nationally generalisable findings.

195 **Recruitment and eligibility**

196 **Participant identification**

197 The population is CYP presenting with emotional difficulties referred to CAMHS. Participants are
 198 identified through the usual referral pathways for the participating sites, which includes NHS and
 199 local authority managed Single/Central Point of Access referral points as well as referrals directly
 200 received and processed by CAMHS teams.

201
 202 The STADIA researchers (NHS personnel, based within the CAMHS SPA/triage team to carry out
 203 research activities on behalf of the team and authorised to access referral information) at each site
 204 review the referrals received by CAMHS to identify CYP presenting with emotional difficulties,
 205 according to a standard proforma (Appendix 1. Screening form). Referrals that mentioned any
 206 current emotional difficulties will be included, regardless of the number, frequency or severity of the
 207 emotional difficulties. Potentially eligible participants are invited to consider taking part in the trial
 208 and provided with written information. The initial invitation follows standardised wording to ensure
 209 clarity and consistency of approach.

210
 211 Identification of participants takes place after referral receipt, but prior to referral acceptance
 212 (Figure 1).

214 **Consent**

215 Prior to consent, eligibility will be confirmed (table 1) during telephone contact with the local STADIA
 216 researcher, who will also provide written and verbal information about the trial, answer questions
 217 and support the electronic consent/assent process. Participants who are eligible and provide verbal
 218 consent to participation during the call will be provided with a personal link to the online electronic
 219 Informed Consent/Assent Form (table 2, appendix 6 and 7, respectively), enabling them to provide
 220 written informed consent/assent.

222 Table 1. Eligibility criteria

223 *Inclusion criteria for the CYP*

- Aged 5 to 17 years.
- Referred to outpatient multidisciplinary specialist CAMHS.
- Presenting with emotional difficulties.
- If aged <16, has an eligible individual with parental responsibility (see parent/carer eligibility criteria below) willing and able to participate in the trial.
- If aged 16-17, has capacity to provide valid written informed consent.
- If aged 16-17 and participating without a parent/carer, able to complete the assessment tool in English.
- If aged 16-17 and participating without a parent/carer, access to internet and email or telephone.

Exclusion criteria for the CYP

- Emergency or urgent referral to outpatient multidisciplinary specialist CAMHS (i.e. requires an expedited assessment) according to local risk assessment procedures.
- Severe learning disability.
- Previously randomised in the STADIA trial.

Inclusion criteria for the parent/carer

- Individual with parental responsibility for the CYP referred to CAMHS; this will be the CYP's mother or father, legally appointed guardian or a person with a residence order concerning the CYP.
 - Adequate knowledge of the CYP to be able to complete the assessment tool (i.e., known for at least 6 months).
 - Has capacity to provide valid written informed consent.
 - Access to internet and email or telephone.
 - Able to complete the assessment tool in English.
- Exclusion criteria for the parent/carer*
- Local authority representatives designated to care for the CYP.

224

The participation and consent/assent requirements for the trial are shown in table 2.

226

Table 2: Consent & Participation

228

Age of CYP referred to CAMHS:	CYP aged <11	CYP aged 11-15		CYP aged 16-17	
Initial contact with:	Parent/carer			Depends on contact details provided with the CAMHS referral*	
Consent provided by:	Parent/carer	Parent/carer	Parent/carer	CYP AND parent/carer (optional)	CYP
Assent provided by:	None	CYP (optional)	None	None	None
Participant(s):	Parent/carer only	CYP and parent/carer dyad	Parent/carer only	CYP and parent/carer dyad	CYP only
Primary participant:**	Parent/carer	Parent/carer	Parent/carer	CYP	CYP
Secondary participant:	None	CYP	Non	Parent/carer	None
DAWBA completed by:	Parent/carer	Parent/carer AND CYP	Parent/carer	CYP AND parent/carer	CYP
Research questionnaires completed by:	Parent/carer report on CYP Parent/carer self-report	Parent/carer report on CYP Parent/carer self-report CYP self-report	Parent/carer report on CYP Parent/carer self-report	CYP self-report Parent/carer report on CYP Parent/carer self-report	CYP self-report

For all CYP aged <16 the initial contact about the study will be with the parent/carer. The involvement of CYP aged 11-15 will be at the discretion of the parent/carer.

* For CYP aged 16-17 if the CYP's contact details are provided on the CAMHS referral the first contact about the study will be with the CYP who can choose to nominate a parent/carer to participate in the trial alongside them or participate alone. If the parent/carer's contact details only are available the first contact will be with the parent/carer and the parent/carer will be asked whether the CYP can also be contacted but may choose to refuse this. The parent/carer will not be able to participate in the STADIA trial without the involvement or consent of the CYP.

** The primary participant is the person who must provide consent as a minimum requirement in order for randomisation to take place. Assent (of CYP aged 11-15) and parental consent (for CYP aged 16 and 17) may also be sought but is not mandatory and therefore will not be required prior to

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

randomisation.

229
230 Participants are free to withdraw at any time and for any reason. Participants may withdraw from
231 the intervention, follow-up questionnaires and/or data collection from records in any combination
232 (e.g., participants who do not complete the intervention will continue to be followed-up,
233 participants withdrawing from follow-up questionnaire completion may continue to consent for data
234 collection from records). Withdrawn participants will not be replaced. Data collected prior to
235 withdrawal will be retained and used in the analysis.

236
237 Where CYP aged 16 or 17 have consented for their own involvement they can continue to
238 participate in the trial in the event of their parent/carer's withdrawal, however, the parent/carer
239 involvement would not continue should the CYP withdraw consent.

240 241 **Randomisation and concealment**

242 Participants will be randomised in a 1:1 ratio to either intervention or control. Allocation will be
243 assigned using a minimisation algorithm balancing on recruiting site, CYP age (5-10, 11-15, 16-17
244 years) and sex, incorporating a probabilistic element to allocation. The allocation algorithm was
245 created by Nottingham Clinical Trials Unit (NCTU) in accordance with their Standard Operating
246 Procedures (SOPs). Allocation is concealed using an automated web system operated by NCTU.

247
248 Randomisation is automatically generated within the online system following submission, and
249 automated verification, of baseline data by the primary participant. Participants are presented with
250 their allocation and further instructions on-screen with email confirmation. Instructions for DAWBA
251 completion are included for those in the intervention arm. Email confirmation is sent to the
252 coordinating centre and site research team.

253
254 It will not be possible to blind participants, site researchers, clinicians and some trial staff to
255 treatment allocation, but treatment allocation data will be restricted to those trial staff who require
256 access to facilitate trial conduct. In particular, it will not be fully possible to blind researchers
257 conducting data collection from records. However, any possible diagnoses identified from the
258 CAMHS records will be recorded verbatim on the data capture form and will be subject to
259 adjudication by the trial adjudication committee (members of the Trial Management Group). The
260 committee will be blinded to treatment allocation and participant ID.

261
262 The risk of contamination between arms is considered low. Access to the DAWBA, and provision of
263 the DAWBA report, is only provided to participants in the intervention arm. SDA tools are not
264 current practice in standard care and it is unlikely that control participants will be asked to complete
265 these at the point of referral receipt. DAWBA completion occurring outside the trial for control arm
266 participants will be collected during follow-up.

267 268 **Interventions**

269 Development and wellbeing assessment (DAWBA)
270 The trial intervention is the DAWBA. (24) The DAWBA has a modular structure, with only those
271 modules relevant to emotional and comorbid disorders included; separation anxiety, specific phobia,
272 social phobia, panic and agoraphobia, generalised anxiety, post-traumatic stress disorder (PTSD),
273 obsessive compulsive disorder (OCD), depression, oppositional defiant disorder (ODD) and conduct
274 disorder. Whereas, the strengths and difficulties questionnaire, bipolar disorder, and body
275 dysmorphic disorder are not included in the STADIA-specific DAWBA report as these modules do not
276 generate diagnostic predictions. No freetext responses are collected.

1
2
3 279 The DAWBA will be self-reported by participants via the secure, standalone online platform created
4 280 and maintained by the DAWBA developer.(24) Access is by a unique ID number and password,
5 281 assigned at the point of randomisation via a stock control system integrated into the randomisation
6 282 system, ensuring accountability of DAWBA slot allocation.
7 283

8 284 The DAWBA may be completed by the parent/carer and/or CYP aged 11+, depending on the consent
9 285 and participation arrangements (Table 2) DAWBA completion will be monitored and the STADIA
10 286 researcher will support and encourage completion. Participants will be able to complete the DAWBA
11 287 in a telephone call with the STADIA researcher if required. Participants are asked to complete all
12 288 modules of the DAWBA presented to them. Should the DAWBA be only partially completed by
13 289 respondents the report will be based only on fully answered modules with missing responses
14 290 identified as such.
15 291

16 292 A trial-specific DAWBA report will be prepared for each participant, based on a standard, study-
17 293 specific template (Appendix 2. Template DAWBA report). The algorithm-derived diagnostic
18 294 predictions will be used to highlight the likelihood of a CYP meeting ICD-10 criteria for the disorders
19 295 assessed; the report is based entirely on the algorithm-derived predictions and is not clinically rated.
20 296 The report will be sent to participants (via post or email) and CAMHS clinicians (via upload to the
21 297 clinical record), as an adjunct to usual clinical practice.
22 298

23 299 Control

24 300 CYP randomised to the control arm will receive usual care (i.e., referral review as usual). Based on
25 301 standard information provided with the referral a clinical decision is made about whether the
26 302 referral is accepted and, if so, a clinician conducts the initial CAMHS assessment as per usual practice
27 303 in the service.
28 304

29 305 Sample size

30 306 A target sample size of 1210 participants will be recruited and randomised, with equal allocation to
31 307 intervention or control.
32 308

33 309 Assuming 45% of control participants have a confirmed diagnosis within 12 months (based on
34 310 unpublished data obtained from the trial sites), detection of an absolute increase of 10% with 90%
35 311 power and 5% two-sided alpha, requires 544 participants per arm for analysis. Allowing for up to
36 312 10% non-collection of the primary outcome, we will randomise 1210 participants.
37 313

38 314 Measures and outcomes

39 315 Primary outcome

40 316 The primary outcome is a clinician-made diagnosis decision about the presence of an emotional
41 317 disorder within 12 months of randomisation i.e. diagnosis of an emotional disorder will be coded as
42 318 'yes'; absence or uncertainty (for example, reflecting ongoing assessment or investigation) will be
43 319 coded as 'no'. Eligible diagnoses are those that reflect 'emotional' or 'internalizing' disorders in
44 320 ICD/DSM (Appendix 3. Eligible emotional disorder diagnoses). The diagnosis must be documented in
45 321 the clinical record within 12 months of randomisation by a mental health services clinician in an
46 322 NHS-delivered or NHS-commissioned service.
47 323

48 324 Diagnoses will be collected from clinical records using a standard proforma. Alternative possible
49 325 diagnoses identified from the clinical notes will be recorded verbatim on the data capture form and
50 326 will be subject to adjudication by members of the Trial Management Group (Appendix 4. Outcome
51 327 Definition and Adjudication Plan).
52 328
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

329
330 Secondary outcomes
331 Secondary outcomes are detailed in table 3.
332

For peer review only

333 *Table 3. Secondary outcome definitions*

334

Outcome	Measurement	Definition
Acceptance of index referral	Collected from records	Whether the index referral (i.e., the referral made to CAMHS at the point of recruitment to the STADIA trial) was accepted or declined. Acceptance is defined as being offered an appointment within CAMHS, whether or not the initial appointment was attended or subsequent appointments were offered/attended. Collected within 12 months of randomisation.
Acceptance of any referral within 12 months of randomisation	Collected from records	Whether the index referral or any subsequent referral to CAMHS (if made) was accepted or not . Acceptance as defined above for index referral. Collected within 12 months of randomisation.
Discharge from CAMHS within 12 months	Collected from records	Whether the child/young person was discharged from CAMHS (following acceptance of the index referral) during the 12-months post-randomisation.
Re-referral to CAMHS within 12 months	Collected from records	Whether the child/young person was re-referred to CAMHS (for those whose index referral was turned down by CAMHS or those whose index referral was accepted but were subsequently discharged) during the 12-months post-randomisation.
Confirmed diagnosis decision	Collected from records	Diagnosis of an emotional disorder or confirmed absence of an emotional disorder coded as 'yes' vs. uncertainty about the presence of an emotional disorder coded as 'no'. Diagnosis as defined for primary outcome, collected within 12 months of randomisation.
Time from randomisation to diagnosis of emotional disorder	Collected from records	Date of diagnosis will be the first documented eligible diagnosis. Diagnosis as defined for primary outcome, collected within 12 months of randomisation.
Diagnoses made over the 12 month period from randomisation	Collected from records	The diagnosis must be documented in the clinical record within 12 months of randomisation by a mental health services clinician in an NHS-delivered or NHS-commissioned service. All diagnoses made within 12 months will be included. Measured using a standard proforma (pre-specified diagnoses).
Treatment offered for diagnosed emotional disorder	Collected from records	Whether treatment was offered for a diagnosed emotional disorder, as defined for primary outcome, collected within 12 months of randomisation.
Any treatment / interventions given	Collected from records	All treatments/interventions offered by CAMHS for any reason within 12 months of randomisation, whether or not there is a documented diagnosis will be included.

Outcome	Measurement	Definition
Time from randomisation to the decision to offer treatment for a diagnosed emotional disorder	Collected from records	Date of decision will be the first date that the decision to offer treatment for a diagnosed emotional disorder is documented in the clinical notes, collected within 12 months of randomisation.
Time from randomisation to start of first treatment for a diagnosed emotional disorder	Collected from records	Date of treatment will be the first date that any treatment offered for a diagnosed emotional disorder is started. Treatment and diagnosed emotional disorder as defined, collected within 12 months of randomisation.
Time from randomisation to the decision to offer any treatment	Collected from records	Date of decision will be the first date that the decision to offer any treatment is documented in the clinical notes, , collected within 12 months of randomisation.
Time from randomisation to start of any treatment	Collected from records	Date of treatment will be the first date that any treatment offered is started. Treatment as defined, collected within 12 months of randomisation.
Participant-reported diagnoses received in the 12 months post-randomisation	Participant self-report	Participants will be asked to report whether or not they received a diagnosis of the child/young person's difficulties from CAMHS in the 12 months post-randomisation and if so, what diagnosis was given and by whom.
Depression symptoms in the CYP	Mood and Feelings Questionnaire (MFQ)	Mood and Feelings Questionnaire (MFQ) (25) is a valid and reliable measure of depression in CYP.(26, 27) 33-items are answered on a 3-point scale ("not true" = 0, "somewhat true" = 1 point, "true" = 2 points). Scores range from 0 to 66 with higher scores indicating more severe depressive symptoms. A score of 27 or higher may be indicative of depression. MFQ collected at baseline, 6 and 12 months post-randomisation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Outcome	Measurement	Definition
Anxiety symptoms in the CYP	Revised CYP’s Anxiety Depression Scale (RCADS)	<p>Revised CYP’s Anxiety and Depression Scale (RCADS)(28) RCADS is a 47-item questionnaire that measures the reported frequency of various symptoms of anxiety and low mood. Each item is rated on a 4-point scale (never = 0, sometimes = 1, often = 2, always = 3). An overall anxiety and low mood score is generated, with separate sub-scale scores for separation anxiety, social phobia, generalised anxiety, panic, obsessive compulsive disorder and major depression. RCADS demonstrates good psychometric properties.(29) Total anxiety and depression scores range from 0 to 141.</p> <p>We will record scores for each of the 6 sub-scales. For analysis metric, we will use the total anxiety score. RCADS collected at baseline, 6 and 12 months post-randomisation.</p>
Comorbid oppositional defiant / conduct disorder symptoms in the CYP	Strengths and Difficulties Questionnaire (SDQ)	<p>Strengths & Difficulties Questionnaire (SDQ):(30) A 25-item emotional and behavioural screening questionnaire for CYP.</p> <p>Each item is rated on a 3-point scale (not true, somewhat true, certainly true). Values of 0, 1 or 2 are assigned to each response.</p> <p>SDQ comprises 5 sub-scales and an impact supplement. The impact supplement asks effect of difficulties on homelife, friendships, education and leisure activities.</p> <p>SDQ has demonstrated reasonable psychometric properties.(31-34) Scores on the ‘conduct problems’ subscale will be used in the analysis of this outcome.</p> <p>Sub-scale scores range from 0 to 10. SDQ collected at baseline, 6 and 12 months post-randomisation.</p>
Functional Impairment in the CYP	Strengths and Difficulties Questionnaire (SDQ)	Impact supplement scores will be used to determine functional impairment. Impact scores range from 0 to 10. Collected at baseline, 6 and 12-months post-randomisation.

Outcome	Measurement	Definition
Self-harm thoughts in the CYP	CYP self-report self-harm measure	CYP will be asked to report the frequency of thoughts of self-harm. Frequency of thoughts of self-harm are rated over the last 6 months in the following categories and scored accordingly: Not at all (0) Once or twice (1) Three or more times (2) Collected at baseline, 6 months and 12-months post-randomisation.
Self-harm behaviours in the CYP	CYP self-report self-harm measure	CYP will be asked to report frequency of instances of self-harm behaviour. Frequency of self-harm behaviour are rated over the last 6 months in the following categories and scored accordingly: Not at all (0) Once (1) Two or more times (2) Collected at baseline, 6 months and 12-months post-randomisation.
Depression symptoms in the parent/carer	Patient Health Questionnaire (PHQ-9)	PHQ-9:(35) PHQ-9 is frequently used as a screening tool for depression in general populations. Each of the nine DSM-IV depression criteria are scored as "0" (not at all) to "3" (nearly every day) depending on the frequency with which they were experienced over the last 2 weeks. Total scores range from 0 to 27 with higher scores indicating increased severity of depression, collected at baseline, 6 and 12-months post-randomisation.
Anxiety symptoms in the parent/carer	Generalised Anxiety Disorder Assessment (GAD-7)	GAD-7:(36) GAD-7 is a measure of the severity of anxiety in general populations. 7 items are rated according to the frequency with which they have been experienced over the past 2 weeks (0 = 'not at all', 1 = 'several days', 2 = 'more than half the days', and 3 = 'nearly every day'). Total scores range from 0 to 21 with higher scores indicating more severe anxiety. Collected at baseline, 6 and 12-months post-randomisation.
Time off education, employment or training because of emotional difficulties for the CYP	Resource use questionnaire	Days missed from education, employment or training (as applicable) for the CYP due to emotional difficulties. Collected at baseline, 6 and 12-months post-randomisation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Outcome	Measurement	Definition
Health economic outcome measures		
Health related quality of life in the CYP	Child Health Utility 9D (CHU9D) and EuroQol Quality of Life Questionnaire 5 Domains for Young People (EQ-5D-Y)	<p>CHU9D (37) consists of nine individual items with five levels of response per question (scored 1-5), that assess the CYP functioning “today”. The following domains are included; worry, sadness, pain, tiredness, annoyance, school, sleep, daily routine and activities.</p> <p>EuroQol-5D youth descriptive system (38) comprises 5 domains; mobility, looking after myself, doing usual activities, having pain or discomfort and feeling worried, sad or unhappy, values of 1, 2 or 3 are assigned to each response. The EuroQol Visual Analogue Scale (EQ-VAS) asks recipients to self-assess their health state ‘today’ from 0 (worst imaginable health) to 100 (best imaginable health), representing individual preferences.</p> <p>These measures will be self-reported by CYP aged 11+, with proxy versions also completed by the parent/carer for CYP <16.</p> <p>Both collected at baseline, 6 and 12-months post-randomisation.</p>
Health-related quality of life in the parent/carer	EuroQol Quality of Life Questionnaire 5 Domains, 5 Levels (EQ-5D-5L)	<p>The EuroQol 5-dimension multi attribute utility instrument (39) comprises 5 domains; mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain is scored between 1 and 5. This descriptive profile, in combination with a valuation set, produces a single index for health status representing societal preferences. The index score ranges from -0.59 to 1, with 0 representing death, 1 of-perfect health, and <0 of health states worse than death. The EQ-VAS is again included within the EQ-5D instrument Collected at baseline, 6 and 12-months post-randomisation.</p>

335
336

1
2
3 337 *Health economic measures*

4 338 Health related quality of life (HRQoL) outcome measures are detailed in table 3.

5 339

6 340 *Resource Use*

7 341 Data will be collected on health care, education, and social care resource use for both the CYP and
8 342 parents/carers, using a purposely designed resource use collection tool. The questionnaire was
9 343 developed by health economists, in tandem with feedback from PPI representatives, addressing
10 344 primary, secondary, and social care costs, alongside the broader patient-borne costs. These data will
11 345 be attributable to the emotional difficulties of the young person and be self-reported by the
12 346 parent/carer with supplementary information obtained from CYP aged 16 and 17. Administrative
13 347 records of treatments/interventions offered by CAMHS during the trial period may be considered as
14 348 a supplementary source of data.

15 349

16 350 *Socio-demographic data*

17 351 The following socio-demographic data will be collected primarily from the participant-reported
18 352 questionnaires; age at randomisation, sex, gender, ethnicity, paid employment, and, derived from
19 353 the postcode of the child's primary residence, the index of Multiple Deprivation score.

20 354

21 355 *Data collection*

22 356 Data will be collected through participant reported questionnaires (parent/carer and CYP self-report
23 357 aged 11+) and from clinical records. Participant reported outcomes will be collected at baseline and
24 358 6- and 12-months post-randomisation (Appendix 5. Summary of assessments). Questionnaires are
25 359 intended to be completed online by participants in the first instance - to maximise rates of
26 360 completion and retention there will be an option for telephone completion, should participants have
27 361 difficulty accessing or completing the questionnaires online.

28 362

29 363 Outcomes collected from records will be reported for the 12-month period following randomisation.

30 364

31 365 **Data management and analysis**

32 366 *Data management*

33 367 Arrangements for data handling are specified in the Data Management Plan (DMP). Central and on-
34 368 site monitoring will be carried out as required following a risk assessment and as documented in the
35 369 monitoring plan. Monitoring activities will be carried out by the coordinating centre on behalf of the
36 370 trial sponsor.

37 371

38 372 Data will be held on servers located within The University of Nottingham data centres. Security is
39 373 both physical (secure limited access) and electronic (behind firewalls, access via user accounts).

40 374 Personal data recorded on all documents will be regarded as strictly confidential and handled and
41 375 stored in accordance with the Data Protection Act 2018.

42 376

43 377 *Statistical analysis*

44 378 The primary approach to between-group comparative analyses will be by modified intention-to-treat
45 379 (i.e. including all participants who have been randomised and without imputation of missing
46 380 outcome data).

47 381

48 382 The primary comparative analysis will employ a generalised linear mixed model to compare the
49 383 proportions in each group with a clinician-made diagnosis decision within 12 months of
50 384 randomisation, adjusted for minimisation variables. The comparison will be presented as both an
51 385 absolute (risk difference) and relative (risk ratio) effect, along with 95% confidence intervals.

52 386

53

54

55

56

57

58

59

60

1
2
3 387 Secondary outcomes will be analysed using appropriate mixed effect regression models dependent
4 388 on data type and will adjust for factors used in the minimisation and baseline value of the outcome
5 389 where measured. For outcomes measured at multiple time points, these will be analysed using a
6 390 mixed model with a treatment by time interaction to obtain estimates of treatment effect at each
7 391 follow-up time.
8 392

9
10 393 Appropriate interaction terms will be included in the primary regression analyses in order to conduct
11 394 subgroup analyses according to sex and age of the CYP.
12 395

13 396 Statistical analysis will be conducted using Stata v17.0 (or later).
14 397

15 398 Health economic analysis

16 399 In accordance with NICE guidance, primary analysis will take an NHS and personal social services
17 400 perspective. Unit costs will be attached to participant reports of health care resource use or
18 401 recorded treatments/interventions offered by CAMHS. The cost of the DAWBA itself will be
19 402 distributed at the participant-level across the intervention arm of the trial. Sensitivity analyses will
20 403 take a wider perspective to capture the broader societal costs inclusive of out-of-pocket expenses
21 404 and productivity losses. Indices of HRQoL for the EQ-5D, EQ-5D-Y, and CHU9D will be derived using
22 405 relevant population tariffs, and quality adjusted life years estimated using area under the curve
23 406 (AUC).
24 407

25
26 408 The economic evaluation will take an incremental approach between the two groups using an
27 409 intention-to-treat (ITT) population (irrespective of treatment received) and a 12-month time horizon.
28 410 The outcome for the primary cost utility analysis will be the joint young person and parent/carer
29 411 QALYs. The outcome for the secondary cost effectiveness analysis will be confirmed diagnosis
30 412 decisions. Outcomes will be paired with their respective direct-to-NHS costs, bootstrapped, and
31 413 scattered on the cost effectiveness plane to characterise the uncertainty in incremental estimates.
32 414 Using the net monetary benefit framework,(40) Cost Effectiveness Acceptability Curves (CEACs) will
33 415 be constructed to show the non-parametric probability the intervention is a cost effective option,
34 416 compared to usual care, across a range of willingness to pay thresholds per QALY, and within the
35 417 secondary analysis per confirmed diagnosis decision. While the receipt of any diagnosis of emotional
36 418 difficulties in young people would likely lead to large divergences in lifecourse outcomes, the
37 419 heterogeneity of conditions considered for diagnosis (Appendix 3) renders CUA modelling across the
38 420 lifecourse infeasible. Secondary analysis is expected to be fully captured within the 12-month time
39 421 horizon.
40 422

41
42
43 423 A full statistical analysis plan (SAP) and health economics analysis plan (HEAP) will be developed and
44 424 agreed prior to database lock and un-blinding of the analysing statistician and health economist.
45 425

46 426 **Embedded qualitative study**

47 427 During the internal pilot, semi-structured interviews are undertaken with a sample of participants
48 428 who consented to be invited to participate in qualitative interviews. Researchers, clinicians, service
49 429 managers and commissioners are identified by site leads. The proposed sample size is 25
50 430 participants (parent/carer and CYP aged 16-17), 25 staff and 15 service managers and
51 431 commissioners. Interviews address: a) the feasibility of recruitment; b) the acceptability and usability
52 432 of the interventions and procedure; c) how the intervention is used and how this deployment could
53 433 be refined for the main trial. Interviews are conducted by the qualitative researcher (KN) in person,
54 434 or by phone or video call based on participant preferences and pandemic restrictions.
55 435

56
57
58 436 A process evaluation, conducted during the main trial phase, will aim to identify the barriers and
59 437 facilitators to implementation of the intervention. Semi-structured interviews will be conducted with
60

1
2
3 438 a further sample of participants and clinicians to explore the perceived functioning of the
4 439 intervention, the organisation of the service and reflective experiences on outcomes.
5 440

6 441 Qualitative interview data will be recorded and encrypted on a password protected Dictaphone and
7 442 transferred securely to medical transcription company Dict8 for transcription. Transcriptions will be
8 443 anonymised. Audio files will be destroyed after transcripts have been checked. Anonymised
9 444 transcriptions will be analysed and stored on password protected computers and the secure
10 445 University of Nottingham server.
11 446

12 447 Qualitative analysis

13 448 All qualitative interview data will be initially analysed by the qualitative researcher (KN) using
14 449 interpretative thematic approaches to coding, and adopt the framework method,(41) with input
15 450 from the qualitative lead (LT), Chief Investigator (KSa) and PPI leads (CE & AL). NVIVO 12 will be used
16 451 to manage the qualitative data.
17 452

18 453 **Patient and public involvement**

19 454 Prior to submission, the proposal was informed by consultations with a person with lived
20 455 parent/carer experience of CAMHS, including contribution to and review of the proposal,
21 456 recruitment strategy, participant trial experience and consideration of burden of the intervention,
22 457 and establishing a PPI workstream.
23 458

24 459 Following award, the PPI Co-I team recruited two representatives naïve of the study design to
25 460 provide independent review of the trial via their membership of the Trial Steering Committee (TSC).
26 461 Both TSC members are persons with lived parent/carer experience of CAMHS.
27 462

28 463 During study set up, PPI Co-I expertise was utilised to support researcher recruitment via the design
29 464 and deployment of role plays within interviews.(42) This was to gain insight into candidates'
30 465 capabilities when dealing with sensitive and challenging participant scenarios. Additionally, they
31 466 contributed to design of researcher training materials, to support standardised approaches across
32 467 trial sites. Iterative and creative design PPI activities were integral in the development of the STADIA
33 468 trial logo and branding to ensure accessibility and acceptability to CYP and parents.
34 469

35 470 Since study commencement participatory design approaches have seen PPI co-design of the
36 471 resource use questionnaire, qualitative interviews and the protocol for a Study Within A Trial (SWAT)
37 472 to support participant engagement with follow-up. Additionally, collaborative working between the
38 473 PPI and Qualitative workstreams has enabled examination of the qualitative themes using principles
39 474 of the Framework Method(41) for independent verification of those themes.
40 475

41 476 Two PPI advisory panels have been established, meeting on average every 3 months since month 9
42 477 of the study. "STADIA PPI Panel" has 8 adult members, with lived parent/carer experience of
43 478 CAMHS. "STADIA Labs" has 6 CYP members, aged 15 to 19 at inception, with lived experience of
44 479 CAMHS. These groups have been involved in many traditional activities such as review of PIS and
45 480 consent forms, consultation on language and content for participant reminder text messages. PPI co-
46 481 production activities are also seeing the development of age appropriate study newsletters and the
47 482 design of STADIA information videos including decision making about video concept, audience,
48 483 message, aesthetic and content. PPI group members are provided with supplementary training
49 484 about PPI practices and involvement opportunities. Due to the Covid-19 pandemic, PPI meetings
50 485 have had to move online and so the PPI team are investing in knowledge transfer and upskilling PPI
51 486 representatives in different ways of working and collaborating online.
52 487

1
2
3 488 There are a range of planned flexible opportunities for participating in project feedback and
4 489 dissemination activities including co-facilitating and presenting at the interactive dissemination
5 490 workshop / consensus meeting, publication authorship as peer researcher and presenting at
6 491 conferences to showcase the project findings.
7
8 492
9 493

494 **ETHICS AND DISSEMINATION**

495 **Ethics**

497 The study was reviewed and received favourable opinion from the South Birmingham Research
498 Ethics Committee (Ref. 19/WM/0133) on 12 June 2019; subsequent amendments have been
499 approved. The current, approved protocol is version 4.0 dated 03 February 2021.
500

501 **Safety**

502 The trial intervention is conceptually similar to usual clinical practice (i.e., CYP referred to CAMHS
503 may be sent questionnaires about their difficulties), therefore the risks of the trial are considered
504 comparable. The DAWBA is widely used in research for data collection therefore, although utilised as
505 an intervention in the STADIA trial, the risks may be regarded as similar to those of an
506 observational/questionnaire study. Data to inform safety oversight will therefore be collected during
507 routine follow-up, from existing outcome measures. There is no separate adverse event or serious
508 adverse event reporting.
509

510 The number of participants meeting pre-defined safety outcomes will be reported on an ongoing
511 basis to the Trial Management Group (TMG) and TSC. Data will be presented by arms to the Data
512 Monitoring Committee (DMC).
513

514 **Trial oversight**

515 Nottinghamshire Healthcare NHS Foundation Trust will undertake role of Sponsor as defined by the
516 UK Policy Framework for Health and Social Care Research.⁽⁴³⁾ Delegated responsibilities will be
517 assigned to the Chief Investigator, participating NHS Trusts and the trial coordinating centre,
518 Nottingham Clinical Trials Unit (NCTU).
519

520 The full co-applicant team and NCTU staff responsible for the day-to-day management of the trial
521 will form the TMG, responsible for monitoring recruitment and retention rates and implementing
522 strategies to ensure targets are met. Independent Trial Steering and Data Monitoring Committees
523 will operate in accordance with trial-specific Charters.
524

525 **Dissemination**

526 Results of this trial will be reported to the funder and published in full in the HTA Journal series and
527 also submitted for publication in a peer reviewed journal.
528

529 **Data Sharing**

530 Anonymised trial data may be shared with researchers external to the trial research team in
531 accordance with the NCTU's data sharing procedure.
532

533 **Figures**

534 Figure 1: Participant flow
535

536 **Authors' contributions**

537 FD, LW, AB, BD, CE, JG, MJ, AL, TM, AM, SR, KSp, LT, EB, JL, KN, CP, KSt and KSa made substantial
538 contributions to conception and design or acquisition of data; took part in drafting the article or
539
60

1
2
3 539 revising it critically for important intellectual content; agreed to submit to the current journal; gave
4 540 final approval of the version to be published; and agree to be accountable for all aspects of the work.
5 541 KSa is guarantor for the paper. FD and LW contributed equally to this paper.
6 542

543 **Funding statement**

9 544 This study was funded as a result of a commissioned call by the National Institute for Health
10 545 Research (NIHR) Health Technology Assessment programme (Grant Reference Number 16/96/09).
11 546 The views expressed are those of the authors and not necessarily those of the NIHR or the
12 547 Department of Health and Social Care.
13 548

14 549 The funder will have no role in the collection, management, analysis, and interpretation of data;
15 550 writing of the report; and the decision to submit the report for publication.
16 551

17 552 **Competing interests**

18 553 The authors declare no competing interests.
19 554

20 555 **Acknowledgements**

21 556 We would like to acknowledge and thank all the parent/carers and young people participating in the
22 557 trial and the research sites involved in recruiting participants and data collection. The authors would
23 558 also like to thank the wider STADIA team for their input, including the PPI Advisory Panels, members
24 559 of the independent Trial Steering and Data Monitoring Committees, and the Nottingham Clinical
25 560 Trials Unit, who are the trial coordinating centre.
26 561

27 562 Finally, thanks to the trial sponsor, Nottinghamshire Healthcare NHS Foundation Trust
28 563 (researchsponsor@nottshc.nhs.uk).
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Review only

1
2
3 565 **REFERENCES**
4 566


- 5 567 1. Sadler K, Vizard T, Ford T, Marcheselli F, Pearce N, Mandalia D, et al. Mental Health of
6 568 Children and Young People in England, 2017: NHS Digital; 2018 [Available from:
7 569 [https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-of-children-and-](https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-of-children-and-young-people-in-england/2017/2017)
8 570 [young-people-in-england/2017/2017](https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-of-children-and-young-people-in-england/2017/2017).
9 571 2. Goodyer IM RS, Barrett B, Byford S, Dubicka B, Hill J, Holland F, Kelvin R, Midgley N, Roberts
10 572 C, Senior R, Target M, Widmer B, Wilkinson P, Fonagy P. Cognitive behavioural therapy and short-
11 573 term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with
12 574 unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised
13 575 controlled trial. *Health Technology Assessment*. 2017;21(12).
14 576 3. Simmons M, Wilkinson P, Dubicka B. Measurement Issues: Depression measures in children
15 577 and adolescents. *Child and Adolescent Mental Health*. 2015;20(4):230-41.
16 578 4. Colman IW, MEJ. Croudace, TJ. Jones, PB. Forty-Year Psychiatric Outcomes Following
17 579 Assessment for Internalizing Disorder in Adolescence. *American Journal of Psychiatry*.
18 580 2007;164(1):126-33.
19 581 5. Orchard F, Pass L, Marshall T, Reynolds S. Clinical characteristics of adolescents referred for
20 582 treatment of depressive disorders. *Child and Adolescent Mental Health*. 2017;22(2):61-8.
21 583 6. Frith E. Access and waiting times in children and young people's mental health services.:
22 584 Education Policy Institute; 2017 [Available from: [https://epi.org.uk/wp-](https://epi.org.uk/wp-content/uploads/2018/01/EPI_Access-and-waiting-times_.pdf)
23 585 [content/uploads/2018/01/EPI_Access-and-waiting-times_.pdf](https://epi.org.uk/wp-content/uploads/2018/01/EPI_Access-and-waiting-times_.pdf).
24 586 7. Michelson D, Rock S, Holliday S, Murphy E, Myers G, Tilki S, et al. Improving psychiatric
25 587 diagnosis in multidisciplinary child and adolescent mental health services. *The Psychiatrist*.
26 588 2011;35:454-9.
27 589 8. O'Connor C, Downs J, McNicholas F, Cross L, Shetty H. Documenting diagnosis in child and
28 590 adolescent mental healthcare: A content analysis of diagnostic statements in a psychiatric case
29 591 register. *Children and Youth Services Review*. 2020;113:104948.
30 592 9. Allsopp K, Kinderman P. The use of diagnoses in mental health service eligibility and
31 593 exclusion criteria. *Journal of mental health (Abingdon, England)*. 2021;30(1):97-103.
32 594 10. Martin A-M, Fishman R, Baxter L, Ford T. Practitioners' attitudes towards the use of
33 595 standardized diagnostic assessment in routine practice: A qualitative study in two Child and
34 596 Adolescent Mental Health Services. *Clinical Child Psychology and Psychiatry*. 2011;16(3):407-20.
35 597 11. Craddock N, Antebi D, Attenburrow M-J, Bailey A, Carson A, Cowen P, et al. Wake-up call for
36 598 British psychiatry. *British Journal of Psychiatry*. 2008;193(1):6-9.
37 599 12. National Institute for Health and Clinical Excellence. Depression in Children and Young
38 600 People: Quality Standard London: National Institute for Health and Clinical Excellence; 2013
39 601 [Available from: <https://www.nice.org.uk/guidance/cg28>.
40 602 13. Fitzpatrick C AN-N, Kehoe A, Devlin N, Glackin S, Power L, et al. Do we miss depressive
41 603 disorders and suicidal behaviours in clinical practice. *Clinical Child Psychology and Psychiatry*.
42 604 2012;17:449-58.
43 605 14. National Institute for Health and Clinical Excellence. Depression in Children and Young
44 606 People: Identification and Management in Primary, Community and Secondary Care – Update
45 607 London: National Institute for Health and Clinical Excellence,; 2015 [Available from:
46 608 <https://www.nice.org.uk/guidance/cg28>.
47 609 15. Last A, Henley, W., Norman, S., Goodman, R., Ford, T. Innovations in Practice: Feasibility of
48 610 the development and well-being assessment as an adjunct to clinical assessment in child and
49 611 adolescent mental health services. . *Child and Adolescent Mental Health*. 2014;19:142-6.
50 612 16. Reeves K, Charter E, Ford T. Measurement Issues: Is standardised diagnostic assessment
51 613 feasible as an adjunct to clinical practice? A systematic review. *Child and Adolescent Mental Health*.
52 614 2016;21(1):51-63.
53
54
55
56
57
58
59
60

- 1
2
3 615 17. Goodman R, Ford T, Richards H, Gatward R, Meltzer H. The Development and Well-Being
4 616 Assessment: Description and Initial Validation of an Integrated Assessment of Child and Adolescent
5 617 Psychopathology. *Journal of Child Psychology and Psychiatry*. 2000;41(5):645-55.
6 618 18. Hall CL, Davies EB, Andr n P, Murphy T, Bennett S, Brown BJ, et al. Investigating a therapist-
7 619 guided, parent-assisted remote digital behavioural intervention for tics in children and adolescents—
8 620 ‘Online Remote Behavioural Intervention for Tics’ (ORBIT) trial: protocol of an internal pilot study
9 621 and single-blind randomised controlled trial. *BMJ Open*. 2019;9(1):e027583.
10 622 19. Pickles A, Le Couteur A, Leadbitter K, Salomone E, Cole-Fletcher R, Tobin H, et al. Parent-
11 623 mediated social communication therapy for young children with autism (PACT): long-term follow-up
12 624 of a randomised controlled trial. *The Lancet*. 2016;388(10059):2501-9.
13 625 20. Ford T, Last A, Henley W, Norman S, Guglani S, Kelesidi K, et al. Can standardized diagnostic
14 626 assessment be a useful adjunct to clinical assessment in child mental health services? A randomized
15 627 controlled trial of disclosure of the Development and Well-Being Assessment to practitioners. *Social
16 628 Psychiatry and Psychiatric Epidemiology*. 2013;48(4):583-93.
17 629 21. Aebi M, Kuhn C, Metzke CW, Stringaris A, Goodman R, Steinhausen H-C. The use of the
18 630 development and well-being assessment (DAWBA) in clinical practice: a randomized trial. *European
19 631 child & adolescent psychiatry*. 2012;21(10):559-67.
20 632 22. Meltzer H, Gatward R, Goodman R, Ford T. The mental health of children and adolescents in
21 633 Great Britain London: Office for National Statistics; 2000 [Available from:
22 634 [http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/rel/psychi-
23 635 atric-morbidity/the-mental-health-of-children-and-adolescents-in-great-britain/1999-
24 636 survey/mental-health-of-children-and-adolescents-in-great-britain.pdf](http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/rel/psychiatric-morbidity/the-mental-health-of-children-and-adolescents-in-great-britain/1999-survey/mental-health-of-children-and-adolescents-in-great-britain.pdf).
25 637 23. Green H, McGinnity A, Meltzer H, Ford T, Goodman R. Mental health of children and young
26 638 people in Great Britain, 2004 Basingstoke, Hampshire: Palgrave Macmillan; 2005 [Available from:
27 639 [https://webarchive.nationalarchives.gov.uk/20180307185414/http://digital.nhs.uk/catalogue/PUBO
28 640 6116](https://webarchive.nationalarchives.gov.uk/20180307185414/http://digital.nhs.uk/catalogue/PUBO6116).
29 641 24. Youth in Mind. Information for researchers and clinicians about the Development and Well-
30 642 Being Assessment: Youth in Mind; 2012 [Available from: <http://www.dawba.info/>.
31 643 25. Angold A, Costello EJ, Messer SC, Pickles A. Development of a short questionnaire for use in
32 644 epidemiological studies of depression in children and adolescents. *International Journal of Methods
33 645 in Psychiatric Research*. 1995;5(4):237-49.
34 646 26. Wood A, Kroll L, Moore A, Harrington R. Properties of the mood and feelings questionnaire
35 647 in adolescent psychiatric outpatients: a research note. 1995;36:327-34.
36 648 27. Daviss WB, Birmaher B, Melhem NA, Axelson DA, Michaels SM, Brent DA. Criterion validity of
37 649 the Mood and Feelings Questionnaire for depressive episodes in clinic and non-clinic subjects.
38 650 2006;47:927-34.
39 651 28. Chorpita BF, Yim L, Moffitt C, Umemoto LA, Francis SE. Assessment of symptoms of DSM-IV
40 652 anxiety and depression in children: a revised child anxiety and depression scale. *Behaviour Research
41 653 and Therapy*. 2000;38(8):835-55.
42 654 29. Chorpita BF, Moffitt CE, Gray J. Psychometric properties of the Revised Child Anxiety and
43 655 Depression Scale in a clinical sample. *Behaviour Research and Therapy*. 2005;43(3):309-22.
44 656 30. Goodman R. The Extended Version of the Strengths and Difficulties Questionnaire as a Guide
45 657 to Child Psychiatric Caseness and Consequent Burden. *Journal of Child Psychology and Psychiatry*.
46 658 1999;40(5):791-9.
47 659 31. Yao S, Zhang C, Zhu X, Jing X, McWhinnie CM, Abela JRZ. Measuring Adolescent
48 660 Psychopathology: Psychometric Properties of the Self-Report Strengths and Difficulties
49 661 Questionnaire in a Sample of Chinese Adolescents. *Journal of Adolescent Health*. 2009;45(1):55-62.
50 662 32. Goodman R. Psychometric Properties of the Strengths and Difficulties Questionnaire. *Journal
51 663 of the American Academy of Child & Adolescent Psychiatry*. 2001;40(11):1337-45.
52 664 33. Muris P, Meesters C, van den Berg F. The Strengths and Difficulties Questionnaire (SDQ).
53 665 *European child & adolescent psychiatry*. 2003;12(1):1-8.

- 1
2
3 666 34. Lundh LG, Wangby-Lundh, M., & Bjarehed, J. . Self reported emotional and behavioral
4 667 problems in Swedish 14 to 15-year-old adolescents: A study with the self-report version of the
5 668 Strengths and Difficulties Questionnaire. *Scandinavian Journal of Psychology*. 2008;49:523-32.
6 669 35. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
7 670 measure. *Journal of general internal medicine*. 2001;16(9):606-13.
8 671 36. Spitzer RL, Kroenke K, Williams JW, Löwe B. A brief measure for assessing generalized
9 672 anxiety disorder: The gad-7. *Archives of Internal Medicine*. 2006;166(10):1092-7.
10 673 37. Stevens K. Developing a descriptive system for a new preference-based measure of health-
11 674 related quality of life for children. *Quality of Life Research*. 2009;18(8):1105-13.
12 675 38. Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin N, et al. Development of the EQ-5D-
13 676 Y: a child-friendly version of the EQ-5D. *Quality of life research : an international journal of quality of*
14 677 *life aspects of treatment, care and rehabilitation*. 2010;19(6):875-86.
15 678 39. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and
16 679 preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of Life Research*.
17 680 2011;20(10):1727-36.
18 681 40. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed,
19 682 something blue: a framework for the marriage of health economics and cost-effectiveness
20 683 analysis. *Health Economics*. 2002;11(5):415-30.
21 684 41. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the
22 685 analysis of qualitative data in multi-disciplinary health research. *BMC Medical Research*
23 686 *Methodology*. 2013;13(1):117.
24 687 42. Furniss D, Lang AR, Ewart C. Enhancing Patient Ergonomics with Patient and Public
25 688 Involvement in Research Projects. . In: Holden RJ, Valdez RS, editors. *The Patient Factor: A Handbook*
26 689 *on Patient Ergonomics*: CRC Press; 2001.
27 690 43. Health Research Authority. UK Policy Framework for Health and Social Care Research: Health
28 691 Research Authority; 2017 [Available from: [https://www.hra.nhs.uk/planning-and-improving-](https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/)
29 692 [research/policies-standards-legislation/uk-policy-framework-health-social-care-research/](https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/)
30
31
32
33

34 693
35 694
36 695
37 696
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Participant flow



* For sites where the waiting time for the CAMHS acceptance decision usually exceeds 10 working days from referral receipt, recruitment activities may start and/or continue beyond 10 working days from referral receipt, providing the intervention period can be completed prior to the CAMHS referral decision.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

STANDARDISED Diagnostic Assessment for children and adolescents with emotional difficulties (STADIA): a multi-centre randomised controlled trial

SCREENING

Site Number:	<input type="text"/>
Screening Number:	<input type="text"/>
Sponsor:	Nottinghamshire Healthcare NHS Foundation Trust
CRF Version:	Final v1.1 – 30 April 2019

1 **Site Number:**

2

3 **Screening Number:**

4



5

6

7 **REFERRAL SCREENING**

8

9 If the young person is <16:	Yes	<input type="checkbox"/>
10 Does the referral information include contact details for a named parent/carer?	No	<input type="checkbox"/>
11 <i>If 'no' await parent/carer contact details before proceeding</i>	N/A	<input type="checkbox"/>
12		
13 If the young person is <16:	Yes	<input type="checkbox"/>
14 Is the named parent/carer a local authority representative designated to care	No	<input type="checkbox"/>
15 for the child/young person?	Not known	<input type="checkbox"/>
16 <i>If 'yes' do not proceed</i>	N/A	<input type="checkbox"/>
17 <i>If not known, confirm during telephone eligibility check at enrolment</i>		
18		
19 If the young person is aged 16 or 17:	Young person	<input type="checkbox"/>
20 Whose contact details are given on the referral form?	Parent/carer	<input type="checkbox"/>
21 <i>If young person contact details are provided, they should be contacted in</i>	Both	<input type="checkbox"/>
22 <i>the first instance</i>	N/A	<input type="checkbox"/>
23		
24		
25		
26		

27

28

29 **EMOTIONAL DIFFICULTIES**

30

31 **Emotional difficulties may be indicated by the use of any of the following key words or phrases.*

32 *Tick all that apply. If 'other' record details and seek advice from the PI or NCTU before proceeding.*

33

34 None	<input type="checkbox"/>
35 Agitated / agitation	<input type="checkbox"/>
36 Anger	<input type="checkbox"/>
37 Anxiety / anxious / generalised anxiety	<input type="checkbox"/>
38 Avoids things/people/places	<input type="checkbox"/>
39 Can't leave the house	<input type="checkbox"/>
40 Completing rituals / asking parents to carry out rituals	<input type="checkbox"/>
41 Compulsions	<input type="checkbox"/>
42 Depressed / depression / low / low mood / sad	<input type="checkbox"/>
43 Difficulties sleeping	<input type="checkbox"/>
44 Distress	<input type="checkbox"/>
45 Fears and worries / fears relating to safety (germs, fire)	<input type="checkbox"/>
46 Feeling low	<input type="checkbox"/>
47 Feels flat / empty / blank	<input type="checkbox"/>
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

1 **Site Number:**

--	--	--

2
3
4 **Screening Number:**

--	--	--	--



EMOTIONAL DIFFICULTIES

**Emotional difficulties may be indicated by the use of any of the following key words or phrases.*

Tick all that apply. If 'other' record details and seek advice from the PI or NCTU before proceeding.

Feels hopeless	<input type="checkbox"/>
Feels worthless / stupid	<input type="checkbox"/>
Flashbacks	<input type="checkbox"/>
Hypervigilance	<input type="checkbox"/>
Irritable	<input type="checkbox"/>
Low motivation	<input type="checkbox"/>
Low self-esteem / Hates self	<input type="checkbox"/>
Mood swings / moody	<input type="checkbox"/>
Negative thoughts	<input type="checkbox"/>
Nightmares (if trauma also present)	<input type="checkbox"/>
No (or loss of) energy	<input type="checkbox"/>
No (or loss of) interest in things / gave up... / lack of wanting to do things	<input type="checkbox"/>
Not going to school / unable to go to school	<input type="checkbox"/>
Not sleeping / poor sleep	<input type="checkbox"/>
Obsessions	<input type="checkbox"/>
OCD	<input type="checkbox"/>
Phobia	<input type="checkbox"/>
Panic / panic attacks	<input type="checkbox"/>
PTSD	<input type="checkbox"/>
Self-harm / DSH / Cutting	<input type="checkbox"/>
Suicidal	<input type="checkbox"/>
Suicidal thoughts / thoughts of ending life / thinks about killing self	<input type="checkbox"/>
Tearful	<input type="checkbox"/>
Thoughts of death	<input type="checkbox"/>

1 **Site Number:**

2

3 **Screening Number:**

4



5
6
7 **EMOTIONAL DIFFICULTIES**

8
9 **Emotional difficulties may be indicated by the use of any of the following key words or phrases.*
10 *Tick all that apply. If 'other' record details and seek advice from the PI or NCTU before proceeding.*

11 Tiredness / fatigue	<input type="checkbox"/>
12 Touching objects	<input type="checkbox"/>
13 Trauma	<input type="checkbox"/>
14 Weepy	<input type="checkbox"/>
15 Withdrawal / withdrawn	<input type="checkbox"/>
16 Worried / worrying (incl. worries/concerns about their appearance)	<input type="checkbox"/>
17 Other (please specify)	<input type="checkbox"/>

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 **FOR ALL REFERRALS SCREENED, ENTER SUMMARY DATA ON THE SCREENING & ENROLMENT LOG.**
33 **IF THE YOUNG PERSON APPEARS TO BE ELIGIBLE PROCEED TO THE INVITATION TELEPHONE CALL (CALL 1)**
34 **AND ENTER DETAILS ON THE TRIAL DATABASE.**

35
36
37
38
39
40 **SIGN-OFF STATEMENT**

41 *Completed by the researcher conducting the referral screening.*

42
43
44 To the best of my knowledge, I confirm that I have made every reasonable effort to ensure that ALL of
45 the data in this Case Record Form is a true, accurate and complete report.

46 Print Name	
47 Signature	
48 Date	<input type="text"/> - <input type="text"/> - <input type="text"/>

DAWBA Report

The DAWBA collects information about a range of common emotional and behavioural difficulties, and uses this information to produce a report to highlight the level of difficulties.

How to understand the ratings

These ratings compare your responses with the responses from large numbers of other parents and young people across the UK. Many parents and young people find this sort of comparison helpful, but it is just a guide and not the same as a face-to-face assessment with a specialist.

To make it easier to read, we have grouped the ratings into four categories. Each category is different. This shows how your [child's] (*delete as appropriate*) difficulties compare with other children / young people:



Close to average

In the general population most children/ young people (roughly 80 out of 100) are in the "close to average" category.



Slightly raised

If the ratings are in the "slightly raised" category this means the difficulties are slightly higher than average. Roughly 10 out of 100 children / young people are in this category.



High

Around 5 in 100 children / young people score in the "high" category. This means that the difficulties are more severe than average.



Very high

Around 5 in 100 children score in the "very high" category. This means that the difficulties appear to be more severe than we find in 95 out of every 100 children / young people.



The rating is only a rough guide. As high ratings can be a "false alarm", please use your own judgement. Not all difficulties need treating. Some difficulties get better by themselves, particularly if they are mild or if they have only been there for a short time.

Most strengths and difficulties lie on a scale. There will be children / young people at each end of the scale but most children / young people will fall somewhere in between.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Your [child's] (*delete as appropriate*) ratings:

- **Close to average / Slightly raised / High / Very high** for worrying a lot about different things (general fears and worries)
- **Close to average / Slightly raised / High / Very high** for worries about separation from key "attachment figures" such as parents (separation anxiety)
- **Close to average / Slightly raised / High / Very high** for specific fears (specific phobia)
- **Close to average / Slightly raised / High / Very high** for social fears (social anxiety)
- **Close to average / Slightly raised / High / Very high** for panic attacks
- **Close to average / Slightly raised / High / Very high** for fears of crowds, public places, open spaces etc (agoraphobia)
- **Close to average / Slightly raised / High / Very high** for stress linked to particularly frightening events (post-traumatic stress)
- **Close to average / Slightly raised / High / Very high** for obsessions or compulsions
- **Close to average / Slightly raised / High / Very high** for depression or loss of interest
- **Close to average / Slightly raised / High / Very high** for disruptive and uncooperative behaviours (troublesome behaviour)
- **Close to average / Slightly raised / High / Very high** for antisocial or aggressive behaviours that can get people into serious trouble (troublesome behaviour)

1
2
3 *Appendix 3. Eligible emotional disorder diagnoses*
4
5

6	Anxiety disorder
7	Separation anxiety disorder
8	Specific phobia (any)
9	Social phobia or Social anxiety disorder
10	Agoraphobia
11	Panic disorder (DSM5 additionally has Panic Attack with a specifier)
12	Phobic anxiety disorder (unspecified)
13	Selective mutism
14	Generalized anxiety disorder
15	Obsessive-compulsive and related disorders
16	Body dysmorphic disorder
17	Acute stress reaction
18	Acute Stress Disorder
19	Post-traumatic stress disorder
20	Adjustment Disorder
21	Other anxiety disorder
22	Mixed anxiety and depressive disorder
23	Depression
24	Depressive episode (any / mild / moderate / severe)
25	Depressive disorder
26	Recurrent depressive disorder (any / mild / moderate / severe)
27	Major Depressive disorder
28	Persistent Depressive disorder
29	Other depressive episode
30	Persistent mood (affective) disorder (including cyclothymic disorder / dysthymic disorder)
31	Other / Unspecified mood (affective) disorder
32	Bipolar disorder
33	Bipolar affective disorder
34	Manic episode
35	Childhood emotional disorder unspecified (F93.9)
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	



**STANDARDISED Diagnostic Assessment for children and adolescents with emotional difficulties (STADIA):
A multi-centre randomised controlled trial**

OUTCOME DEFINITION & ADJUDICATION PLAN

Final 1.0 – 25 February 2020

EMOTIONAL DISORDER DIAGNOSES RECORDED IN THE 12 MONTHS POST-RANDOMISATION

CONSTITUTES A CLINICAL DIAGNOSIS	REFER FOR ADJUDICATION	DOES NOT CONSTITUTE A CLINICAL DIAGNOSIS
<ul style="list-style-type: none"> - The presence of an <u>eligible diagnosis</u> within the diagnosis tab of the clinical record. - The presence of an <u>eligible diagnosis</u> in the clinical record preceded by the heading 'diagnosis'. - The presence of an <u>eligible diagnosis</u> in the clinical record preceded by a heading such as 'current difficulties' or 'presenting problems', except where this has been documented in the write up of the first appointment or in reference to the information received at referral (as this may simply reflect a pre-existing or referrer-made diagnosis). - A clear confirmatory statement including use of an <u>eligible diagnosis</u>, for example: <i>Meets the diagnostic criteria for...</i> <i>Presentation is explained by a diagnosis of...</i> 	<ul style="list-style-type: none"> - The presence of <u>similar diagnostic terms</u> within the diagnosis tab of the clinical record. - The presence of an <u>eligible diagnosis</u> preceded by a heading such as 'current difficulties' or 'presenting problems', documented in the write up of the first appointment or in reference to the information received at referral. - The presence of <u>similar diagnostic terms</u> preceded by a heading such as 'diagnosis', 'current difficulties' or 'presenting problems'. - Reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>, but where the context does not provide a clear confirmatory statement, for example: <i>?...</i> <i>Possible...</i> <i>Assessed for...</i> <i>...-type symptoms / behaviour</i> <i>...-like symptoms / behaviour</i> <i>Symptoms of...</i> <i>History of...</i> 	<ul style="list-style-type: none"> - No reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>. - A clear statement about the absence of an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>, for example: <i>No evidence of...</i> <i>...not meeting criteria for disorder</i>
<i>Data collection and entry: instructions for researchers</i>		
<i>Use the checklist of eligible emotional disorder diagnoses.</i>	<i>Document these as other emotional disorders.</i>	<i>Check 'none of the above' in the checklist of emotional disorder diagnoses and answer 'no' to 'other emotional disorder diagnoses'.</i>

Note: For definition of underlined terms see the Glossary below.

NO EMOTIONAL DISORDER

If there are no emotional disorder diagnoses documented in the CAMHS notes in 12 months post-randomisation, researchers will select one of the following options:

1. A clinician has documented the absence of emotional disorder.
2. Uncertainty about the presence of an emotional disorder is documented in the notes (for example, reflecting ongoing assessment / investigation).
3. There is no diagnostic information relating to emotional disorders documented in the CAMHS record.

A clinician has documented the <u>absence</u> of emotional disorder.	Uncertainty about the presence of an emotional disorder is documented in the notes (for example, reflecting ongoing assessment / investigation).	There is <u>no diagnostic information</u> relating to emotional disorders documented in the CAMHS record.
<ul style="list-style-type: none"> - Nothing in the clinical record is assessed to constitute a documented clinical diagnosis, AND - There is a clear statement about the absence of one or more of the <u>eligible diagnoses</u> or <u>similar diagnostic terms</u>, for example: <div style="text-align: center;"><i>No evidence of...</i> <i>...not meeting criteria for disorder</i></div> 	<ul style="list-style-type: none"> - Nothing in the clinical record is assessed to constitute a documented clinical diagnosis, AND - Reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>, but where the context does not provide a clear confirmatory statement, for example: <div style="text-align: center;">?... <i>Possible...</i> <i>Assessed for...</i> <i>...-type symptoms / behaviour</i> <i>...-like symptoms / behaviour</i> <i>Symptoms of...</i> <i>History of...</i></div> 	<ul style="list-style-type: none"> - Nothing in the clinical record is assessed to constitute a documented clinical diagnosis, AND - There is no reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>.* - If emotional difficulties are identified they are described only by reference to the presenting symptoms with no attempt made to link these to an eligible diagnosis, for example: <div style="text-align: center;"><i>Presenting issue - Mood swings</i> <i>Describing examples of ruminating thoughts.</i></div> <p>* Note that this includes children/young people who have <u>not been seen by CAMHS</u> in the 12-months post-randomisation.</p>
<i>Document these as absence of emotional disorder.</i>	REFER FOR ADJUDICATION	MAY REQUIRE ADJUDICATION

EMOTIONAL DISORDER DIAGNOSIS ADJUDICATION OUTCOME	
<p>The Adjudication Committee will first consider whether the record:</p> <ol style="list-style-type: none"> 1) Constitutes a clinical diagnosis 2) Does not constitute a clinical diagnosis 	<p>If (1) then the Adjudication Committee will determine which of the eligible emotional disorder diagnoses apply.</p> <p>If (2) then the Adjudication Committee will determine whether the record constitutes:</p> <ol style="list-style-type: none"> a) Absence of emotional disorder b) Uncertainty about the presence of emotional disorder c) No diagnostic information

TREATMENTS / INTERVENTIONS GIVEN

CONSTITUTES A TREATMENT / INTERVENTION	REFER FOR ADJUDICATION
- The presence of an <u>eligible treatment / intervention</u> documented within the clinical record.	- Documented intervention by CAMHS where the description does not include an <u>eligible treatment / intervention</u> .
<i>Data collection and entry: instructions for researchers</i>	
<i>Use the checklist of eligible treatments / interventions.</i>	<i>Document these as other treatments / interventions.</i>

TREATMENTS / INTERVENTIONS ADJUDICATION OUTCOME

The Adjudication Committee will first consider whether the record: 1) Constitutes a treatment / intervention 2) Does not constitute a treatment / intervention	If (1) then the Adjudication Committee will determine whether the record should be categorised: a) As an existing treatment / intervention b) As an 'other' treatment / intervention
----------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GLOSSARY

Eligible diagnosis	One of the pre-specified diagnoses listed on the data collection form. These should be considered present only when the <u>exact phrase</u> and/or corresponding ICD/DSM code is documented.
Similar diagnostic terms	Words or phrases which are similar to the eligible diagnoses, but without use of the exact wording or corresponding ICD/DSM code (e.g., separation anxiety WITHOUT use of the term disorder) or where the exact words are used alongside additional phrases (e.g., OCD-type behaviour or OCD-like symptoms).
Eligible treatment / intervention	One of the pre-specified treatments / interventions listed on the data collection form.
Adjudication Committee	The Adjudication Committee will comprise the clinician members of the Trial Management Group. A minimum of two clinicians will review terms referred for adjudication, with a third consulted if a consensus is not reached. The Adjudication Committee will be blinded to treatment allocation for the purposes of adjudication.

Appendix 5. Summary of assessments

Time-point	Maximum 10 working days from referral receipt ¹			6 months post-randomisation	12 months post-randomisation	
Activity	Screening and invitation	Eligibility and enrolment	Consent and baseline	Follow-Up		
Initial eligibility screen of referral information	X			Randomisation Intervention DAWBA in addition to usual practice Or Usual practice only		
Telephone invitation to participate	X					
Verbal agreement to participate		X				
Confirm eligibility		X				
Obtain enrolment data		X				
Participant enrolment		X				
Written informed consent/assent (online)			X			
Baseline demographics (parent/carer and CYP aged 16 & 17)			X			
Mood and Feelings Questionnaire (MFQ)			X			
Revised Child's Anxiety Depression Scale (RCADS)			X			
Strengths and Difficulties Questionnaire (SDQ) ²			X			
Child Revised Impact of Events Scale (CRIES-8)(42) ³			X			
CYP self-report self-harm measure			X			
Patient Health Questionnaire (PHQ-9) - parent/carer only			X			
Generalised Anxiety Disorder Assessment (GAD-7) - parent/carer only			X			
Child Health Utility 9D (CHU9D)			X			
EuroQol-5D youth (EQ-5D-Y)			X			
EuroQol-5D five level (EQ-5D-5L)			X			
Resource Use Questionnaire - parent/carer and CYP aged 16 & 17			X			
Data collection from records ⁴			X			
¹ For sites where the waiting time for the CAMHS acceptance decision usually exceeds 10 working days from referral receipt, recruitment activities may start and/or continue beyond 10 working days from referral receipt, providing the intervention period can be completed prior to the CAMHS referral decision.						
² For participants in the intervention arm, the baseline SDQ will be collected as part of the DAWBA, completed post-randomisation.						
³ Additional data collection undertaken to explore post-traumatic stress disorder symptoms in CYP during the Covid-19 pandemic						
⁴ Data collection from records will be completed periodically throughout the 12 month follow-up period.						

ADD LOCAL HEADER

Standardised Diagnostic Assessment for children and young people with emotional difficulties (STADIA)

Informed Consent Form for the Parent/Carer

Final v2.0 13 August 2020

Name of Principal Investigator: [add local PI name]

IRAS Project ID: 255635

Participant Trial ID:

(To be completed after randomisation)

--	--	--	--	--

We are doing this research to find out how to make sure children and young people get the help they need when they are referred to CAMHS. We have invited you to take part in this research because a young person you care for has been referred to CAMHS. You can decide whether or not to take part in this research. If you agree to take part in the STADIA Trial, please read and acknowledge each of the following statements.

<i>A drop-down menu will be provided within the online electronic Informed Consent Form so that the person providing consent has the option to acknowledge/agree to each of the following statements.</i>	
1.	I confirm that I have read and understand the Participant Information Sheet, Version <insert current PIS version number and date > for the above research. <i>(Only for the parent/carer of children/young people aged 11-15)</i> [My child and] I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.
2.	<i>Only for the parent/carer of children/young people aged 11-15</i> I have spoken to my child about the research and they are aware of the study.
3.	I understand that mine and my child’s participation is voluntary and that I am free to withdraw at any time, without giving any reason, and without my child’s medical care or legal rights being affected. I understand that should I withdraw, then the information collected so far cannot be deleted and that this information may still be used in the research.
4.	I understand that relevant sections of my child’s CAMHS records and data collected in the trial may be looked at by authorised individuals from the Nottingham Clinical Trials Unit (University of Nottingham), the Sponsor (Nottinghamshire Healthcare NHS Foundation Trust), NHS bodies, the trial research group and regulatory authorities where it is relevant to taking part in this study. I give permission for these individuals to have access to these records and for my consent form to be retained by the Nottingham Clinical Trials Unit.
5.	I give permission for the Nottingham Clinical Trials Unit, the Sponsor and the trial research group to collect, store, analyse and publish information obtained from mine and my child’s participation in this trial. I understand that our personal details will be kept confidential.
6.	I understand that the Nottingham Clinical Trials Unit and the trial research group will be provided with mine and my child’s personal details to send questionnaires by email and study-related correspondence during the trial. I give my permission for this information to be kept and for these individuals to contact me.
7.	I understand that if I fill out the DAWBA, I will receive a copy of the DAWBA report and a copy will also be provided to the CAMHS team and kept in my child’s CAMHS records.
8.	I agree to my child’s GP being informed of their participation in this trial.
9.	I understand that the anonymised information collected about me and my child may be used to support other research in the future and may be shared with other researchers.
10.	I agree to take part in the above trial.

Please also answer yes or no to the following options.

<i>A drop-down menu will be provided within the online electronic Informed Consent Form so that the person providing consent has the option to answer yes or no to each of the following optional statements.</i>			
1.	<i>Interviews about your experiences</i> I agree to be contacted about the STADIA interview study. I understand that there is no obligation to take part and I will just be informed of what the study will involve.	Yes	No
2.	<i>Future studies</i> I agree to be contacted about other research studies in the future. I understand that there is no obligation to take part and I will just be informed of what the future research would involve.	Yes	No
3.	<i>Results of the STADIA study</i> I would like to receive a summary of the results at the end of the STADIA study.	Yes	No
4.	<i>Only for the parent/carer of children/young people aged 11-15</i> <i>Questionnaires</i> I agree to my child being invited to complete questionnaires about their mood and feelings for the research.	Yes	No
5.	I consent to [INSERT NHS TRUST NAME] passing identifiable data (my child's NHS number, name and date of birth) to the organisations that are responsible for health information including NHS Digital. This will be used to request data from the Children and Young People's Health Services Data Set and the Mental Health Services Data Set.	Yes	No

Type your name here:

Name of parent/carer

Date [system generated]

Type the name of your child here:

Name of child/young person

Date [system generated]

System use only:

Name of person taking consent
(You must be on the delegation log)

Date [system generated]

NB. Signatures will not be collected as consent will be obtained online. Participants will be asked to complete the eICF and write their name before submitting the online form; the date will be system-generated. The name of the researcher who provided the study information and the date the eICF was generated will also be recorded within the online system.

The online electronic Informed Consent Form (eICF) will be retained within the trial database. Printable (PDF) copies will be generated and retained within the Investigator Site File and CAMHS records. A copy will be sent by email to the participant.

ADD LOCAL HEADER

Standardised Diagnostic Assessment for children and young people with emotional difficulties (STADIA)

Assent form for young people aged 11-15

Final v1.0 28-Mar-2019

Name of Principal Investigator: [add local PI name]

IRAS Project ID: 255635

Participant Trial ID:

(To be completed after randomisation)

--	--	--	--	--

We are doing this research to find out how to make sure people get the help they need when they are referred to CAMHS. We are asking you to help with this research but you can decide whether or not to take part.

If you agree to help with the STADIA Trial please answer the following questions.

<i>A drop-down menu will be provided within the online electronic Assent Form so that the young person providing assent has the option to acknowledge/agree to each of the following statements.</i>			
1.	Have you read the information about the research or has someone explained it to you?	Yes	No
2.	Do you understand what the research is about?	Yes	No
3.	Have you been able to ask all the questions you want?	Yes	No
4.	Do you understand that it's your choice whether or not to take part and it's OK to stop taking part at any time?	Yes	No
5.	Do you want to help with the research by completing some questionnaires about your mood and feelings?	Yes	No

Type your name here:

Name of child/young person

Date [system generated]

System use only:

Name of person taking consent
(You must be on the delegation log)

Date [system generated]

NB. Signatures will not be collected as consent will be obtained online. Participants will be asked to complete the eICF and write their name before submitting the online form; the date will be system-generated. The name of the researcher who provided the study information and the date the eICF was generated will also be recorded within the online system. The online electronic Informed Consent Form (eICF) will be retained within the trial database. Printable (PDF) copies will be generated and retained within the Investigator Site File and CAMHS records. A copy will be sent by email to the participant.

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

			Page Number (line)
Administrative information			
Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1(1-2)

1	Trial registration	#2a	Trial identifier and registry name. If not yet	2 (68)
2			registered, name of intended registry	
3				
4				
5				
6	Trial registration:	#2b	All items from the World Health Organization Trial	Throughout
7	data set		Registration Data Set	
8				
9				
10				
11				
12	Protocol version	#3	Date and version identifier	18 (499)
13				
14				
15	Funding	#4	Sources and types of financial, material, and other	19 (544-547)
16			support	
17				
18				
19				
20	Roles and	#5a	Names, affiliations, and roles of protocol	1 (5-9)
21	responsibilities:		contributors	
22				
23	contributorship			
24				
25				
26				
27				
28	Roles and	#5b	Name and contact information for the trial sponsor	19 (562-563)
29	responsibilities:			
30				
31	sponsor contact			
32				
33	information			
34				
35				
36				
37				
38	Roles and	#5c	Role of study sponsor and funders, if any, in study	19 (544-550)
39	responsibilities:		design; collection, management, analysis, and	
40			interpretation of data; writing of the report; and the	
41	sponsor and funder		decision to submit the report for publication,	
42			including whether they will have ultimate authority	
43			over any of these activities	
44				
45				
46				
47				
48				
49				
50				
51				
52	Roles and	#5d	Composition, roles, and responsibilities of the	18 (515-523)
53	responsibilities:		coordinating centre, steering committee, endpoint	
54			adjudication committee, data management team,	
55	committees			
56				
57				
58				
59				
60				

and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)

Introduction

Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-4 (91-148)
Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	3-4, 7-8 (129-148)
Objectives	#7	Specific objectives or hypotheses	4 (150-176)
Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4 (182-183)

Methods:

Participants, interventions, and outcomes

1	Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	5 (190-193)
2				
3				
4				
5				
6				
7				
8				
9				
10				
11	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	5-6 (see table 1)
12				
13				
14				
15				
16				
17				
18				
19				
20				
21	Interventions:	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	7-8 (269-303)
22	description			
23				
24				
25				
26				
27				
28				
29	Interventions:	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)	n/a
30	modifications			
31				
32				
33				
34				
35				
36				
37				
38				
39	Interventions:	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)	7-8 (269-303)
40	adherence			
41				
42				
43				
44				
45				
46	Interventions:	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	7-8 (269-303)
47	concomitant care			
48				
49				
50				
51	Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from	8-14 (316-337)
52				
53				
54				
55				
56				
57				
58				
59				
60				

baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure 1)	5-7 (197-239) and see figure 1
42 43 44 45 46 47 48 49 50 51	Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	8 (306-312)
52 53 54 55 56 57 58 59 60	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	5 (197-212)

Methods:

Assignment of interventions (for controlled trials)

52 53 54 55 56 57 58 59 60	Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce	7 (242-246)
----------------------------------------------------	-----------------------------------------------	----------------------	---------------------------------------------------------------------------------------------------------------------------------------------	-------------

1 predictability of a random sequence, details of any
 2
 3 planned restriction (eg, blocking) should be
 4
 5 provided in a separate document that is
 6
 7 unavailable to those who enrol participants or
 8
 9 assign interventions
 10

11
 12 Allocation [#16b](#) Mechanism of implementing the allocation 7 (248-252)

13 concealment sequence (eg, central telephone; sequentially
 14
 15 mechanism numbered, opaque, sealed envelopes), describing
 16
 17 any steps to conceal the sequence until
 18
 19 interventions are assigned
 20
 21
 22
 23

24 Allocation: [#16c](#) Who will generate the allocation sequence, who 7 (244-252)

25 implementation will enrol participants, and who will assign
 26
 27 participants to interventions
 28
 29
 30

31 Blinding (masking) [#17a](#) Who will be blinded after assignment to 7 (254-260)

32 interventions (eg, trial participants, care providers,
 33
 34 outcome assessors, data analysts), and how
 35
 36
 37
 38

39 Blinding (masking): [#17b](#) If blinded, circumstances under which unblinding is 7 (254-256)

40 emergency permissible, and procedure for revealing a
 41
 42 unblinding participant's allocated intervention during the trial
 43
 44
 45
 46

47 **Methods: Data**

48 collection,

49 management, and

50 analysis
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60

1	Data collection plan	#18a	Plans for assessment and collection of outcome,	15 (356-363)
2			baseline, and other trial data, including any related	
3			processes to promote data quality (eg, duplicate	
4			measurements, training of assessors) and a	
5			description of study instruments (eg,	
6			questionnaires, laboratory tests) along with their	
7			reliability and validity, if known. Reference to	
8			where data collection forms can be found, if not in	
9			the protocol	
10				
11				
12				
13				
14				
15				
16				
17				
18				
19				
20				
21				
22	Data collection plan:	#18b	Plans to promote participant retention and	15 (359-362)
23	retention		complete follow-up, including list of any outcome	
24			data to be collected for participants who	
25			discontinue or deviate from intervention protocols	
26				
27				
28				
29				
30				
31				
32	Data management	#19	Plans for data entry, coding, security, and storage,	15 (367-375)
33			including any related processes to promote data	
34			quality (eg, double data entry; range checks for	
35			data values). Reference to where details of data	
36			management procedures can be found, if not in	
37			the protocol	
38				
39				
40				
41				
42				
43				
44				
45				
46				
47	Statistics: outcomes	#20a	Statistical methods for analysing primary and	15-17 (378-451)
48			secondary outcomes. Reference to where other	
49			details of the statistical analysis plan can be found,	
50			if not in the protocol	
51				
52				
53				
54				
55				
56				
57				
58				
59				
60				

1	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup	15-17 (378-451)
2				
3	analyses		and adjusted analyses)	
4				
5				
6	Statistics: analysis	#20c	Definition of analysis population relating to	15 (378-380)
7				
8	population and		protocol non-adherence (eg, as randomised	
9				
10	missing data		analysis), and any statistical methods to handle	
11				
12			missing data (eg, multiple imputation)	
13				
14				
15				
16	Methods: Monitoring			
17				
18				
19	Data monitoring:	#21a	Composition of data monitoring committee (DMC);	18 (522-523)
20				
21	formal committee		summary of its role and reporting structure;	
22				
23			statement of whether it is independent from the	
24				
25			sponsor and competing interests; and reference to	
26				
27			where further details about its charter can be	
28				
29			found, if not in the protocol. Alternatively, an	
30				
31			explanation of why a DMC is not needed	
32				
33				
34				
35				
36	Data monitoring:	#21b	Description of any interim analyses and stopping	18 (520-523)
37				
38	interim analysis		guidelines, including who will have access to these	
39				
40			interim results and make the final decision to	
41				
42			terminate the trial	
43				
44				
45				
46	Harms	#22	Plans for collecting, assessing, reporting, and	18 (502-512)
47				
48			managing solicited and spontaneously reported	
49				
50			adverse events and other unintended effects of	
51				
52			trial interventions or trial conduct	
53				
54				
55				
56				
57				
58				
59				
60				

1	Auditing	#23	Frequency and procedures for auditing trial	18 (520-523)
2				
3				
4			conduct, if any, and whether the process will be	
5				
6			independent from investigators and the sponsor	
7				
8				
9	Ethics and			
10				
11	dissemination			
12				
13				
14	Research ethics	#24	Plans for seeking research ethics committee /	18 (497-499)
15				
16	approval		institutional review board (REC / IRB) approval	
17				
18				
19	Protocol	#25	Plans for communicating important protocol	18 (497-499)
20				
21	amendments		modifications (eg, changes to eligibility criteria,	
22			outcomes, analyses) to relevant parties (eg,	
23				
24			investigators, REC / IRBs, trial participants, trial	
25				
26			registries, journals, regulators)	
27				
28				
29				
30				
31	Consent or assent	#26a	Who will obtain informed consent or assent from	6 (see table 2)
32				
33			potential trial participants or authorised surrogates,	
34				
35			and how (see Item 32)	
36				
37				
38				
39	Consent or assent:	#26b	Additional consent provisions for collection and	6 (table 2)
40				
41	ancillary studies		use of participant data and biological specimens in	
42				
43			ancillary studies, if applicable	
44				
45				
46				
47	Confidentiality	#27	How personal information about potential and	15 (372-375)
48				
49			enrolled participants will be collected, shared, and	
50				
51			maintained in order to protect confidentiality	
52				
53			before, during, and after the trial	
54				
55				
56				
57				
58				
59				
60				

1	Declaration of	#28	Financial and other competing interests for	19 (553)
2				
3	interests		principal investigators for the overall trial and each	
4			study site	
5				
6				
7				
8				
9	Data access	#29	Statement of who will have access to the final trial	15 (372-375)
10				
11			dataset, and disclosure of contractual agreements	
12				
13			that limit such access for investigators	
14				
15				
16	Ancillary and post	#30	Provisions, if any, for ancillary and post-trial care,	n/a
17	trial care		and for compensation to those who suffer harm	
18			from trial participation	
19				
20				
21				
22				
23				
24	Dissemination	#31a	Plans for investigators and sponsor to	18 (526-527)
25	policy: trial results		communicate trial results to participants,	
26			healthcare professionals, the public, and other	
27			relevant groups (eg, via publication, reporting in	
28			results databases, or other data sharing	
29			arrangements), including any publication	
30			restrictions	
31				
32				
33				
34				
35				
36				
37				
38				
39				
40				
41	Dissemination	#31b	Authorship eligibility guidelines and any intended	18-19 (537-541)
42	policy: authorship		use of professional writers	
43				
44				
45				
46	Dissemination	#31c	Plans, if any, for granting public access to the full	18 (530-531)
47	policy: reproducible		protocol, participant-level dataset, and statistical	
48				
49	research		code	
50				
51				
52				
53				
54	Appendices			
55				
56				
57				
58				
59				
60				

1 Informed consent [#32](#) Model consent form and other related Supplementary
2 materials documentation given to participants and materials 6 & 7
3 authorised surrogates
4
5
6
7

8 Biological [#33](#) Plans for collection, laboratory evaluation, and n/a
9 specimens storage of biological specimens for genetic or
10 molecular analysis in the current trial and for future
11 use in ancillary studies, if applicable
12
13
14
15
16
17
18

19 None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative
20 Commons Attribution License CC-BY-NC. This checklist can be completed online using
21 <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with
22 [Penelope.ai](#)
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

STANDARDISED Diagnostic Assessment for children and young people with emotional difficulties (STADIA): protocol for a multi-centre randomised controlled trial

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2021-053043.R2
Article Type:	Protocol
Date Submitted by the Author:	10-Mar-2022
Complete List of Authors:	<p>Day, Florence; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Wyatt, Laura; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Bhardwaj, Anupam; Cambridgeshire and Peterborough NHS Foundation Trust</p> <p>Dubicka, Bernadka; The University of Manchester; Pennine Care NHS Foundation Trust</p> <p>Ewart, Colleen; University of Nottingham, STADIA Patient and Public Involvement co-lead, Institute of Mental Health</p> <p>Gledhill, Julia; Central and North West London NHS Foundation Trust</p> <p>James, Marilyn; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Lang, Alexandra; University of Nottingham, Faculty of Engineering</p> <p>Marshall, Tamsin; Berkshire Healthcare NHS Foundation Trust</p> <p>Montgomery, Alan; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Reynolds, Shirley; University of Reading, School of Psychology and Clinical Language Sciences</p> <p>Sprange, Kirsty; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Thomson, Louise; University of Nottingham, Institute of Mental Health, School of Medicine</p> <p>Bradley, Ellen; University of Nottingham, Institute of Mental Health, School of Medicine</p> <p>Lathe, James; University of Nottingham, Nottingham Clinical Trials Unit, University of Nottingham</p> <p>Newman, Kristina; Nottinghamshire Healthcare NHS Foundation Trust, Institute of Mental Health</p> <p>Partlett, Chris; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Starr, Kath; University of Nottingham, Nottingham Clinical Trials Unit, School of Medicine</p> <p>Sayal, Kapil; University of Nottingham, Institute of Mental Health, School of Medicine; Nottinghamshire Healthcare NHS Foundation Trust, Institute of Mental Health</p>
Primary Subject Heading:	Mental health

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Secondary Subject Heading:	Mental health
Keywords:	Child & adolescent psychiatry < PSYCHIATRY, Depression & mood disorders < PSYCHIATRY, HEALTH ECONOMICS



1
2
3 1 **STANDARDISED Diagnostic Assessment for children and young people with emotional difficulties**
4 2 **(STADIA): protocol for a multi-centre randomised controlled trial**
5 3

6 4
7 4 **Authors:**

8 5 Florence Day^{1*}, Laura Wyatt^{1*}, Anupam Bhardwaj², Bernadka Dubicka³, Colleen Ewart⁴, Julia Gledhill⁵,
9 6 Marilyn James¹, Alexandra Lang⁶, Tamsin Marshall⁷, Alan Montgomery¹, Shirley Reynolds⁸, Kirsty
10 7 Sprange¹, Louise Thomson⁹, Ellen Bradley⁹, James Lathe¹, Kristina Newman¹⁰, Chris Partlett¹, Kath
11 8 Starr¹ & Kapil Sayal^{9,10}

12 9 *joint first authors
13 10

14 11 **Corresponding author:**

15 12 Professor Kapil Sayal
16 13 Institute of Mental Health
17 14 School of Medicine
18 15 University of Nottingham
19 16 Nottingham, NG8 1BB
20 17

21 18 Email: kapil.sayal@nottingham.ac.uk
22 19
23 20

24 21 Word count, excluding title page, abstract, references, figures and tables: 4505
25 22

26 23 1 Nottingham Clinical Trials Unit, School of Medicine, University of Nottingham, Nottingham NG7
27 24 2RD

28 25 2 Cambridge and Peterborough Foundation Trust, Brookside CAMHS, Cambridge CB2 8AH

29 26 3 Pennine Care NHS Foundation Trust, Ashton-under-Lyne OL6 7SR

30 27 4 STADIA Patient and Public Involvement co-lead, Institute of Mental Health, University of
31 28 Nottingham, Nottingham NG8 1BB

32 29 5 Central and North West London NHS Foundation Trust, Harrow CAMHS, Ash Tree Clinic, South
33 30 Harrow HA2 8EQ

34 31 6 Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD

35 32 7 Berkshire Healthcare NHS Foundation Trust, Fitzwilliam House, Bracknell RG12 1BQ

36 33 8 School of Psychology and Clinical Language Sciences, University of Reading, Reading RG6 6DZ

37 34 9 Institute of Mental Health, School of Medicine, University of Nottingham, Nottingham NG8 1BB

38 35 10 Nottinghamshire Healthcare NHS Foundation Trust, Institute of Mental Health, Nottingham NG8
39 36 1BB
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 38 **ABSTRACT**
4
5 39

6 40 **Introduction**

7 41 Emotional disorders (such as anxiety and depression) are associated with considerable distress and
8 42 impairment in day-to-day function for affected children and young people and for their families.
9 43 Effective evidence-based interventions are available but require appropriate identification of
10 44 difficulties to enable timely access to services. Standardised Diagnostic Assessment (SDA) tools may
11 45 aid in the detection of emotional disorders, but there is limited evidence on the utility of SDA tools
12 46 in routine care and equipoise amongst professionals about their clinical value.
13 47

14 48 **Methods and analysis**

15 49 A multi-centre, two-arm, parallel group RCT, with embedded qualitative and health economic
16 50 components. Participants will be randomised in a 1:1 ratio to either the Development and Wellbeing
17 51 Assessment (DAWBA) SDA tool as an adjunct to usual clinical care, or usual care only.
18 52

19 53 A total of 1,210 participants (Children and Young People referred to outpatient, specialist Child and
20 54 Adolescent Mental Health Services (CAMHS) with emotional difficulties and their parent/carers) will
21 55 be recruited from at least 6 sites in England.
22 56

23 57 The primary outcome is a clinician-made diagnosis about the presence of an emotional disorder
24 58 within 12-months of randomisation. Secondary outcomes include referral acceptance, diagnosis and
25 59 treatment of emotional disorders, symptoms of emotional difficulties and comorbid disorders and
26 60 associated functional impairment.
27 61

28 62 **Ethics and dissemination**

29 63 The study received favourable opinion from the South Birmingham Research Ethics Committee (Ref.
30 64 19/WM/0133). Results of this trial will be reported to the funder and published in full in the HTA
31 65 Journal series and also submitted for publication in a peer reviewed journal.
32 66

33 67 **Registration details**

34 68 The STADIA trial was prospectively registered as ISRCTN15748675 on 29 May 2019.
35 69

36 70 **Keywords**

37 71 RCT; CAMHS; standardised diagnostic assessment; DAWBA; emotional disorders; diagnosis;
38 72 outcomes; health economics; cost effectiveness; cost utility.
39 73
40 74

41 75 **ARTICLE SUMMARY**
42 76

43 77 **Strengths and limitations of this study**

- 44 78
- 45 79 • Large real-world multicentre randomised controlled trial of the DAWBA SDA tool as an adjunct
46 80 to usual care versus usual care only.
 - 47 81 • Trial procedures are carried out remotely with all data collection and the DAWBA completed
48 82 online or via telephone, facilitating post-trial implementation into future service delivery models
49 83 and routine clinical care.
 - 50 84 • The embedded health economic component permits evaluation of both clinical and cost
51 85 effectiveness.
 - 52 86 • Embedded qualitative work will support optimal delivery and implementation to enhance
53 87 acceptability, effectiveness and long-term uptake.
 - 54 88 • Participants, researchers and clinicians cannot be blinded to treatment allocation.
- 55 89
56 90

89 INTRODUCTION

90
91 Emotional disorders cause considerable distress for affected Children and Young People (CYP) and
92 their families, with adverse effects on family and peer relationships, quality of life, social
93 involvement and activities, academic attainment and occupational opportunities, ultimately
94 affecting life chances.(1-4) Emotional disorders are frequently comorbid with other disorders (2, 5),
95 and are associated with self-harm and completed suicide. Effective evidence-based interventions are
96 available but require appropriate identification of presenting difficulties to enable timely access to
97 services and earlier recovery.(3)

98
99 The prevalence of emotional disorders has increased considerably over the past two decades.(1) In
100 the UK, CYP with clinically significant emotional difficulties may be referred to outpatient specialist
101 Child and Adolescent Mental Health Services (CAMHS). However, insufficient information is a
102 common reason for referrals being declined.(6) There is limited evidence to inform optimal
103 approaches to determine which referrals should be accepted, contributing to a large variation in
104 acceptance rates.(6) Likewise there is a lack of evidence on how best to conduct assessments for
105 suspected emotional difficulties to optimise outcomes. Acceptance criteria and assessment
106 procedures differ across services and there is no single standardised approach.

107
108 The multi-disciplinary nature of CAMHS means CYP are assessed by practitioners from different
109 professional backgrounds, with variations in training, ethos and conceptualisations of presenting
110 difficulties. The type and scope of assessments offered vary. Assessments are often conducted by
111 practitioners without formal diagnostic training(7) and recording of potential diagnostic information
112 can be influenced by patient, clinician and service related contextual considerations(8). The validity
113 and value of mental health diagnoses have been questioned, reflecting concerns around restricting
114 service access (9), stigma or labelling.(7, 10, 11) This can mean that in routine practice, assessments
115 are often undertaken without the aim of making or recording a diagnosis.

116
117 However, NICE guidelines for management and treatment are usually based on diagnostic
118 classification of disorders, so the ability to offer evidence-based interventions requires that the CYP's
119 difficulties are appropriately identified. Although NICE Quality Standards(12) state that CYP with
120 suspected depression should have the diagnosis confirmed and recorded, this is highly variable in
121 practice.(7, 13) The use of diagnostic assessments has been recommended so that important
122 problems are detected and appropriate interventions are offered.(3, 11) The NICE guidelines for
123 depression have recommended the use of standardised diagnostic assessment (SDA) tools as
124 potential adjuncts in the detection of depression within CAMHS.(14) It has further been
125 recommended that SDA tools should be used as an adjunct to clinical assessments, potentially at the
126 point of referral receipt, to enable the allocation of cases to the most appropriate professional.(10,
127 15, 16)

128
129 One such SDA tool is the Development and Well-Being Assessment (DAWBA), a structured package
130 of questionnaires and interviews which can be completed online or by telephone and yields
131 algorithm-based diagnostic information.(17) The DAWBA has established reliability and validity (17)
132 and has been widely used for screening, diagnosis and outcome measurement in research in both
133 clinical and community settings (18, 19), including trials of SDAs (20, 21) and large scale
134 epidemiological research.(1, 22, 23) A previous randomised controlled trial (RCT) using the DAWBA
135 highlighted that, for emotional disorders, disclosing DAWBA diagnosis information to clinicians can
136 improve the level of agreement between the DAWBA and clinical diagnoses, suggesting that the
137 DAWBA can aid clinical detection of emotional disorders.(21) It also improved detection of comorbid
138 disorders. A UK trial found higher levels of agreement between DAWBA and clinical diagnoses,
139 following disclosure of DAWBA information, in relation to anxiety disorders.(20) Practitioners

1
2
3 140 acknowledged that the additional information could supplement the assessment and aid detection
4 141 of difficulties.(10)

5 142
6 143 Hence, it might be expected that the introduction of an SDA tool following CAMHS referral receipt
7 144 could enable resources to be better targeted and a timely conclusion to assessments with a
8 145 diagnostic decision, increase the likelihood that an appropriate evidence-based treatment is offered,
9 146 and lead to improved outcomes and better experience of care for CYP and their families. However,
10 147 there is limited evidence on the utility of SDA tools for informing optimal approaches to assessment
11 148 within routine clinical practice.

12 149 13 150 **Aims and Objectives**

14 151 The aim is to evaluate the clinical and cost effectiveness of the DAWBA SDA tool, as an adjunct to
15 152 usual clinical care for CYP presenting with emotional difficulties referred to CAMHS.

16 153
17 154 Specific objectives are to:

- 18 155 1. Conduct an RCT to determine the effectiveness of the DAWBA as an adjunct to usual clinical care
19 156 on diagnosis and treatment of emotional disorders, symptoms of emotional difficulties and
20 157 comorbid disorders and associated functional impairment.
- 21 158 2. Undertake an internal pilot to assess recruitment and acceptability.
- 22 159 3. Include a qualitative component within the pilot phase to address:
23 160 a) The feasibility of recruitment.
24 161 b) The acceptability and usability of the interventions and procedure.
25 162 c) How the intervention is used and could be refined for the main trial.
- 26 163 4. Conduct a process evaluation alongside the main trial which will:
27 164 a) Optimise the design and delivery of the DAWBA to enhance acceptability, effectiveness and
28 165 long-term uptake.
29 166 b) Identify the barriers and facilitators to implementation of the DAWBA from the perspectives
30 167 of CYP, parents, and CAMHS practitioners, managers and commissioners.
- 31 168 5. Estimate cost effectiveness of the use of the DAWBA versus usual care.
- 32 169 6. Make evidence-based recommendations for assessment procedures within CAMHS and produce
33 170 practice guidelines for clinical decision-making around the referral acceptance and assessment
34 171 processes.

35 172 36 173 37 174 38 175 39 176 40 177 41 178 42 179 **METHODS AND ANALYSIS**

43 180 44 181 **Design**

45 182 A multi-centre, two-arm, parallel group RCT, with embedded qualitative and health economic
46 183 components.

47 184
48 185 An internal pilot period, completed in the first 9 months of recruitment, will determine feasibility of
49 186 recruitment and follow-up, assessed by the independent Trial Steering Committee against pre-
50 187 defined stop/go criteria. The study start date is 01-Nov-2018 and end date is 31-Oct-2022.

51 188 52 189 **Setting**

190 Recruitment will take place in at least six NHS Trusts in England, providing outpatient
 191 multidisciplinary specialist CAMHS. Sites are geographically dispersed covering urban and rural
 192 areas, thus are likely to be socio-demographically representative of CAMHS referrals in England,
 193 enabling nationally generalisable findings.

195 **Recruitment and eligibility**

196 **Participant identification**

197 The population is CYP presenting with emotional difficulties referred to CAMHS. Participants are
 198 identified through the usual referral pathways for the participating sites, which includes NHS and
 199 local authority managed Single/Central Point of Access referral points as well as referrals directly
 200 received and processed by CAMHS teams.

201
 202 The STADIA researchers (NHS personnel, based within the CAMHS SPA/triage team to carry out
 203 research activities on behalf of the team and authorised to access referral information) at each site
 204 review the referrals received by CAMHS to identify CYP presenting with emotional difficulties,
 205 according to a standard proforma (Appendix 1. Screening form). Referrals that mentioned any
 206 current emotional difficulties will be included, regardless of the number, frequency or severity of the
 207 emotional difficulties. Potentially eligible participants are invited to consider taking part in the trial
 208 and provided with written information. The initial invitation follows standardised wording to ensure
 209 clarity and consistency of approach.

210
 211 Identification of participants takes place after referral receipt, but prior to referral acceptance
 212 (Figure 1).

214 **Consent**

215 Prior to consent, eligibility will be confirmed (table 1) during telephone contact with the local STADIA
 216 researcher, who will also provide written and verbal information about the trial, answer questions
 217 and support the electronic consent/assent process. Participants who are eligible and provide verbal
 218 consent to participation during the call will be provided with a personal link to the online electronic
 219 Informed Consent/Assent Form (table 2, appendix 2 and 3, respectively), enabling them to provide
 220 written informed consent/assent.

222 Table 1. Eligibility criteria

223 *Inclusion criteria for the CYP*

- Aged 5 to 17 years.
- Referred to outpatient multidisciplinary specialist CAMHS.
- Presenting with emotional difficulties.
- If aged <16, has an eligible individual with parental responsibility (see parent/carer eligibility criteria below) willing and able to participate in the trial.
- If aged 16-17, has capacity to provide valid written informed consent.
- If aged 16-17 and participating without a parent/carer, able to complete the assessment tool in English.
- If aged 16-17 and participating without a parent/carer, access to internet and email or telephone.

Exclusion criteria for the CYP

- Emergency or urgent referral to outpatient multidisciplinary specialist CAMHS (i.e. requires an expedited assessment) according to local risk assessment procedures.
- Severe learning disability.
- Previously randomised in the STADIA trial.

Inclusion criteria for the parent/carer

- Individual with parental responsibility for the CYP referred to CAMHS; this will be the CYP's mother or father, legally appointed guardian or a person with a residence order concerning the CYP.
- Adequate knowledge of the CYP to be able to complete the assessment tool (i.e., known for at least 6 months).
- Has capacity to provide valid written informed consent.
- Access to internet and email or telephone.
- Able to complete the assessment tool in English.

Exclusion criteria for the parent/carer

- Local authority representatives designated to care for the CYP.

224

The participation and consent/assent requirements for the trial are shown in table 2.

226

Table 2: Consent & Participation

228

Age of CYP referred to CAMHS:	CYP aged <11	CYP aged 11-15		CYP aged 16-17	
Initial contact with:	Parent/carer			Depends on contact details provided with the CAMHS referral*	
Consent provided by:	Parent/carer	Parent/carer	Parent/carer	CYP AND parent/carer (optional)	CYP
Assent provided by:	None	CYP (optional)	None	None	None
Participant(s):	Parent/carer only	CYP and parent/carer dyad	Parent/carer only	CYP and parent/carer dyad	CYP only
Primary participant:**	Parent/carer	Parent/carer	Parent/carer	CYP	CYP
Secondary participant:	None	CYP	Non	Parent/carer	None
DAWBA completed by:	Parent/carer	Parent/carer AND CYP	Parent/carer	CYP AND parent/carer	CYP
Research questionnaires completed by:	Parent/carer report on CYP Parent/carer self-report	Parent/carer report on CYP Parent/carer self-report CYP self-report	Parent/carer report on CYP Parent/carer self-report	CYP self-report Parent/carer report on CYP Parent/carer self-report	CYP self-report

For all CYP aged <16 the initial contact about the study will be with the parent/carer. The involvement of CYP aged 11-15 will be at the discretion of the parent/carer.

* For CYP aged 16-17 if the CYP's contact details are provided on the CAMHS referral the first contact about the study will be with the CYP who can choose to nominate a parent/carer to participate in the trial alongside them or participate alone. If the parent/carer's contact details only are available the first contact will be with the parent/carer and the parent/carer will be asked whether the CYP can also be contacted but may choose to refuse this. The parent/carer will not be able to participate in the STADIA trial without the involvement or consent of the CYP.

** The primary participant is the person who must provide consent as a minimum requirement in order for randomisation to take place. Assent (of CYP aged 11-15) and parental consent (for CYP aged 16 and 17) may also be sought but is not mandatory and therefore will not be required prior to

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

randomisation.

229
230 Participants are free to withdraw at any time and for any reason. Participants may withdraw from
231 the intervention, follow-up questionnaires and/or data collection from records in any combination
232 (e.g., participants who do not complete the intervention will continue to be followed-up,
233 participants withdrawing from follow-up questionnaire completion may continue to consent for data
234 collection from records). Withdrawn participants will not be replaced. Data collected prior to
235 withdrawal will be retained and used in the analysis.

236
237 Where CYP aged 16 or 17 have consented for their own involvement they can continue to
238 participate in the trial in the event of their parent/carer's withdrawal, however, the parent/carer
239 involvement would not continue should the CYP withdraw consent.

240 241 **Randomisation and concealment**

242 Participants will be randomised in a 1:1 ratio to either intervention or control. Allocation will be
243 assigned using a minimisation algorithm balancing on recruiting site, CYP age (5-10, 11-15, 16-17
244 years) and sex, incorporating a probabilistic element to allocation. The allocation algorithm was
245 created by Nottingham Clinical Trials Unit (NCTU) in accordance with their Standard Operating
246 Procedures (SOPs). Allocation is concealed using an automated web system operated by NCTU.

247
248 Randomisation is automatically generated within the online system following submission, and
249 automated verification, of baseline data by the primary participant. Participants are presented with
250 their allocation and further instructions on-screen with email confirmation. Instructions for DAWBA
251 completion are included for those in the intervention arm. Email confirmation is sent to the
252 coordinating centre and site research team.

253
254 It will not be possible to blind participants, site researchers, clinicians and some trial staff to
255 treatment allocation, but treatment allocation data will be restricted to those trial staff who require
256 access to facilitate trial conduct. In particular, it will not be fully possible to blind researchers
257 conducting data collection from records. However, any possible diagnoses identified from the
258 CAMHS records will be recorded verbatim on the data capture form and will be subject to
259 adjudication by the trial adjudication committee (members of the Trial Management Group). The
260 committee will be blinded to treatment allocation and participant ID.

261
262 The risk of contamination between arms is considered low. Access to the DAWBA, and provision of
263 the DAWBA report, is only provided to participants in the intervention arm. SDA tools are not
264 current practice in standard care and it is unlikely that control participants will be asked to complete
265 these at the point of referral receipt. DAWBA completion occurring outside the trial for control arm
266 participants will be collected during follow-up.

267 268 **Interventions**

269 Development and wellbeing assessment (DAWBA)
270 The trial intervention is the DAWBA. (24) The DAWBA has a modular structure, with only those
271 modules relevant to emotional and comorbid disorders included; separation anxiety, specific phobia,
272 social phobia, panic and agoraphobia, generalised anxiety, post-traumatic stress disorder (PTSD),
273 obsessive compulsive disorder (OCD), depression, oppositional defiant disorder (ODD) and conduct
274 disorder. Whereas, the strengths and difficulties questionnaire, bipolar disorder, and body
275 dysmorphic disorder are not included in the STADIA-specific DAWBA report as these modules do not
276 generate diagnostic predictions. No freetext responses are collected.

1
2
3 279 The DAWBA will be self-reported by participants via the secure, standalone online platform created
4 280 and maintained by the DAWBA developer.(24) Access is by a unique ID number and password,
5 281 assigned at the point of randomisation via a stock control system integrated into the randomisation
6 282 system, ensuring accountability of DAWBA slot allocation.
7 283

8 284 The DAWBA may be completed by the parent/carer and/or CYP aged 11+, depending on the consent
9 285 and participation arrangements (Table 2) DAWBA completion will be monitored and the STADIA
10 286 researcher will support and encourage completion. Participants will be able to complete the DAWBA
11 287 in a telephone call with the STADIA researcher if required. Participants are asked to complete all
12 288 modules of the DAWBA presented to them. Should the DAWBA be only partially completed by
13 289 respondents the report will be based only on fully answered modules with missing responses
14 290 identified as such.
15 291

16 292 A trial-specific DAWBA report will be prepared for each participant, based on a standard, study-
17 293 specific template (Appendix 4. Template DAWBA report). The algorithm-derived diagnostic
18 294 predictions will be used to highlight the likelihood of a CYP meeting ICD-10 criteria for the disorders
19 295 assessed; the report is based entirely on the algorithm-derived predictions and is not clinically rated.
20 296 The report will be sent to participants (via post or email) and CAMHS clinicians (via upload to the
21 297 clinical record), as an adjunct to usual clinical practice.
22 298

23 299 Control

24 300 CYP randomised to the control arm will receive usual care (i.e., referral review as usual). Based on
25 301 standard information provided with the referral a clinical decision is made about whether the
26 302 referral is accepted and, if so, a clinician conducts the initial CAMHS assessment as per usual practice
27 303 in the service.
28 304

29 305 **Sample size**

30 306 A target sample size of 1210 participants will be recruited and randomised, with equal allocation to
31 307 intervention or control.
32 308

33 309 Assuming 45% of control participants have a confirmed diagnosis within 12 months (based on
34 310 unpublished data obtained from the trial sites), detection of an absolute increase of 10% with 90%
35 311 power and 5% two-sided alpha, requires 544 participants per arm for analysis. Allowing for up to
36 312 10% non-collection of the primary outcome, we will randomise 1210 participants.
37 313

38 314 **Measures and outcomes**

39 315 Primary outcome

40 316 The primary outcome is a clinician-made diagnosis decision about the presence of an emotional
41 317 disorder within 12 months of randomisation i.e. diagnosis of an emotional disorder will be coded as
42 318 'yes'; absence or uncertainty (for example, reflecting ongoing assessment or investigation) will be
43 319 coded as 'no'. Eligible diagnoses are those that reflect 'emotional' or 'internalizing' disorders in
44 320 ICD/DSM (Appendix 5. Eligible emotional disorder diagnoses). The diagnosis must be documented in
45 321 the clinical record within 12 months of randomisation by a mental health services clinician in an
46 322 NHS-delivered or NHS-commissioned service.
47 323

48 324 Diagnoses will be collected from clinical records using a standard proforma. Alternative possible
49 325 diagnoses identified from the clinical notes will be recorded verbatim on the data capture form and
50 326 will be subject to adjudication by members of the Trial Management Group (Appendix 6. Outcome
51 327 Definition and Adjudication Plan).
52 328
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

329
330 Secondary outcomes
331 Secondary outcomes are detailed in table 3.
332

For peer review only

333 *Table 3. Secondary outcome definitions*

334

Outcome	Measurement	Definition
Acceptance of index referral	Collected from records	Whether the index referral (i.e., the referral made to CAMHS at the point of recruitment to the STADIA trial) was accepted or declined. Acceptance is defined as being offered an appointment within CAMHS, whether or not the initial appointment was attended or subsequent appointments were offered/attended. Collected within 12 months of randomisation.
Acceptance of any referral within 12 months of randomisation	Collected from records	Whether the index referral or any subsequent referral to CAMHS (if made) was accepted or not . Acceptance as defined above for index referral. Collected within 12 months of randomisation.
Discharge from CAMHS within 12 months	Collected from records	Whether the child/young person was discharged from CAMHS (following acceptance of the index referral) during the 12-months post-randomisation.
Re-referral to CAMHS within 12 months	Collected from records	Whether the child/young person was re-referred to CAMHS (for those whose index referral was turned down by CAMHS or those whose index referral was accepted but were subsequently discharged) during the 12-months post-randomisation.
Confirmed diagnosis decision	Collected from records	Diagnosis of an emotional disorder or confirmed absence of an emotional disorder coded as 'yes' vs. uncertainty about the presence of an emotional disorder coded as 'no'. Diagnosis as defined for primary outcome, collected within 12 months of randomisation.
Time from randomisation to diagnosis of emotional disorder	Collected from records	Date of diagnosis will be the first documented eligible diagnosis. Diagnosis as defined for primary outcome, collected within 12 months of randomisation.
Diagnoses made over the 12 month period from randomisation	Collected from records	The diagnosis must be documented in the clinical record within 12 months of randomisation by a mental health services clinician in an NHS-delivered or NHS-commissioned service. All diagnoses made within 12 months will be included. Measured using a standard proforma (pre-specified diagnoses).
Treatment offered for diagnosed emotional disorder	Collected from records	Whether treatment was offered for a diagnosed emotional disorder, as defined for primary outcome, collected within 12 months of randomisation.
Any treatment / interventions given	Collected from records	All treatments/interventions offered by CAMHS for any reason within 12 months of randomisation, whether or not there is a documented diagnosis will be included.

Outcome	Measurement	Definition
Time from randomisation to the decision to offer treatment for a diagnosed emotional disorder	Collected from records	Date of decision will be the first date that the decision to offer treatment for a diagnosed emotional disorder is documented in the clinical notes, collected within 12 months of randomisation.
Time from randomisation to start of first treatment for a diagnosed emotional disorder	Collected from records	Date of treatment will be the first date that any treatment offered for a diagnosed emotional disorder is started. Treatment and diagnosed emotional disorder as defined, collected within 12 months of randomisation.
Time from randomisation to the decision to offer any treatment	Collected from records	Date of decision will be the first date that the decision to offer any treatment is documented in the clinical notes, , collected within 12 months of randomisation.
Time from randomisation to start of any treatment	Collected from records	Date of treatment will be the first date that any treatment offered is started. Treatment as defined, collected within 12 months of randomisation.
Participant-reported diagnoses received in the 12 months post-randomisation	Participant self-report	Participants will be asked to report whether or not they received a diagnosis of the child/young person's difficulties from CAMHS in the 12 months post-randomisation and if so, what diagnosis was given and by whom.
Depression symptoms in the CYP	Mood and Feelings Questionnaire (MFQ)	Mood and Feelings Questionnaire (MFQ) (25) is a valid and reliable measure of depression in CYP.(26, 27) 33-items are answered on a 3-point scale ("not true" = 0, "somewhat true" = 1 point, "true" = 2 points). Scores range from 0 to 66 with higher scores indicating more severe depressive symptoms. A score of 27 or higher may be indicative of depression. MFQ collected at baseline, 6 and 12 months post-randomisation.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46

Outcome	Measurement	Definition
Anxiety symptoms in the CYP	Revised CYP's Anxiety Depression Scale (RCADS)	<p>Revised CYP's Anxiety and Depression Scale (RCADS)(28)</p> <p>RCADS is a 47-item questionnaire that measures the reported frequency of various symptoms of anxiety and low mood. Each item is rated on a 4-point scale (never = 0, sometimes = 1, often = 2, always = 3).</p> <p>An overall anxiety and low mood score is generated, with separate sub-scale scores for separation anxiety, social phobia, generalised anxiety, panic, obsessive compulsive disorder and major depression.</p> <p>RCADS demonstrates good psychometric properties.(29)</p> <p>Total anxiety and depression scores range from 0 to 141.</p> <p>We will record scores for each of the 6 sub-scales. For analysis metric, we will use the total anxiety score. RCADS collected at baseline, 6 and 12 months post-randomisation.</p>

For peer review only

Outcome	Measurement	Definition
Comorbid oppositional defiant / conduct disorder symptoms in the CYP	Strengths and Difficulties Questionnaire (SDQ)	<p>Strengths & Difficulties Questionnaire (SDQ):(30) A 25-item emotional and behavioural screening questionnaire for CYP.</p> <p>Each item is rated on a 3-point scale (not true, somewhat true, certainly true). Values of 0, 1 or 2 are assigned to each response.</p> <p>SDQ comprises 5 sub-scales and an impact supplement. The impact supplement asks effect of difficulties on homelife, friendships, education and leisure activities.</p> <p>SDQ has demonstrated reasonable psychometric properties.(31-34) Scores on the 'conduct problems' subscale will be used in the analysis of this outcome.</p> <p>Sub-scale scores range from 0 to 10. SDQ collected at baseline, 6 and 12 months post-randomisation.</p>
Functional Impairment in the CYP	Strengths and Difficulties Questionnaire (SDQ)	Impact supplement scores will be used to determine functional impairment. Impact scores range from 0 to 10. Collected at baseline, 6 and 12-months post-randomisation.

Outcome	Measurement	Definition
Self-harm thoughts in the CYP	CYP self-report self-harm measure	CYP will be asked to report the frequency of thoughts of self-harm. Frequency of thoughts of self-harm are rated over the last 6 months in the following categories and scored accordingly: Not at all (0) Once or twice (1) Three or more times (2) Collected at baseline, 6 months and 12-months post-randomisation.
Self-harm behaviours in the CYP	CYP self-report self-harm measure	CYP will be asked to report frequency of instances of self-harm behaviour. Frequency of self-harm behaviour are rated over the last 6 months in the following categories and scored accordingly: Not at all (0) Once (1) Two or more times (2) Collected at baseline, 6 months and 12-months post-randomisation.
Depression symptoms in the parent/carer	Patient Health Questionnaire (PHQ-9)	PHQ-9:(35) PHQ-9 is frequently used as a screening tool for depression in general populations. Each of the nine DSM-IV depression criteria are scored as "0" (not at all) to "3" (nearly every day) depending on the frequency with which they were experienced over the last 2 weeks. Total scores range from 0 to 27 with higher scores indicating increased severity of depression, collected at baseline, 6 and 12-months post-randomisation.
Anxiety symptoms in the parent/carer	Generalised Anxiety Disorder Assessment (GAD-7)	GAD-7:(36) GAD-7 is a measure of the severity of anxiety in general populations. 7 items are rated according to the frequency with which they have been experienced over the past 2 weeks (0 = 'not at all', 1 = 'several days', 2 = 'more than half the days', and 3 = 'nearly every day'). Total scores range from 0 to 21 with higher scores indicating more severe anxiety. Collected at baseline, 6 and 12-months post-randomisation.
Time off education, employment or training because of emotional difficulties for the CYP	Resource use questionnaire	Days missed from education, employment or training (as applicable) for the CYP due to emotional difficulties. Collected at baseline, 6 and 12-months post-randomisation.

Outcome	Measurement	Definition
Health economic outcome measures		
Health related quality of life in the CYP	Child Health Utility 9D (CHU9D) and EuroQol Quality of Life Questionnaire 5 Domains for Young People (EQ-5D-Y)	<p>CHU9D (37) consists of nine individual items with five levels of response per question (scored 1-5), that assess the CYP functioning “today”. The following domains are included; worry, sadness, pain, tiredness, annoyance, school, sleep, daily routine and activities.</p> <p>EuroQol-5D youth descriptive system (38) comprises 5 domains; mobility, looking after myself, doing usual activities, having pain or discomfort and feeling worried, sad or unhappy, values of 1, 2 or 3 are assigned to each response. The EuroQol Visual Analogue Scale (EQ-VAS) asks recipients to self-assess their health state ‘today’ from 0 (worst imaginable health) to 100 (best imaginable health), representing individual preferences.</p> <p>These measures will be self-reported by CYP aged 11+, with proxy versions also completed by the parent/carer for CYP <16.</p> <p>Both collected at baseline, 6 and 12-months post-randomisation.</p>
Health-related quality of life in the parent/carer	EuroQol Quality of Life Questionnaire 5 Domains, 5 Levels (EQ-5D-5L)	<p>The EuroQol 5-dimension multi attribute utility instrument (39) comprises 5 domains; mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each domain is scored between 1 and 5. This descriptive profile, in combination with a valuation set, produces a single index for health status representing societal preferences. The index score ranges from -0.59 to 1, with 0 representing death, 1 of-perfect health, and <0 of health states worse than death. The EQ-VAS is again included within the EQ-5D instrument Collected at baseline, 6 and 12-months post-randomisation.</p>

335

336

1
2
3 337 *Health economic measures*

4 338 Health related quality of life (HRQoL) outcome measures are detailed in table 3.
5 339

6 340 *Resource Use*

7 341 Data will be collected on health care, education, and social care resource use for both the CYP and
8 342 parents/carers, using a purposely designed resource use collection tool. The questionnaire was
9 343 developed by the study's health economics team at Nottingham following discussions with the
10 344 study's Patient and Public Involvement (PPI) team and representatives. This was an iterative process
11 345 until all parties including the PPI team and representatives, the health economics team and the
12 346 wider Trial Management Group were reassured the questionnaire was fit for purpose. It collects data
13 347 on all aspects of healthcare interventions including medication, inpatient and outpatient hospital
14 348 visits and primary and community care use as well as societal and education costs. It also includes
15 349 sections specifically designed to quantify the effect of time off work for parents/carers (including
16 350 friends and family) to quantify the wider social cost i.e. implications for productivity. In addition, it
17 351 measures effects on time lost from education or training for the child/young person because of
18 352 emotional difficulties. A similar approach to capturing resource use information was employed by
19 353 members of the study team for a feasibility trial involving parents and carers of children with ADHD
20 354 (40).
21 355

22 356 These data will be attributable to the emotional difficulties of the young person and be self-reported
23 357 by the parent/carer with supplementary information obtained from CYP aged 16 and 17.
24 358 Administrative records of treatments/interventions offered by CAMHS during the trial period may be
25 359 considered as a supplementary source of data.
26 360

27 361
28 362 *Socio-demographic data*

29 363 The following socio-demographic data will be collected primarily from the participant-reported
30 364 questionnaires; age at randomisation, sex, gender, ethnicity, paid employment, and, derived from
31 365 the postcode of the child's primary residence, the index of Multiple Deprivation score.
32 366

33 367 *Data collection*

34 368 Data will be collected through participant reported questionnaires (parent/carer and CYP self-report
35 369 aged 11+) and from clinical records. Participant reported outcomes will be collected at baseline and
36 370 6- and 12-months post-randomisation (Appendix 7. Summary of assessments). Questionnaires are
37 371 intended to be completed online by participants in the first instance - to maximise rates of
38 372 completion and retention there will be an option for telephone completion, should participants have
39 373 difficulty accessing or completing the questionnaires online.
40 374

41 375 Outcomes collected from records will be reported for the 12-month period following randomisation.
42 376

43 377 **Data management and analysis**

44 378 *Data management*

45 379 Arrangements for data handling are specified in the Data Management Plan (DMP). Central and on-
46 380 site monitoring will be carried out as required following a risk assessment and as documented in the
47 381 monitoring plan. Monitoring activities will be carried out by the coordinating centre on behalf of the
48 382 trial sponsor.
49 383

50 384 Data will be held on servers located within The University of Nottingham data centres. Security is
51 385 both physical (secure limited access) and electronic (behind firewalls, access via user accounts).
52 386 Personal data recorded on all documents will be regarded as strictly confidential and handled and
53 387 stored in accordance with the Data Protection Act 2018.
54
55
56
57
58
59
60

388

389 Statistical analysis

390 The primary approach to between-group comparative analyses will be by modified intention-to-treat
391 (i.e. including all participants who have been randomised and without imputation of missing
392 outcome data).

393

394 The primary comparative analysis will employ a generalised linear mixed model to compare the
395 proportions in each group with a clinician-made diagnosis decision within 12 months of
396 randomisation, adjusted for minimisation variables. The comparison will be presented as both an
397 absolute (risk difference) and relative (risk ratio) effect, along with 95% confidence intervals.

398

399 Secondary outcomes will be analysed using appropriate mixed effect regression models dependent
400 on data type and will adjust for factors used in the minimisation and baseline value of the outcome
401 where measured. For outcomes measured at multiple time points, these will be analysed using a
402 mixed model with a treatment by time interaction to obtain estimates of treatment effect at each
403 follow-up time.

404

405 Appropriate interaction terms will be included in the primary regression analyses in order to conduct
406 subgroup analyses according to sex and age of the CYP.

407

408 Statistical analysis will be conducted using Stata v17.0 (or later).

409

410 Health economic analysis

411 In accordance with NICE guidance, primary analysis will take an NHS and personal social services
412 perspective. Unit costs will be attached to participant reports of health care resource use or
413 recorded treatments/interventions offered by CAMHS. The cost of the DAWBA itself will be
414 distributed at the participant-level across the intervention arm of the trial. Sensitivity analyses will
415 take a wider perspective to capture the broader societal costs inclusive of out-of-pocket expenses
416 and productivity losses. Indices of HRQoL for the EQ-5D, EQ-5D-Y, and CHU9D will be derived using
417 relevant population tariffs, and quality adjusted life years estimated using area under the curve
418 (AUC).

419

420 The economic evaluation will take an incremental approach between the two groups using an
421 intention-to-treat (ITT) population (irrespective of treatment received) and a 12-month time horizon.
422 The outcome for the primary cost utility analysis will be the joint young person and parent/carer
423 QALYs. The outcome for the secondary cost effectiveness analysis will be confirmed diagnosis
424 decisions. Outcomes will be paired with their respective direct-to-NHS costs, bootstrapped, and
425 scattered on the cost effectiveness plane to characterise the uncertainty in incremental estimates.
426 Using the net monetary benefit framework,⁽⁴¹⁾ Cost Effectiveness Acceptability Curves (CEACs) will
427 be constructed to show the non-parametric probability the intervention is a cost effective option,
428 compared to usual care, across a range of willingness to pay thresholds per QALY, and within the
429 secondary analysis per confirmed diagnosis decision. While the receipt of any diagnosis of emotional
430 difficulties in young people would likely lead to large divergences in lifecourse outcomes, the
431 heterogeneity of conditions considered for diagnosis (Appendix 5) renders CUA modelling across the
432 lifecourse infeasible. Secondary analysis is expected to be fully captured within the 12-month time
433 horizon.

434

435 A full statistical analysis plan (SAP) and health economics analysis plan (HEAP) will be developed and
436 agreed prior to database lock and un-blinding of the analysing statistician and health economist.

437

438 Embedded qualitative study

1
2
3 439 During the internal pilot, semi-structured interviews are undertaken with a sample of participants
4 440 who consented to be invited to participate in qualitative interviews. Researchers, clinicians, service
5 441 managers and commissioners are identified by site leads. The proposed sample size is 25
6 442 participants (parent/carer and CYP aged 16-17), 25 staff and 15 service managers and
7 443 commissioners. Interviews address: a) the feasibility of recruitment; b) the acceptability and usability
8 444 of the interventions and procedure; c) how the intervention is used and how this deployment could
9 445 be refined for the main trial. Interviews are conducted by the qualitative researcher (KN) in person,
10 446 or by phone or video call based on participant preferences and pandemic restrictions.
11 447

12 448 A process evaluation, conducted during the main trial phase, will aim to identify the barriers and
13 449 facilitators to implementation of the intervention. Semi-structured interviews will be conducted with
14 450 a further sample of participants and clinicians to explore the perceived functioning of the
15 451 intervention, the organisation of the service and reflective experiences on outcomes.
16 452

17 453 Qualitative interview data will be recorded and encrypted on a password protected Dictaphone and
18 454 transferred securely to medical transcription company Dict8 for transcription. Transcriptions will be
19 455 anonymised. Audio files will be destroyed after transcripts have been checked. Anonymised
20 456 transcriptions will be analysed and stored on password protected computers and the secure
21 457 University of Nottingham server.
22 458

23 459 Qualitative analysis

24 460 All qualitative interview data will be initially analysed by the qualitative researcher (KN) using
25 461 interpretative thematic approaches to coding, and adopt the framework method,(42) with input
26 462 from the qualitative lead (LT), Chief Investigator (KSa) and PPI leads (CE & AL). NVIVO 12 will be used
27 463 to manage the qualitative data.
28 464

29 465 Patient and public involvement

30 466 Prior to submission, the proposal was informed by consultations with a person with lived
31 467 parent/carer experience of CAMHS, including contribution to and review of the proposal,
32 468 recruitment strategy, participant trial experience and consideration of burden of the intervention,
33 469 and establishing a PPI workstream.
34 470

35 471 Following award, the PPI Co-I team recruited two representatives naïve of the study design to
36 472 provide independent review of the trial via their membership of the Trial Steering Committee (TSC).
37 473 Both TSC members are persons with lived parent/carer experience of CAMHS.
38 474

39 475 During study set up, PPI Co-I expertise was utilised to support researcher recruitment via the design
40 476 and deployment of role plays within interviews.(43) This was to gain insight into candidates'
41 477 capabilities when dealing with sensitive and challenging participant scenarios. Additionally, they
42 478 contributed to design of researcher training materials, to support standardised approaches across
43 479 trial sites. Iterative and creative design PPI activities were integral in the development of the STADIA
44 480 trial logo and branding to ensure accessibility and acceptability to CYP and parents.
45 481

46 482 Since study commencement participatory design approaches have seen PPI co-design of the
47 483 resource use questionnaire, qualitative interviews and the protocol for a Study Within A Trial (SWAT)
48 484 to support participant engagement with follow-up. Additionally, collaborative working between the
49 485 PPI and Qualitative workstreams has enabled examination of the qualitative themes using principles
50 486 of the Framework Method(42) for independent verification of those themes.
51 487

52 488 Two PPI advisory panels have been established, meeting on average every 3 months since month 9
53 489 of the study. "STADIA PPI Panel" has 8 adult members, with lived parent/carer experience of
54 490

1
2
3 490 CAMHS. "STADIA Labs" has 6 CYP members, aged 15 to 19 at inception, with lived experience of
4 491 CAMHS. These groups have been involved in many traditional activities such as review of PIS and
5 492 consent forms, consultation on language and content for participant reminder text messages. PPI co-
6 493 production activities are also seeing the development of age appropriate study newsletters and the
7 494 design of STADIA information videos including decision making about video concept, audience,
8 495 message, aesthetic and content. PPI group members are provided with supplementary training
9 496 about PPI practices and involvement opportunities. Due to the Covid-19 pandemic, PPI meetings
11 497 have had to move online and so the PPI team are investing in knowledge transfer and upskilling PPI
12 498 representatives in different ways of working and collaborating online.

13 499
14 500 There are a range of planned flexible opportunities for participating in project feedback and
15 501 dissemination activities including co-facilitating and presenting at the interactive dissemination
16 502 workshop / consensus meeting, publication authorship as peer researcher and presenting at
17 503 conferences to showcase the project findings.

18 504

19 505

20 506 **ETHICS AND DISSEMINATION**

21 507

22 508 **Ethics**

23 509 The study was reviewed and received favourable opinion from the South Birmingham Research
24 510 Ethics Committee (Ref. 19/WM/0133) on 12 June 2019; subsequent amendments have been
25 511 approved. The current, approved protocol is version 4.0 dated 03 February 2021.

26 512

27 513 **Safety**

28 514 The trial intervention is conceptually similar to usual clinical practice (i.e., CYP referred to CAMHS
29 515 may be sent questionnaires about their difficulties), therefore the risks of the trial are considered
30 516 comparable. The DAWBA is widely used in research for data collection therefore, although utilised as
31 517 an intervention in the STADIA trial, the risks may be regarded as similar to those of an
32 518 observational/questionnaire study. Data to inform safety oversight will therefore be collected during
33 519 routine follow-up, from existing outcome measures. There is no separate adverse event or serious
34 520 adverse event reporting.

35 521

36 522 The number of participants meeting pre-defined safety outcomes will be reported on an ongoing
37 523 basis to the Trial Management Group (TMG) and TSC. Data will be presented by arms to the Data
38 524 Monitoring Committee (DMC).

39 525

40 526 **Trial oversight**

41 527 Nottinghamshire Healthcare NHS Foundation Trust will undertake role of Sponsor as defined by the
42 528 UK Policy Framework for Health and Social Care Research.(44) Delegated responsibilities will be
43 529 assigned to the Chief Investigator, participating NHS Trusts and the trial coordinating centre,
44 530 Nottingham Clinical Trials Unit (NCTU).

45 531

46 532 The full co-applicant team and NCTU staff responsible for the day-to-day management of the trial
47 533 will form the TMG, responsible for monitoring recruitment and retention rates and implementing
48 534 strategies to ensure targets are met. Independent Trial Steering and Data Monitoring Committees
49 535 will operate in accordance with trial-specific Charters.

50 536

51 537 **Dissemination**

52 538 Results of this trial will be reported to the funder and published in full in the HTA Journal series and
53 539 also submitted for publication in a peer reviewed journal.

54 540

55

1
2
3 541 **Data Sharing**

4 542 Anonymised trial data may be shared with researchers external to the trial research team in
5 543 accordance with the NCTU's data sharing procedure.
6 544

7 545 **Figures**

8 546 Figure 1: Participant flow
9 547

10 548 **Authors' contributions**

11 549 FD, LW, AB, BD, CE, JG, MJ, AL, TM, AM, SR, KSp, LT, EB, JL, KN, CP, KSt and KSa made substantial
12 550 contributions to conception and design or acquisition of data; took part in drafting the article or
13 551 revising it critically for important intellectual content; agreed to submit to the current journal; gave
14 552 final approval of the version to be published; and agree to be accountable for all aspects of the work.
15 553 KSa is guarantor for the paper. FD and LW contributed equally to this paper.
16 554

17 555 **Funding statement**

18 556 This study was funded as a result of a commissioned call by the National Institute for Health
19 557 Research (NIHR) Health Technology Assessment programme (Grant Reference Number 16/96/09).
20 558 The views expressed are those of the authors and not necessarily those of the NIHR or the
21 559 Department of Health and Social Care.
22 560

23 561 The funder will have no role in the collection, management, analysis, and interpretation of data;
24 562 writing of the report; and the decision to submit the report for publication.
25 563

26 564 **Competing interests**

27 565 The authors declare no competing interests.
28 566

29 567 **Acknowledgements**

30 568 We would like to acknowledge and thank all the parent/carers and young people participating in the
31 569 trial and the research sites involved in recruiting participants and data collection. The authors would
32 570 also like to thank the wider STADIA team for their input, including the PPI Advisory Panels, members
33 571 of the independent Trial Steering and Data Monitoring Committees, and the Nottingham Clinical
34 572 Trials Unit, who are the trial coordinating centre.
35 573

36 574 Finally, thanks to the trial sponsor, Nottinghamshire Healthcare NHS Foundation Trust
37 575 (researchsponsor@nottshc.nhs.uk).
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

577 **REFERENCES**


- 578
- 579 1. Sadler K, Vizard T, Ford T, Marcheselli F, Pearce N, Mandalia D, et al. Mental Health of
580 Children and Young People in England, 2017: NHS Digital; 2018 [Available from:
581 [https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-of-children-and-](https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-of-children-and-young-people-in-england/2017/2017)
582 [young-people-in-england/2017/2017](https://digital.nhs.uk/data-and-information/publications/statistical/mental-health-of-children-and-young-people-in-england/2017/2017).
583
- 584 2. Goodyer IM RS, Barrett B, Byford S, Dubicka B, Hill J, Holland F, Kelvin R, Midgley N, Roberts
585 C, Senior R, Target M, Widmer B, Wilkinson P, Fonagy P. Cognitive behavioural therapy and short-
586 term psychoanalytic psychotherapy versus brief psychosocial intervention in adolescents with
587 unipolar major depression (IMPACT): a multicentre, pragmatic, observer-blind, randomised
588 controlled trial. *Health Technology Assessment*. 2017;21(12).
589
- 590 3. Simmons M, Wilkinson P, Dubicka B. Measurement Issues: Depression measures in children
591 and adolescents. *Child and Adolescent Mental Health*. 2015;20(4):230-41.
592
- 593 4. Colman IW, MEJ. Croudace, TJ. Jones, PB. Forty-Year Psychiatric Outcomes Following
594 Assessment for Internalizing Disorder in Adolescence. *American Journal of Psychiatry*.
595 2007;164(1):126-33.
596
- 597 5. Orchard F, Pass L, Marshall T, Reynolds S. Clinical characteristics of adolescents referred for
598 treatment of depressive disorders. *Child and Adolescent Mental Health*. 2017;22(2):61-8.
599
- 600 6. Frith E. Access and waiting times in children and young people's mental health services.:
601 Education Policy Institute; 2017 [Available from: [https://epi.org.uk/wp-](https://epi.org.uk/wp-content/uploads/2018/01/EPI_Access-and-waiting-times_.pdf)
602 [content/uploads/2018/01/EPI_Access-and-waiting-times_.pdf](https://epi.org.uk/wp-content/uploads/2018/01/EPI_Access-and-waiting-times_.pdf).
603
- 604 7. Michelson D, Rock S, Holliday S, Murphy E, Myers G, Tilki S, et al. Improving psychiatric
605 diagnosis in multidisciplinary child and adolescent mental health services. *The Psychiatrist*.
606 2011;35:454-9.
607
- 608 8. O'Connor C, Downs J, McNicholas F, Cross L, Shetty H. Documenting diagnosis in child and
609 adolescent mental healthcare: A content analysis of diagnostic statements in a psychiatric case
610 register. *Children and Youth Services Review*. 2020;113:104948.
611
- 612 9. Allsopp K, Kinderman P. The use of diagnoses in mental health service eligibility and
613 exclusion criteria. *Journal of mental health (Abingdon, England)*. 2021;30(1):97-103.
614
- 615 10. Martin A-M, Fishman R, Baxter L, Ford T. Practitioners' attitudes towards the use of
616 standardized diagnostic assessment in routine practice: A qualitative study in two Child and
617 Adolescent Mental Health Services. *Clinical Child Psychology and Psychiatry*. 2011;16(3):407-20.
618
- 619 11. Craddock N, Antebi D, Attenburrow M-J, Bailey A, Carson A, Cowen P, et al. Wake-up call for
620 British psychiatry. *British Journal of Psychiatry*. 2008;193(1):6-9.
621
- 622 12. National Institute for Health and Clinical Excellence. Depression in Children and Young
623 People: Quality Standard London: National Institute for Health and Clinical Excellence; 2013
624 [Available from: <https://www.nice.org.uk/guidance/cg28>.
625
- 626 13. Fitzpatrick C AN-N, Kehoe A, Devlin N, Glackin S, Power L, et al. Do we miss depressive
627 disorders and suicidal behaviours in clinical practice. *Clinical Child Psychology and Psychiatry*.
628 2012;17:449-58.
629
- 630 14. National Institute for Health and Clinical Excellence. Depression in Children and Young
631 People: Identification and Management in Primary, Community and Secondary Care – Update
632 London: National Institute for Health and Clinical Excellence,; 2015 [Available from:
633 <https://www.nice.org.uk/guidance/cg28>.
634
- 635 15. Last A, Henley, W., Norman, S., Goodman, R., Ford, T. Innovations in Practice: Feasibility of
636 the development and well-being assessment as an adjunct to clinical assessment in child and
637 adolescent mental health services. . *Child and Adolescent Mental Health*. 2014;19:142-6.
638
- 639 16. Reeves K, Charter E, Ford T. Measurement Issues: Is standardised diagnostic assessment
640 feasible as an adjunct to clinical practice? A systematic review. *Child and Adolescent Mental Health*.
641 2016;21(1):51-63.
642

- 1
2
3 627 17. Goodman R, Ford T, Richards H, Gatward R, Meltzer H. The Development and Well-Being
4 628 Assessment: Description and Initial Validation of an Integrated Assessment of Child and Adolescent
5 629 Psychopathology. *Journal of Child Psychology and Psychiatry*. 2000;41(5):645-55.
6 630 18. Hall CL, Davies EB, Andr n P, Murphy T, Bennett S, Brown BJ, et al. Investigating a therapist-
7 631 guided, parent-assisted remote digital behavioural intervention for tics in children and adolescents—
8 632 ‘Online Remote Behavioural Intervention for Tics’ (ORBIT) trial: protocol of an internal pilot study
9 633 and single-blind randomised controlled trial. *BMJ Open*. 2019;9(1):e027583.
10 634 19. Pickles A, Le Couteur A, Leadbitter K, Salomone E, Cole-Fletcher R, Tobin H, et al. Parent-
11 635 mediated social communication therapy for young children with autism (PACT): long-term follow-up
12 636 of a randomised controlled trial. *The Lancet*. 2016;388(10059):2501-9.
13 637 20. Ford T, Last A, Henley W, Norman S, Guglani S, Kelesidi K, et al. Can standardized diagnostic
14 638 assessment be a useful adjunct to clinical assessment in child mental health services? A randomized
15 639 controlled trial of disclosure of the Development and Well-Being Assessment to practitioners. *Social
16 640 Psychiatry and Psychiatric Epidemiology*. 2013;48(4):583-93.
17 641 21. Aebi M, Kuhn C, Metzke CW, Stringaris A, Goodman R, Steinhausen H-C. The use of the
18 642 development and well-being assessment (DAWBA) in clinical practice: a randomized trial. *European
19 643 child & adolescent psychiatry*. 2012;21(10):559-67.
20 644 22. Meltzer H, Gatward R, Goodman R, Ford T. The mental health of children and adolescents in
21 645 Great Britain London: Office for National Statistics; 2000 [Available from:
22 646 [http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/rel/psychi-
23 647 atric-morbidity/the-mental-health-of-children-and-adolescents-in-great-britain/1999-
24 648 survey/mental-health-of-children-and-adolescents-in-great-britain.pdf](http://webarchive.nationalarchives.gov.uk/20160105160709/http://www.ons.gov.uk/ons/rel/psychiatric-morbidity/the-mental-health-of-children-and-adolescents-in-great-britain/1999-survey/mental-health-of-children-and-adolescents-in-great-britain.pdf).
25 649 23. Green H, McGinnity A, Meltzer H, Ford T, Goodman R. Mental health of children and young
26 650 people in Great Britain, 2004 Basingstoke, Hampshire: Palgrave Macmillan; 2005 [Available from:
27 651 [https://webarchive.nationalarchives.gov.uk/20180307185414/http://digital.nhs.uk/catalogue/PUBO
28 652 6116](https://webarchive.nationalarchives.gov.uk/20180307185414/http://digital.nhs.uk/catalogue/PUBO6116).
29 653 24. Youth in Mind. Information for researchers and clinicians about the Development and Well-
30 654 Being Assessment: Youth in Mind; 2012 [Available from: <http://www.dawba.info/>.
31 655 25. Angold A, Costello EJ, Messer SC, Pickles A. Development of a short questionnaire for use in
32 656 epidemiological studies of depression in children and adolescents. *International Journal of Methods
33 657 in Psychiatric Research*. 1995;5(4):237-49.
34 658 26. Wood A, Kroll L, Moore A, Harrington R. Properties of the mood and feelings questionnaire
35 659 in adolescent psychiatric outpatients: a research note. 1995;36:327-34.
36 660 27. Daviss WB, Birmaher B, Melhem NA, Axelson DA, Michaels SM, Brent DA. Criterion validity of
37 661 the Mood and Feelings Questionnaire for depressive episodes in clinic and non-clinic subjects.
38 662 2006;47:927-34.
39 663 28. Chorpita BF, Yim L, Moffitt C, Umemoto LA, Francis SE. Assessment of symptoms of DSM-IV
40 664 anxiety and depression in children: a revised child anxiety and depression scale. *Behaviour Research
41 665 and Therapy*. 2000;38(8):835-55.
42 666 29. Chorpita BF, Moffitt CE, Gray J. Psychometric properties of the Revised Child Anxiety and
43 667 Depression Scale in a clinical sample. *Behaviour Research and Therapy*. 2005;43(3):309-22.
44 668 30. Goodman R. The Extended Version of the Strengths and Difficulties Questionnaire as a Guide
45 669 to Child Psychiatric Caseness and Consequent Burden. *Journal of Child Psychology and Psychiatry*.
46 670 1999;40(5):791-9.
47 671 31. Yao S, Zhang C, Zhu X, Jing X, McWhinnie CM, Abela JRZ. Measuring Adolescent
48 672 Psychopathology: Psychometric Properties of the Self-Report Strengths and Difficulties
49 673 Questionnaire in a Sample of Chinese Adolescents. *Journal of Adolescent Health*. 2009;45(1):55-62.
50 674 32. Goodman R. Psychometric Properties of the Strengths and Difficulties Questionnaire. *Journal
51 675 of the American Academy of Child & Adolescent Psychiatry*. 2001;40(11):1337-45.
52 676 33. Muris P, Meesters C, van den Berg F. The Strengths and Difficulties Questionnaire (SDQ).
53 677 *European child & adolescent psychiatry*. 2003;12(1):1-8.

- 1
2
3 678 34. Lundh LG, Wangby-Lundh, M., & Bjarehed, J. . Self reported emotional and behavioral
4 679 problems in Swedish 14 to 15-year-old adolescents: A study with the self-report version of the
5 680 Strengths and Difficulties Questionnaire. *Scandinavian Journal of Psychology*. 2008;49:523-32.
6 681 35. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
7 682 measure. *Journal of general internal medicine*. 2001;16(9):606-13.
8 683 36. Spitzer RL, Kroenke K, Williams JW, Löwe B. A brief measure for assessing generalized
9 684 anxiety disorder: The gad-7. *Archives of Internal Medicine*. 2006;166(10):1092-7.
10 685 37. Stevens K. Developing a descriptive system for a new preference-based measure of health-
11 686 related quality of life for children. *Quality of Life Research*. 2009;18(8):1105-13.
12 687 38. Wille N, Badia X, Bonsel G, Burström K, Cavrini G, Devlin N, et al. Development of the EQ-5D-
13 688 Y: a child-friendly version of the EQ-5D. *Quality of life research : an international journal of quality of*
14 689 *life aspects of treatment, care and rehabilitation*. 2010;19(6):875-86.
15 690 39. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and
16 691 preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). *Quality of Life Research*.
17 692 2011;20(10):1727-36.
18 693 40. Hall CL, James M, Brown S, Martin JL, Brown N, Selby K, et al. Protocol investigating the
19 694 clinical utility of an objective measure of attention, impulsivity and activity (QbTest) for optimising
20 695 medication management in children and young people with ADHD 'QbTest Utility for Optimising
21 696 Treatment in ADHD' (QUOTA): a feasibility randomised controlled trial. *BMJ Open*.
22 697 2018;8(2):e021104.
23 698 41. Hoch JS, Briggs AH, Willan AR. Something old, something new, something borrowed,
24 699 something blue: a framework for the marriage of health economics and cost-effectiveness
25 700 analysis. *Health Economics*. 2002;11(5):415-30.
26 701 42. Gale NK, Heath G, Cameron E, Rashid S, Redwood S. Using the framework method for the
27 702 analysis of qualitative data in multi-disciplinary health research. *BMC Medical Research*
28 703 *Methodology*. 2013;13(1):117.
29 704 43. Furniss D, Lang AR, Ewart C. Enhancing Patient Ergonomics with Patient and Public
30 705 Involvement in Research Projects. . In: Holden RJ, Valdez RS, editors. *The Patient Factor: A Handbook*
31 706 *on Patient Ergonomics*: CRC Press; 2001.
32 707 44. Health Research Authority. UK Policy Framework for Health and Social Care Research: Health
33 708 Research Authority; 2017 [Available from: [https://www.hra.nhs.uk/planning-and-improving-](https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/)
34 709 [research/policies-standards-legislation/uk-policy-framework-health-social-care-research/](https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/)

39 710
40 711
41 712
42 713
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 1: Participant flow



* For sites where the waiting time for the CAMHS acceptance decision usually exceeds 10 working days from referral receipt, recruitment activities may start and/or continue beyond 10 working days from referral receipt, providing the intervention period can be completed prior to the CAMHS referral decision.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



STAndardised Diagnostic Assessment for children and adolescents with emotional difficulties (STADIA): a multi-centre randomised controlled trial

SCREENING

Site Number:	<input type="text"/>
Screening Number:	<input type="text"/>
Sponsor:	Nottinghamshire Healthcare NHS Foundation Trust
CRF Version:	Final v1.1 – 30 April 2019

1 **Site Number:**

2

3 **Screening Number:**

4



REFERRAL SCREENING	
<i>Complete for <u>all</u> referrals screened for eligibility:</i>	
NHS Number <i>Local use only</i>	<input type="text"/>
Trust Number <i>Local use only</i>	<input type="text"/>
Date of referral receipt (dd-mmm-yyyy)	<input type="text"/> - <input type="text"/> - <input type="text"/>
Date of screening (dd-mmm-yyyy)	<input type="text"/> - <input type="text"/> - <input type="text"/>
Young person's sex	Male <input type="checkbox"/> Female <input type="checkbox"/>
Young person's age <i>If <5 or >17 do not proceed</i>	<input type="text"/>
Has the young person been previously enrolled and randomised in the STADIA trial? <i>If yes, do not proceed</i>	Yes <input type="checkbox"/> No <input type="checkbox"/>
Does the referral mention any of the following Covid-19 related words/phrases? <i>Tick all that apply.</i>	
Covid-19 / Covid	<input type="checkbox"/>
Coronavirus	<input type="checkbox"/>
Lockdown	<input type="checkbox"/>
School closure / exams cancelled	<input type="checkbox"/>
Does the referral mention emotional difficulties*? <i>If no, do not proceed</i>	Yes <input type="checkbox"/> No <input type="checkbox"/>
Is this an emergency or urgent referral (according to local CAMHS triage / SPA team risk assessment)? <i>If yes, do not proceed</i>	Yes <input type="checkbox"/> No <input type="checkbox"/>
Does the young person have severe learning disability (e.g., the referral mentions this or that they attend a special school for children with severe learning difficulties)? <i>If 'yes' do not proceed</i> <i>If not known, confirm during telephone eligibility check at enrolment</i>	Yes <input type="checkbox"/> No <input type="checkbox"/> Not known <input type="checkbox"/>

Site Number:

--	--	--

Screening Number:

--	--	--	--



REFERRAL SCREENING		
If the young person is <16:	Yes	<input type="checkbox"/>
Does the referral information include contact details for a named parent/carer?	No	<input type="checkbox"/>
<i>If 'no' await parent/carer contact details before proceeding</i>	N/A	<input type="checkbox"/>
If the young person is <16:	Yes	<input type="checkbox"/>
Is the named parent/carer a local authority representative designated to care for the child/young person?	No	<input type="checkbox"/>
<i>If 'yes' do not proceed</i>	Not known	<input type="checkbox"/>
<i>If not known, confirm during telephone eligibility check at enrolment</i>	N/A	<input type="checkbox"/>
If the young person is aged 16 or 17:	Young person	<input type="checkbox"/>
Whose contact details are given on the referral form?	Parent/carer	<input type="checkbox"/>
<i>If young person contact details are provided, they should be contacted in the first instance</i>	Both	<input type="checkbox"/>
	N/A	<input type="checkbox"/>

EMOTIONAL DIFFICULTIES	
*Emotional difficulties may be indicated by the use of any of the following key words or phrases.	
Tick all that apply. If 'other' record details and seek advice from the PI or NCTU before proceeding.	
None	<input type="checkbox"/>
Agitated / agitation	<input type="checkbox"/>
Anger	<input type="checkbox"/>
Anxiety / anxious / generalised anxiety	<input type="checkbox"/>
Avoids things/people/places	<input type="checkbox"/>
Can't leave the house	<input type="checkbox"/>
Completing rituals / asking parents to carry out rituals	<input type="checkbox"/>
Compulsions	<input type="checkbox"/>
Depressed / depression / low / low mood / sad	<input type="checkbox"/>
Difficulties sleeping	<input type="checkbox"/>
Distress	<input type="checkbox"/>
Fears and worries / fears relating to safety (germs, fire)	<input type="checkbox"/>
Feeling low	<input type="checkbox"/>
Feels flat / empty / blank	<input type="checkbox"/>

1 **Site Number:**

2

3 **Screening Number:**

4



5
6
7 **EMOTIONAL DIFFICULTIES**

8 **Emotional difficulties may be indicated by the use of any of the following key words or phrases.*

9 *Tick all that apply. If 'other' record details and seek advice from the PI or NCTU before proceeding.*

10 Feels hopeless	<input type="checkbox"/>
11 Feels worthless / stupid	<input type="checkbox"/>
12 Flashbacks	<input type="checkbox"/>
13 Hypervigilance	<input type="checkbox"/>
14 Irritable	<input type="checkbox"/>
15 Low motivation	<input type="checkbox"/>
16 Low self-esteem / Hates self	<input type="checkbox"/>
17 Mood swings / moody	<input type="checkbox"/>
18 Negative thoughts	<input type="checkbox"/>
19 Nightmares (if trauma also present)	<input type="checkbox"/>
20 No (or loss of) energy	<input type="checkbox"/>
21 No (or loss of) interest in things / gave up... / lack of wanting to do things	<input type="checkbox"/>
22 Not going to school / unable to go to school	<input type="checkbox"/>
23 Not sleeping / poor sleep	<input type="checkbox"/>
24 Obsessions	<input type="checkbox"/>
25 OCD	<input type="checkbox"/>
26 Phobia	<input type="checkbox"/>
27 Panic / panic attacks	<input type="checkbox"/>
28 PTSD	<input type="checkbox"/>
29 Self-harm / DSH / Cutting	<input type="checkbox"/>
30 Suicidal	<input type="checkbox"/>
31 Suicidal thoughts / thoughts of ending life / thinks about killing self	<input type="checkbox"/>
32 Tearful	<input type="checkbox"/>
33 Thoughts of death	<input type="checkbox"/>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Site Number:

--	--	--

Screening Number:

--	--	--	--

**EMOTIONAL DIFFICULTIES**

**Emotional difficulties may be indicated by the use of any of the following key words or phrases.*

Tick all that apply. If 'other' record details and seek advice from the PI or NCTU before proceeding.

Tiredness / fatigue	<input type="checkbox"/>
Touching objects	<input type="checkbox"/>
Trauma	<input type="checkbox"/>
Weepy	<input type="checkbox"/>
Withdrawal / withdrawn	<input type="checkbox"/>
Worried / worrying (incl. worries/concerns about their appearance)	<input type="checkbox"/>
Other (please specify)	<input type="checkbox"/>

FOR ALL REFERRALS SCREENED, ENTER SUMMARY DATA ON THE SCREENING & ENROLMENT LOG.

IF THE YOUNG PERSON APPEARS TO BE ELIGIBLE PROCEED TO THE INVITATION TELEPHONE CALL (CALL 1) AND ENTER DETAILS ON THE TRIAL DATABASE.

SIGN-OFF STATEMENT

Completed by the researcher conducting the referral screening.

To the best of my knowledge, I confirm that I have made every reasonable effort to ensure that ALL of the data in this Case Record Form is a true, accurate and complete report.

Print Name														
Signature														
Date	<table border="1"> <tr> <td> </td> <td> </td> <td> </td> <td>-</td> <td> </td> <td> </td> <td> </td> <td> </td> <td>-</td> <td> </td> <td> </td> <td> </td> <td> </td> </tr> </table>				-					-				
			-					-						

ADD LOCAL HEADER

Standardised Diagnostic Assessment for children and young people with emotional difficulties (STADIA)

Informed Consent Form for the Parent/Carer

Final v2.0 13 August 2020

Name of Principal Investigator: [add local PI name]

IRAS Project ID: 255635

Participant Trial ID:
(To be completed after randomisation)

--	--	--	--	--

We are doing this research to find out how to make sure children and young people get the help they need when they are referred to CAMHS. We have invited you to take part in this research because a young person you care for has been referred to CAMHS. You can decide whether or not to take part in this research. If you agree to take part in the STADIA Trial, please read and acknowledge each of the following statements.

<i>A drop-down menu will be provided within the online electronic Informed Consent Form so that the person providing consent has the option to acknowledge/agree to each of the following statements.</i>	
1.	I confirm that I have read and understand the Participant Information Sheet, Version <insert current PIS version number and date > for the above research. <i>(Only for the parent/carer of children/young people aged 11-15) [My child and]</i> I have had the opportunity to consider the information, ask questions and have had these answered satisfactorily.
2.	<i>Only for the parent/carer of children/young people aged 11-15</i> I have spoken to my child about the research and they are aware of the study.
3.	I understand that mine and my child’s participation is voluntary and that I am free to withdraw at any time, without giving any reason, and without my child’s medical care or legal rights being affected. I understand that should I withdraw, then the information collected so far cannot be deleted and that this information may still be used in the research.
4.	I understand that relevant sections of my child’s CAMHS records and data collected in the trial may be looked at by authorised individuals from the Nottingham Clinical Trials Unit (University of Nottingham), the Sponsor (Nottinghamshire Healthcare NHS Foundation Trust), NHS bodies, the trial research group and regulatory authorities where it is relevant to taking part in this study. I give permission for these individuals to have access to these records and for my consent form to be retained by the Nottingham Clinical Trials Unit.
5.	I give permission for the Nottingham Clinical Trials Unit, the Sponsor and the trial research group to collect, store, analyse and publish information obtained from mine and my child’s participation in this trial. I understand that our personal details will be kept confidential.
6.	I understand that the Nottingham Clinical Trials Unit and the trial research group will be provided with mine and my child’s personal details to send questionnaires by email and study-related correspondence during the trial. I give my permission for this information to be kept and for these individuals to contact me.
7.	I understand that if I fill out the DAWBA, I will receive a copy of the DAWBA report and a copy will also be provided to the CAMHS team and kept in my child’s CAMHS records.
8.	I agree to my child’s GP being informed of their participation in this trial.
9.	I understand that the anonymised information collected about me and my child may be used to support other research in the future and may be shared with other researchers.
10.	I agree to take part in the above trial.

Please also answer yes or no to the following options.

<i>A drop-down menu will be provided within the online electronic Informed Consent Form so that the person providing consent has the option to answer yes or no to each of the following optional statements.</i>			
1.	<i>Interviews about your experiences</i> I agree to be contacted about the STADIA interview study. I understand that there is no obligation to take part and I will just be informed of what the study will involve.	Yes	No
2.	<i>Future studies</i> I agree to be contacted about other research studies in the future. I understand that there is no obligation to take part and I will just be informed of what the future research would involve.	Yes	No
3.	<i>Results of the STADIA study</i> I would like to receive a summary of the results at the end of the STADIA study.	Yes	No
4.	<i>Only for the parent/carer of children/young people aged 11-15</i> <i>Questionnaires</i> I agree to my child being invited to complete questionnaires about their mood and feelings for the research.	Yes	No
5.	I consent to [INSERT NHS TRUST NAME] passing identifiable data (my child's NHS number, name and date of birth) to the organisations that are responsible for health information including NHS Digital. This will be used to request data from the Children and Young People's Health Services Data Set and the Mental Health Services Data Set.	Yes	No

Type your name here:

Name of parent/carer

Date [system generated]

Type the name of your child here:

Name of child/young person

Date [system generated]

System use only:

Name of person taking consent
(You must be on the delegation log)

Date [system generated]

NB. Signatures will not be collected as consent will be obtained online. Participants will be asked to complete the eICF and write their name before submitting the online form; the date will be system-generated. The name of the researcher who provided the study information and the date the eICF was generated will also be recorded within the online system.

The online electronic Informed Consent Form (eICF) will be retained within the trial database. Printable (PDF) copies will be generated and retained within the Investigator Site File and CAMHS records. A copy will be sent by email to the participant.

ADD LOCAL HEADER

Standardised Diagnostic Assessment for children and young people with emotional difficulties (STADIA)

Assent form for young people aged 11-15

Final v1.0 28-Mar-2019

Name of Principal Investigator: [add local PI name]

IRAS Project ID: 255635

Participant Trial ID:

(To be completed after randomisation)

--	--	--	--	--

We are doing this research to find out how to make sure people get the help they need when they are referred to CAMHS. We are asking you to help with this research but you can decide whether or not to take part.

If you agree to help with the STADIA Trial please answer the following questions.

<i>A drop-down menu will be provided within the online electronic Assent Form so that the young person providing assent has the option to acknowledge/agree to each of the following statements.</i>			
1.	Have you read the information about the research or has someone explained it to you?	Yes	No
2.	Do you understand what the research is about?	Yes	No
3.	Have you been able to ask all the questions you want?	Yes	No
4.	Do you understand that it's your choice whether or not to take part and it's OK to stop taking part at any time?	Yes	No
5.	Do you want to help with the research by completing some questionnaires about your mood and feelings?	Yes	No

Type your name here:

 Name of child/young person

 Date [system generated]
System use only:

 Name of person taking consent
 (You must be on the delegation log)

 Date [system generated]

NB. Signatures will not be collected as consent will be obtained online. Participants will be asked to complete the eICF and write their name before submitting the online form; the date will be system-generated. The name of the researcher who provided the study information and the date the eICF was generated will also be recorded within the online system. The online electronic Informed Consent Form (eICF) will be retained within the trial database. Printable (PDF) copies will be generated and retained within the Investigator Site File and CAMHS records. A copy will be sent by email to the participant.

DAWBA Report

The DAWBA collects information about a range of common emotional and behavioural difficulties, and uses this information to produce a report to highlight the level of difficulties.

How to understand the ratings

These ratings compare your responses with the responses from large numbers of other parents and young people across the UK. Many parents and young people find this sort of comparison helpful, but it is just a guide and not the same as a face-to-face assessment with a specialist.

To make it easier to read, we have grouped the ratings into four categories. Each category is different. This shows how your [child's] (*delete as appropriate*) difficulties compare with other children / young people:



Close to average

In the general population most children/ young people (roughly 80 out of 100) are in the "close to average" category.



Slightly raised

If the ratings are in the "slightly raised" category this means the difficulties are slightly higher than average. Roughly 10 out of 100 children / young people are in this category.



High

Around 5 in 100 children / young people score in the "high" category. This means that the difficulties are more severe than average.



Very high

Around 5 in 100 children score in the "very high" category. This means that the difficulties appear to be more severe than we find in 95 out of every 100 children / young people.



The rating is only a rough guide. As high ratings can be a "false alarm", please use your own judgement. Not all difficulties need treating. Some difficulties get better by themselves, particularly if they are mild or if they have only been there for a short time.

Most strengths and difficulties lie on a scale. There will be children / young people at each end of the scale but most children / young people will fall somewhere in between.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Your [child's] (*delete as appropriate*) ratings:

- **Close to average / Slightly raised / High / Very high** for worrying a lot about different things (general fears and worries)
- **Close to average / Slightly raised / High / Very high** for worries about separation from key "attachment figures" such as parents (separation anxiety)
- **Close to average / Slightly raised / High / Very high** for specific fears (specific phobia)
- **Close to average / Slightly raised / High / Very high** for social fears (social anxiety)
- **Close to average / Slightly raised / High / Very high** for panic attacks
- **Close to average / Slightly raised / High / Very high** for fears of crowds, public places, open spaces etc (agoraphobia)
- **Close to average / Slightly raised / High / Very high** for stress linked to particularly frightening events (post-traumatic stress)
- **Close to average / Slightly raised / High / Very high** for obsessions or compulsions
- **Close to average / Slightly raised / High / Very high** for depression or loss of interest
- **Close to average / Slightly raised / High / Very high** for disruptive and uncooperative behaviours (troublesome behaviour)
- **Close to average / Slightly raised / High / Very high** for antisocial or aggressive behaviours that can get people into serious trouble (troublesome behaviour)

Appendix 5. Eligible emotional disorder diagnoses

1	Anxiety disorder
2	
3	Separation anxiety disorder
4	
5	Specific phobia (any)
6	
7	Social phobia or Social anxiety disorder
8	
9	Agoraphobia
10	
11	Panic disorder (DSM5 additionally has Panic Attack with a specifier)
12	
13	Phobic anxiety disorder (unspecified)
14	
15	Selective mutism
16	
17	Generalized anxiety disorder
18	
19	Obsessive-compulsive and related disorders
20	
21	Body dysmorphic disorder
22	
23	Acute stress reaction
24	
25	Acute Stress Disorder
26	
27	Post-traumatic stress disorder
28	
29	Adjustment Disorder
30	
31	Other anxiety disorder
32	
33	Mixed anxiety and depressive disorder
34	
35	Depression
36	
37	Depressive episode (any / mild / moderate / severe)
38	
39	Depressive disorder
40	
41	Recurrent depressive disorder (any / mild / moderate / severe)
42	
43	Major Depressive disorder
44	
45	Persistent Depressive disorder
46	
47	Other depressive episode
48	
49	Persistent mood (affective) disorder (including cyclothymic disorder / dysthymic disorder)
50	
51	Other / Unspecified mood (affective) disorder
52	
53	Bipolar disorder
54	
55	Bipolar affective disorder
56	
57	Manic episode
58	
59	Childhood emotional disorder unspecified (F93.9)
60	



**STANDARDISED Diagnostic Assessment for children and adolescents with emotional difficulties (STADIA):
A multi-centre randomised controlled trial**

OUTCOME DEFINITION & ADJUDICATION PLAN

Final 1.0 – 25 February 2020

EMOTIONAL DISORDER DIAGNOSES RECORDED IN THE 12 MONTHS POST-RANDOMISATION

CONSTITUTES A CLINICAL DIAGNOSIS	REFER FOR ADJUDICATION	DOES NOT CONSTITUTE A CLINICAL DIAGNOSIS
<ul style="list-style-type: none"> - The presence of an <u>eligible diagnosis</u> within the diagnosis tab of the clinical record. - The presence of an <u>eligible diagnosis</u> in the clinical record preceded by the heading 'diagnosis'. - The presence of an <u>eligible diagnosis</u> in the clinical record preceded by a heading such as 'current difficulties' or 'presenting problems', except where this has been documented in the write up of the first appointment or in reference to the information received at referral (as this may simply reflect a pre-existing or referrer-made diagnosis). - A clear confirmatory statement including use of an <u>eligible diagnosis</u>, for example: <i>Meets the diagnostic criteria for...</i> <i>Presentation is explained by a diagnosis of...</i> 	<ul style="list-style-type: none"> - The presence of <u>similar diagnostic terms</u> within the diagnosis tab of the clinical record. - The presence of an <u>eligible diagnosis</u> preceded by a heading such as 'current difficulties' or 'presenting problems', documented in the write up of the first appointment or in reference to the information received at referral. - The presence of <u>similar diagnostic terms</u> preceded by a heading such as 'diagnosis', 'current difficulties' or 'presenting problems'. - Reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>, but where the context does not provide a clear confirmatory statement, for example: <i>?...</i> <i>Possible...</i> <i>Assessed for...</i> <i>...-type symptoms / behaviour</i> <i>...-like symptoms / behaviour</i> <i>Symptoms of...</i> <i>History of...</i> 	<ul style="list-style-type: none"> - No reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>. - A clear statement about the absence of an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>, for example: <i>No evidence of...</i> <i>...not meeting criteria for disorder</i>
<i>Data collection and entry: instructions for researchers</i>		
<i>Use the checklist of eligible emotional disorder diagnoses.</i>	<i>Document these as other emotional disorders.</i>	<i>Check 'none of the above' in the checklist of emotional disorder diagnoses and answer 'no' to 'other emotional disorder diagnoses'.</i>

Note: For definition of underlined terms see the Glossary below.

NO EMOTIONAL DISORDER

If there are no emotional disorder diagnoses documented in the CAMHS notes in 12 months post-randomisation, researchers will select one of the following options:

1. A clinician has documented the absence of emotional disorder.
2. Uncertainty about the presence of an emotional disorder is documented in the notes (for example, reflecting ongoing assessment / investigation).
3. There is no diagnostic information relating to emotional disorders documented in the CAMHS record.

A clinician has documented the <u>absence</u> of emotional disorder.	Uncertainty about the presence of an emotional disorder is documented in the notes (for example, reflecting ongoing assessment / investigation).	There is <u>no diagnostic information</u> relating to emotional disorders documented in the CAMHS record.
<ul style="list-style-type: none"> - Nothing in the clinical record is assessed to constitute a documented clinical diagnosis, AND - There is a clear statement about the absence of one or more of the <u>eligible diagnoses</u> or <u>similar diagnostic terms</u>, for example: <div style="text-align: center;"><i>No evidence of...</i> <i>...not meeting criteria for disorder</i></div> 	<ul style="list-style-type: none"> - Nothing in the clinical record is assessed to constitute a documented clinical diagnosis, AND - Reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>, but where the context does not provide a clear confirmatory statement, for example: <div style="text-align: center;">?... <i>Possible...</i> <i>Assessed for...</i> <i>...-type symptoms / behaviour</i> <i>...-like symptoms / behaviour</i> <i>Symptoms of...</i> <i>History of...</i></div> 	<ul style="list-style-type: none"> - Nothing in the clinical record is assessed to constitute a documented clinical diagnosis, AND - There is no reference to an <u>eligible diagnosis</u> or <u>similar diagnostic terms</u>.* - If emotional difficulties are identified they are described only by reference to the presenting symptoms with no attempt made to link these to an eligible diagnosis, for example: <div style="text-align: center;"><i>Presenting issue - Mood swings</i> <i>Describing examples of ruminating thoughts.</i></div> <p>* Note that this includes children/young people who have <u>not been seen by CAMHS</u> in the 12-months post-randomisation.</p>
<i>Document these as absence of emotional disorder.</i>	REFER FOR ADJUDICATION	MAY REQUIRE ADJUDICATION

EMOTIONAL DISORDER DIAGNOSIS ADJUDICATION OUTCOME	
<p>The Adjudication Committee will first consider whether the record:</p> <ol style="list-style-type: none"> 1) Constitutes a clinical diagnosis 2) Does not constitute a clinical diagnosis 	<p>If (1) then the Adjudication Committee will determine which of the eligible emotional disorder diagnoses apply.</p> <p>If (2) then the Adjudication Committee will determine whether the record constitutes:</p> <ol style="list-style-type: none"> a) Absence of emotional disorder b) Uncertainty about the presence of emotional disorder c) No diagnostic information

TREATMENTS / INTERVENTIONS GIVEN

CONSTITUTES A TREATMENT / INTERVENTION	REFER FOR ADJUDICATION
- The presence of an <u>eligible treatment / intervention</u> documented within the clinical record.	- Documented intervention by CAMHS where the description does not include an <u>eligible treatment / intervention</u> .
<i>Data collection and entry: instructions for researchers</i>	
<i>Use the checklist of eligible treatments / interventions.</i>	<i>Document these as other treatments / interventions.</i>

TREATMENTS / INTERVENTIONS ADJUDICATION OUTCOME

The Adjudication Committee will first consider whether the record: 1) Constitutes a treatment / intervention 2) Does not constitute a treatment / intervention	If (1) then the Adjudication Committee will determine whether the record should be categorised: a) As an existing treatment / intervention b) As an 'other' treatment / intervention
----------------------------------------------------------------------------------------------------------------------------------------------------------------------	--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

GLOSSARY

Eligible diagnosis	One of the pre-specified diagnoses listed on the data collection form. These should be considered present only when the <u>exact phrase</u> and/or corresponding ICD/DSM code is documented.
Similar diagnostic terms	Words or phrases which are similar to the eligible diagnoses, but without use of the exact wording or corresponding ICD/DSM code (e.g., separation anxiety WITHOUT use of the term disorder) or where the exact words are used alongside additional phrases (e.g., OCD-type behaviour or OCD-like symptoms).
Eligible treatment / intervention	One of the pre-specified treatments / interventions listed on the data collection form.
Adjudication Committee	The Adjudication Committee will comprise the clinician members of the Trial Management Group. A minimum of two clinicians will review terms referred for adjudication, with a third consulted if a consensus is not reached. The Adjudication Committee will be blinded to treatment allocation for the purposes of adjudication.

Appendix 7. Summary of assessments

Time-point	Maximum 10 working days from referral receipt ¹			6 months post-randomisation	12 months post-randomisation	
Activity	Screening and invitation	Eligibility and enrolment	Consent and baseline	Follow-Up		
Initial eligibility screen of referral information	X			Randomisation Intervention DAWBA in addition to usual practice Or Usual practice only		
Telephone invitation to participate	X					
Verbal agreement to participate		X				
Confirm eligibility		X				
Obtain enrolment data		X				
Participant enrolment		X				
Written informed consent/assent (online)			X			
Baseline demographics (parent/carer and CYP aged 16 & 17)			X			
Mood and Feelings Questionnaire (MFQ)			X		X	X
Revised Child's Anxiety Depression Scale (RCADS)			X		X	X
Strengths and Difficulties Questionnaire (SDQ) ²			X		X	X
Child Revised Impact of Events Scale (CRIES-8)(42) ³			X		X	X
CYP self-report self-harm measure			X		X	X
Patient Health Questionnaire (PHQ-9) - parent/carer only			X		X	X
Generalised Anxiety Disorder Assessment (GAD-7) - parent/carer only			X		X	X
Child Health Utility 9D (CHU9D)			X		X	X
EuroQol-5D youth (EQ-5D-Y)			X		X	X
EuroQol-5D five level (EQ-5D-5L)			X		X	X
Resource Use Questionnaire - parent/carer and CYP aged 16 & 17			X		X	X
Data collection from records ⁴			X		X	X
¹ For sites where the waiting time for the CAMHS acceptance decision usually exceeds 10 working days from referral receipt, recruitment activities may start and/or continue beyond 10 working days from referral receipt, providing the intervention period can be completed prior to the CAMHS referral decision.						
² For participants in the intervention arm, the baseline SDQ will be collected as part of the DAWBA, completed post-randomisation.						
³ Additional data collection undertaken to explore post-traumatic stress disorder symptoms in CYP during the Covid-19 pandemic						
⁴ Data collection from records will be completed periodically throughout the 12 month follow-up period.						

Reporting checklist for protocol of a clinical trial.

Based on the SPIRIT guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the SPIRIT reporting guidelines, and cite them as:

Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin J, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleža-Jerić K, Laupacis A, Moher D. SPIRIT 2013 Explanation and Elaboration: Guidance for protocols of clinical trials. *BMJ*. 2013;346:e7586

		Reporting Item	Page Number (line)
Administrative information			

1 2 3 4 5 6 7	Title	#1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1(1-2)
8 9 10 11 12	Trial registration	#2a	Trial identifier and registry name. If not yet registered, name of intended registry	2 (68)
13 14 15 16 17 18	Trial registration: data set	#2b	All items from the World Health Organization Trial Registration Data Set	Throughout
19 20 21	Protocol version	#3	Date and version identifier	19 (511)
22 23 24 25 26	Funding	#4	Sources and types of financial, material, and other support	20 (556-559)
27 28 29 30 31 32 33 34	Roles and responsibilities: contributorship	#5a	Names, affiliations, and roles of protocol contributors	1 (5-9)
35 36 37 38 39 40 41 42 43 44	Roles and responsibilities: sponsor contact information	#5b	Name and contact information for the trial sponsor	20 (574-575)
45 46 47 48 49 50 51 52 53 54 55 56 57 58 59	Roles and responsibilities: sponsor and funder	#5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	20 (556-562)

1 2 3 4 5 6 7 8 9 10 11 12 13 14	Roles and responsibilities: committees	#5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	19 (532-535)
15 16 17	Introduction			
18 19 20 21 22 23 24 25 26 27 28 29	Background and rationale	#6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	3-4 (91-148)
30 31 32 33 34 35 36 37	Background and rationale: choice of comparators	#6b	Explanation for choice of comparators	3-4, 7-8 (129-148)
38 39 40	Objectives	#7	Specific objectives or hypotheses	4 (150-176)
41 42 43 44 45 46 47 48 49 50 51 52	Trial design	#8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, non-inferiority, exploratory)	4 (182-183)
53 54 55 56 57 58	Methods: Participants,			

1 2 3 4	interventions, and outcomes		
5 6 7 8 9 10 11 12 13 14	Study setting	#9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained
15 16 17 18 19 20 21 22 23 24	Eligibility criteria	#10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)
25 26 27 28 29 30 31	Interventions: description	#11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered
32 33 34 35 36 37 38 39 40 41	Interventions: modifications	#11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving / worsening disease)
42 43 44 45 46 47 48 49	Interventions: adherence	#11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return; laboratory tests)
50 51 52 53 54 55	Interventions: concomitant care	#11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Outcomes	#12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	8-15 (316-337)
19 20 21 22 23 24 25 26 27 28 29 30 31	Participant timeline	#13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure 1)	5-7 (197-239) and see figure 1
32 33 34 35 36 37 38 39 40 41 42 43	Sample size	#14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	8 (306-312)
44 45 46 47 48	Recruitment	#15	Strategies for achieving adequate participant enrolment to reach target sample size	5 (197-212)
49 50 51 52 53 54 55 56 57 58	Methods: Assignment of interventions (for controlled trials)			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Allocation: sequence generation	#16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	7 (242-246)
19 20 21 22 23 24 25 26 27 28 29 30	Allocation concealment mechanism	#16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	7 (248-252)
31 32 33 34 35 36 37 38	Allocation: implementation	#16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	7 (244-252)
39 40 41 42 43 44 45 46	Blinding (masking)	#17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	7 (254-260)
47 48 49 50 51 52 53	Blinding (masking): emergency unblinding	#17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	7 (254-256)
54 55 56 57 58 59	Methods: Data collection,			

1 2 3 4	management, and analysis		
5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25	Data collection plan	#18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol
26 27 28 29 30 31 32 33 34 35	Data collection plan: retention	#18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols
36 37 38 39 40 41 42 43 44 45 46 47 48 49	Data management	#19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol
50 51 52 53 54 55	Statistics: outcomes	#20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other

1		details of the statistical analysis plan can be found,	
2		if not in the protocol	
3			
4			
5			
6	Statistics: additional	#20b	Methods for any additional analyses (eg, subgroup
7	analyses		and adjusted analyses)
8			17 (389-408)
9			
10			
11	Statistics: analysis	#20c	Definition of analysis population relating to
12	population and		protocol non-adherence (eg, as randomised
13	missing data		analysis), and any statistical methods to handle
14			missing data (eg, multiple imputation)
15			17 (390-392)
16			
17			
18			
19			
20			
21	Methods: Monitoring		
22			
23			
24	Data monitoring:	#21a	Composition of data monitoring committee (DMC);
25	formal committee		summary of its role and reporting structure;
26			statement of whether it is independent from the
27			sponsor and competing interests; and reference to
28			where further details about its charter can be
29			found, if not in the protocol. Alternatively, an
30			explanation of why a DMC is not needed
31			19 (534-535)
32			
33			
34			
35			
36			
37			
38			
39			
40			
41	Data monitoring:	#21b	Description of any interim analyses and stopping
42	interim analysis		guidelines, including who will have access to these
43			interim results and make the final decision to
44			terminate the trial
45			19 (527-535)
46			
47			
48			
49			
50			
51	Harms	#22	Plans for collecting, assessing, reporting, and
52			managing solicited and spontaneously reported
53			adverse events and other unintended effects of
54			trial interventions or trial conduct
55			19 (514-524)
56			
57			
58			
59			

Auditing	#23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	19 (532-535)
Ethics and dissemination			
Research ethics approval	#24	Plans for seeking research ethics committee / institutional review board (REC / IRB) approval	19 (509-511)
Protocol amendments	#25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC / IRBs, trial participants, trial registries, journals, regulators)	19 (509-511)
Consent or assent	#26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	6 (see table 2)
Consent or assent: ancillary studies	#26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	6 (table 2)
Confidentiality	#27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	16 (384-387)

1 2 3 4 5 6 7	Declaration of interests	#28	Financial and other competing interests for principal investigators for the overall trial and each study site	20 (565)
8 9 10 11 12 13 14	Data access	#29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	16 (384-387)
15 16 17 18 19 20 21 22	Ancillary and post trial care	#30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	n/a
23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39	Dissemination policy: trial results	#31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	19 (538-539)
40 41 42 43 44	Dissemination policy: authorship	#31b	Authorship eligibility guidelines and any intended use of professional writers	20 (549-553)
45 46 47 48 49 50 51 52	Dissemination policy: reproducible research	#31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	20 (542-543)
53 54 55 56 57 58 59 60	Appendices			

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60	Informed consent materials	#32	Model consent form and other related documentation given to participants and authorised surrogates	Supplementary materials 6 & 7
Biological specimens	#33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	n/a	

None The SPIRIT Explanation and Elaboration paper is distributed under the terms of the Creative Commons Attribution License CC-BY-NC. This checklist can be completed online using <https://www.goodreports.org/>, a tool made by the [EQUATOR Network](#) in collaboration with [Penelope.ai](#)